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ABSTRACT 
During the past three decades, the development of marine natural products as drug leads 
has become a promising avenue for research. As our efforts towards the discovery of anticancer 
and antibiotic drug leads from marine organisms, modifications of anticancer drug candidate 
kahalalide F, isolations of new peptides from the mollusk, Elysia rufescens and anticancer drug 
leads from the NCI repository, as well as chemical regulation of antibiotic production from 
marine Pseudomonas aeruginosa were investigated.  
 Kahalalide F (KF) is a potent anticancer lead isolated from the herbivorous marine 
mollusk E. rufescens and its algal diet Bryopsis pennata. Our semisynthesis approach was aimed 
to improve the efficacy or prolong the half-life resulted in 15 KF analogues. These analogues 
included eight elongation products with nonpolar amino acid residues, four analogues with 
modified amino group at the Orn residue, one dehydration product of KF, and two new 
cyclization products of kahalalide G. All the analogues are being evaluated by Wayne State 
University for solid tumor cytotoxicity. 
In the course of the isolation of KF as starting material for its analogues, nine new and 10 
known peptides were isolated from E. rufescens. However, only five structures were determined 
and the remaining four structures could not be assigned due to limited sample amounts (less than 
1 mg). Future work will focus on the structure assignment using FTMS amino acid sequence 
analysis or 700 MHz NMR.  
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During the screening of anticancer drug leads from the NCI repository, 27 extracts from 
marine organisms were tested, and 12 known compounds including tetracyclic aromatic alkaloids, 
diterpenoids and pyrroloaminopropylimidazole alkaloids were purified.  
Bioassay-guided isolation from marine P. aeruginosa collected in the Gulf of Mexico 
afforded 15 known antibiotics including two phenazines, six 2-alkyl-4-quinolones, and seven 
rhamnolipids. 2-Nonyl-4(1H)-quinolone and 2-(1-nonenyl)-4(1H)-quinolone displayed potent 
antimalarial activity, which was first reported here. Based on the metabolic profile of antibiotics 
from P. aeruginosa, chemical regulation and its impact on the yield of these metabolites were 
investigated. Treatment of P. aeruginosa with sceptrin and co-culturing with another 
Pseudomonas sp. increased antibiotic production significantly. This could be attributed to the 
activation of antibiotic biosynthetic gene expression under stress conditions.          
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Cancer is the second leading cause of death worldwide. In 2008, around 12.7 million new 
cancer cases had been diagnosed worldwide, and 7.6 million people died of cancer. This 
accounted for 12.5% of all deaths.1 According to the statistics published by the American Cancer 
Society from 2006 to 2012, the number of people being diagnosed with cancer each year is 
increasing in the U.S. (Figure 1). However, deaths caused by cancer each year are stabilizing 
(Figure 2). The 5-year relative rate of survival of cancer in the U.S. has increased from 49% in 
the 1980s to 67% in the 2000s,1g which can be directly attributed to the improvement of early 
diagnosis and treatments. 
 
Figure 1 Estimated new cancer cases in the U.S from 2006-2012 
Treatments for cancer include surgery, radiation therapy, chemotherapy, hormone therapy, 
and others such as targeted, biological and gene therapies. Major strategies of cancer treatment 
are surgery or radiation therapy followed by chemotherapy, or chemotherapy itself,2 which 
reveals the reliance on chemotherapy for the treatment of cancer. However, chemotherapy has 
significant limitations. Chemotherapeutic drugs can also kill normal cells thus lacking selectivity. 
They might cause MDR as well. These problems result in serious side effects, immunity 
suppression, and poor treatment outcomes. Scientists are making great efforts to overcome these 
problems caused by chemotherapy. One approach is to use targeted therapies which target 
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kinases involved in the regulation of the cell cycle. In 2001, with the launch of a tyrosine kinase 
inhibitor imatinib (Gleevec/Glivec) registered by Novartis, cancer treatment was brought into a 
new era of targeted therapies. However, these types of inhibitors have been reported to acquire 
drug resistance in many clinical cases.3 Efforts are now focusing on the exploration of a new 
generation of kinase inhibitors based on known mechanisms of acquired resistance. Other 
approaches include development of new molecules targeting hormone, MDR proteins which can 
be given in the combination with chemotherapy.  
 
Figure 2 Estimated deaths in the U.S. from 2006-2012 
After analyzing the current approaches for treating cancer, it is apparent that new 
molecules are needed to continue the fight. Major tools used in new drug development include 
the screening of drug leads from natural products and drug design based on combinatorial and 
rational strategies. Natural products provide a major source of new drug candidates. It is 
estimated that there are at least 250,000 species of higher plants around the world, while marine 
organisms are widely distributed over 70% of the earth’s surface. All of these species are able to 
produce secondary metabolites with different activities due to defense, competition, or a number 
of other environmental reasons. In addition, combinatorial and rational methods need model 
compounds. These compounds are often chemically complex and would take humans years to 
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synthesize if they were ever considered as possibilities in the first place. As such natural products 
are becoming more and more important as lead compounds. From the 1940s to 2006, 175 
anticancer drugs were discovered, among which 14% are natural products and 43% are derived 
from natural products by semisynthesis or using them as pharmacophore.4 During the past two 
decades, the development of marine natural products as anticancer drugs has become a promising 
avenue for research. The first commercially available anticancer drug from a marine source was 
ecteinascidin-743 (Yondelis®) isolated from the Caribbean tunicate Ecteinascidia turbinata.5 
Four compounds isolated from marine sources including aplidine, bryostatin 1, spisulosine, and 
salinosporamide A, as well as eight synthetic compounds derived from marine products are 
under phase I or phase II clinical trials.6 Other compounds such as didemnin B, dolastatin 10, 
kahalalide F, discodermolide, and girolline were discontinued due to toxicity or efficacy 
deficiencies. Considering the potency of the dropped compounds, however, modifications were 
conducted. One of the successful cases is soblidotin (TZT-1027) which was derived from 
dolastatin 10. Dolastatin 10 was isolated from the mollusk Dolabella auricularia with promising 
activity against several tumor cell lines.7 It was dropped from the phase II clinical trial due to the 
lack of efficacy and its toxicity.8,9 Its analogue soblidotin which is modified by removing the 
thiazole residue displayed higher potency.10 Currently, soblidotin is under phase III clinical trials 
(Figure 3). Another example is isoKF, an isomer of KF, of which the potency increased 10 times 
by switching the methyl group from C-5 to C-4 at the terminal fatty acid moiety. Kahalalide F 
will be discussed in detail in the first chapter.  
 
Figure 3 Structures of dolastatin 10 and soblidotin 
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Based on the examples of these marine-derived anticancer drugs, the general procedures 
of drug development from natural sources are summarized as in Figure 4. In the first part, three 
projects are involved in several steps in drug development from marine sources aimed to explore 
anticancer drug leads from marine organisms. They consist of the modification of anticancer 
drug candidate kahalalide F, isolation of new peptides from the mollusk Elysia rufescens, and 
anticancer drug leads from the NCI repository.  
 
Figure 4 Procedures of drug development from natural sources 
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1. Introduction 
 
Figure 5 KF and isoKF from Elysia rufescens and Bryopsis pennata 
Kahalalide F (KF), naturally occurring as a mixture with its isomer isoKF, is a 
depsipeptide isolated from the herbivorous marine mollusk Elysia rufescens and its algal diet 
Bryopsis pennata (Figure 5).11,12 The distribution of compounds in the snail and its B. pennata 
food source implied that they were accumulated from either the food source or probably a 
microbial association. Later studies suggested that the peptides are produced by a Vibrio sp. that 
associated with both E. rufescens and B. pennata.13 The 13C NMR spectra display an unequal 
ratio of these two isomers in algal, mollusk, and bacterium by comparing the presence of 4-/5- 
methyl group on the hexanoic lipid chain (Figures 6-8). This also can explain the variance of KF 
production under different environments.  
CHAPTER 1 
SEMISYNTHESIS OF KAHALALIDE F ANALOGUES AS POTENTIAL 
ANTICANCER AGENTS 
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Figure 6 13C NMR spectrum of a mixture of KF and isoKF in E. rufescens at the ratio of 3:1 
 
Figure 7 13C NMR spectrum of a mixture of KF and isoKF in B. pennata at the ratio of 1:1 
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Figure 8 13C NMR spectrum of a mixture of KF and isoKF in a Vibrio sp. at the ratio of 4:1 
Both KF and isoKF exhibit significant activity in vitro against human prostate, breast, 
non-small cell lung, and colon solid tumors.11,12,14 They also showed activity against human 
prostate cancer xenografts.14 The cytotoxicity of KF and isoKF did not correlate with the 
expression level of MDR1 in prostate and breast cancer, indicating their potential in the 
treatment of multiple drug resistant cancers.15 The mechanism of them is not completely 
elucidated. In the NCI-COMPARE analysis which is used to compare the patterns of drug 
sensitivity in 60 human cancer cell lines between target molecule and compounds in the library, 
KF and isoKF appeared negative suggesting that they have a unique mode of action.16 They 
interfere with cell lysosome organization.17 Subsequently, they were shown to down-regulate 
ErbB3 and inhibit Akt signaling.18 The ErbB family comprises epidermal growth factor receptor 
(EGFR) tyrosine kinases that function to mediate cell interactions. In humans, it contains four 
subfamilies, Her1/EGFR/ErbB1, Her2/ErbB2, Her3/ErbB3, and Her4/ErbB4. In cancer cells, 
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with an increasing release of EGF ligands that can bind to ErbB receptors, phosphorylation on 
specific tyrosine residues of ErbB receptors are induced, thus activating intracellular signaling 
pathways to promote cancer cell growth.19 Inhibitors targeting the ErbB family displayed 
potency in cancer prevention.20,21 Several ErbB1 and ErbB2 inhibitors have been approved for 
cancer treatment (Table 1). An ErbB4 inhibitor, dacomitinib, developed by Pfizer has entered 
phase III clinical trials.22 However, there is no ErbB3 inhibitor available thus far. KF and isoKF, 
therefore, could be promising candidates to target the ErbB3 receptor. 
Table 1 ErbB inhibitors approved for cancer treatment 
Year of approval Name Structure Target 
1998 Trastuzumab Antibody ErbB2 
2003 Gefitinib  
O
N O
O N
N
HN
F
Cl
 
ErbB1 
2004 Erlotinib 
N
N
HN C
C
H
O
O
O
O
 
ErbB1 
2004 Cetuximab Antibody ErbB1 
2005 Panitumumab Antibody ErbB1 
2007 Lapatinib 
N
N
O
NH
S
HN
Cl
O
F
O
O  
ErbB1, ErbB2 
2011 Vandetanib 
N
O
O
N
N
HN
F Br  
ErbB1 
2012 Pertuzumab Antibody ErbB2 
KF has completed phase I and phase II clinical trials to treat various solid tumors, such as 
melanoma, colorectal, no-small cell lung, pancreas, prostate cancers,23,24,25 and psoriasis.26 IsoKF 
was in a late phase I study with preliminary evidence of antitumor activity. However, both KF 
and isoKF were discontinued for treatment of cancers recently, in part due to a short half-life (35 
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minutes) and limited efficacy. One goal of this project was to modify KF to produce analogues 
with a higher potency, better delivery, or longer half-life. An SAR of over 130 KF analogues has 
been studied based on an SPPS approach by replacing different amino acid residues.27,28 
However, this total synthesis approach has several drawbacks. Although the SPPS technique is 
well developed, more than 29 steps were involved in the synthesis of KF and its analogues.27 
Challenges such as the peptide cyclization by coupling L-Phe3 with D-Val4 and the formation of 
Z-didehydroaminobutyric acid2 [(Z)-Dhb2] residue decreased the overall yield. Additionally, it is 
estimated to cost over one million dollars to synthesize 1 kg of KF partly due to the high cost of 
Fmoc-D-allo-Ile and Fmoc-D-allo-Thr. A semisynthetic approach based on natural KF isolated 
from B. pennata could provide a less expensive method to produce KF analogues. B. pennata is a 
potentially invasive green alga native in Hawaii.29 When conditions are favorable, B. pennata 
grows quickly and becomes toxic to most herbivorous organisms due to its secondary 
metabolites, thus damaging the ecosystem.29 During the algal bloom season, considerable 
quantities B. pennata is washed onto the seashore. Tons of algae producing kgs of the KF (0.003% 
yield11) can be collected easily. This approach can not only provide a sustainable resource of KF, 
but also benefit environmental improvement. Additionally, the discovery of a culturable 
bacterium provides another opportunity for the sustainable supply of KF.13 Our group has 
synthesized several Orn- derivatives using the semisynthetic approach. Two analogues showed a 
similar or higher potency in selected cancer cell lines.30,31 In this study, an addition of amino acid 
residue on the side chain, the modifications of L-Orn8 and L-Thr12, as well as the formation of a 
new cyclic peptide system were performed to produce KF analogues 1-15 (Figure 9).   
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Compound R1                  R2 Compound R1                   R2 
isoKF (1) H 
H
N
O
O  
D-Phe14-isoKF (7) H HN
O
N
H O
O
 
de-D-Val13-
isoKF (2) H 
O
 
3,4-2F-D-Phe14-
isoKF (8) H HN
O
N
H O
O
F
F
 
D-Val14-isoKF 
(3) H 
H
N
O
N
H O
O
 
carbamyl-KF (9) 
HO
 
H
N
O
O
H
N
O
O
;
 
Val13-Val14-
isoKF (4) H 
H
N
O
N
H O
O
 
carbamyl-de-D-
Val13-isoKF (10) 
HO
 
O
 
D-Leu14-
isoKF (5) H 
H
N
O
N
H O
O
 
4Mecaproyl-de-D-
Val13-isoKF (11) 
O
 
O
 
D-Pro14-isoKF 
(6) H 
H
N
O
O
N
O
 
benzoquinone-KF 
(15) 
O
O
O
 
H
N
O
O
H
N
O
O
;
 
 
Figure 9 Structures of KF analogues  
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2. Results and Discussion 
2.1 Amino Acid Chain Elongation of KF.  According to the SAR study, KF analogues with 
focusing on halogenations of L-Phe3, modifications of L-Orn8, as well as replacements of L-
Thr12 and MeHex with lower polar residues displayed an increase of activity or selectivity.30,32 
Moreover, the 4S-configured MeHex of the N-terminal aliphatic chain can improve the efficacy 
in the xenograft murine model.33 The elongation of the N-terminal aliphatic chain caused 
increased activity,32 which could be attributed to improvement of membrane permeability. 
However, no modification focused on elongation of the side chain of amino acid residues has 
been completed thus far. There was evidence that the substitution of D-configured amino acid 
residue with L-configured might lead to a loss or decrease of activity.34 This is likely attributed to 
the preference of the D-amino acid on the target protein binding site over its L-amino acid 
counterpart.35 In addition, introduction of the D-amino acids may prevent the degradation of 
peptides and consequently enhance the metabolic stability.36 Therefore, elongation with nonploar 
amino acids, mostly D-configured, was explored. Considering that isoKF showed a better 
efficacy than KF in vivo, 4-MeHex was used as the side chain in all the analogues. An analogue 
with the deletion of D-Val13 (2) was prepared to compare the biological activity (Table 2).  
The amino group of L-Orn8 was protected using Fmoc-OSu. N-protected KF was 
hydrolyzed at the amide linkage between L-Thr12 and D-Val13 using MeOH – 6 M HCl (2:1) at 
70 ℃ for 12 hours. The synthesis of C-terminal fragment was started with the formation of 
hexanoic succinimide ester by reacting 4-methylhexanoic acid with HOSu using anhydrous 
DCM in the presence of 2 eq. of EDCI for 2 days, followed by reaction with mono- or di- 
peptides. Final coupling reactions were performed between the Fmoc-KF hydrolysis product and 
the C-terminal fragment in anhydrous DMF using 5 eq. EDCI and HOBt for 2 days, followed by 
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the deprotection of the Fmoc group using 10% piperidine in DMF for 2 hours (Scheme 1). The 
products were purified by HPLC. The overall yield (synthesis and purification) was 45.3%. 
Table 2 Structures of KF analogues 1-8 
        
  isoKF     (1) 
de-D-Val13-
isoKF (2) 
D-Val14-
isoKF (3) 
Val13-Val14-
isoKF (4) 
D-Leu14-
isoKF (5) 
D-Pro14-
isoKF (6) 
D-Phe14-
isoKF (7) 
3,4-2F-D-Phe14-
isoKF (8) 
Structure AA13 D-Val - D-Val L-Val D-Val D-Val D-Val D-Val 
 AA14 - - D-Val L-Val D-Leu trans-D-Pro D-Phe 3,4-2F-D-Phe 
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Scheme 1 Elongation of the amino acid chain of KF 
When performing the partial hydrolysis of Fmoc-KF at 70-80 ℃, a cleavage of the amide 
bond between L-Thr12 and D-Val13 was predominant (70% yield). It is hypothesized that the 
release of the MeHex-D-Val13 fragment is kinetically faster than any other residue, which could 
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result from the presence of the hydroxy group of L-Thr12. The proposed mechanism of the 
partial hydrolysis is based on N→O acyl rearrangement.37 The oxygens on the amide carbonyl 
groups would be protonated under acidic conditions. Only when the nucleophilic β-hydroxy 
group interacts with the carbonyl of D-Val13, a hydroxyoxazolidine could be formed as an 
intermediate, followed by acyl rearrangement to produce an ester which is more easily 
hydrolyzed than the amide linkage (Scheme 2).   
 
Scheme 2 Proposed mechanism of the partial hydrolysis of Fmoc-KF 
In the amidation reaction, EDCI was used as a coupling reagent and HOBt as an activator 
to improve the yield of the reactions (Scheme 3). The amino group may be deprotonated in the 
presence of a base, thus facilitating the reaction. However, even a weak base has the potential to 
cause the racemization of amino acid residues by attacking the α-proton on the amino acid 
residues (Scheme 4). Hence, the presence of base was avoided in the reactions. Another key 
factor in the amidation is to keep the reaction in an anhydrous condition, especially in a small-
scale coupling reaction. Even a small amount of water could cause a low yield of the amide 
product. The challenge was that most of the synthetic C-terminal fragments were obtained as 
sticky solid, from which the water is difficult to remove. Therefore, an excess, mostly 5 eq. of 
EDCI was applied. An excess of EDCI is capable of absorbing water in the reagent or solvent to 
form a urea, thus facilitating the coupling reaction (Scheme 5).     
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Scheme 3 Mechanism of EDCI coupling 
 
 
Scheme 4 Mechanism of racemization of peptide 
 
 
Scheme 5 Formation of a urea when EDCI reacting with water 
The structures of amino acid elongation analogues are confirmed with HRMS, 1H, 13C, 
and/or HSQC NMR overlay experiments. Product 1 is the semisynthetic isoKF. It provided the 
same quasi-molecular ion signals as KF of [M+2H]2+ at m/z 739.4842, [M+H+Na]2+ at m/z 
750.4757, [M+H]+ at m/z 1477.9453 for a molecular formula of C75H125N14O16 (calc. 
1477.9393, Δ +4.1 ppm) (Figure 10). The only difference between 1 and natural KF is that the 
aliphatic chain of natural KF is a mixture of 4-MeHex and 5-MeHex, while that of 1 is 4-MeHex. 
The 1H NMR spectrum of 1 did not show significant difference with KF (Figure 11). However, 
comparison of the 13C NMR spectra between 1 and KF suggested that signals at δC 22.84, 22.89, 
23.61, 27.66, 35.74, 39.13, and 172.98, which are corresponding to 5-MeHex, were missing from 
1 (Figures 12, 13). Therefore, the structure of 1 was confirmed. 
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Figure 10 HRMS spectrum of isoKF (1) 
 
Figure 11 1H NMR spectra of KF (top) and isoKF (1) (bottom) in DMSO-d6 
 
[M+H+Na]2+ 
[M+H]+ 
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Figure 12 13C NMR spectra of KF (top) and isoKF (1) (bottom) in DMSO-d6 
 
Figure 13 13C NMR spectra (δC 10-40, 165-175) of KF (top) and isoKF (1) (bottom) 
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De-D-Val13-isoKF (2) is a molecule with the deletion of D-Val13 compared to isoKF. The 
analogue provided quasi-molecular ion signals of [M+H+Na]2+ at m/z 711.8873, [M+Na]+ at m/z 
1400.8471 for a molecular formula of C70H115N13NaO15 (calc. 1400.8533, Δ -4.4 ppm) (Figure 
14). Comparison of the 13C NMR spectra between isoKF and 2 suggested that 2 lost the signals 
at δC 18.60, 19.86, 28.16, 58.20, and 171.97 representing the residue D-Val13 (Figures 15-17). 
Carbonyl groups at δC 173.19, 171.39, 170.24, and 170.15 corresponding to 4-MeHex, L-Thr12, 
L-Val11, and D-Val10 shifted downfield due to the deletion of D-Val13. 
 
Figure 14 HRMS spectrum of de-D-Val13-isoKF (2) 
[M+Na]+ 
isoKF-99 Da 
[M+H+Na]2+ 
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Figure 15 13C NMR spectrum of de-D-Val13-isoKF (2) in DMSO-d6 
 
Figure 16 13C NMR spectra (δC 166-176) of isoKF (top) and de-D-Val13-isoKF (2) (bottom) 
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Figure 17 13C NMR spectra (δC 16-60) of isoKF (top) and de-D-Val13-isoKF (2) (bottom) 
D-Val14-isoKF (3) is the molecule with an addition of D-Val14 compared to isoKF, and 
Val13-Val14-isoKF (4) is the molecule replacing D-Val13 and D-Val14 of D-Val14-isoKF (3) 
with L-Val13 and L-Val14. They provided quasi-molecular ion signals [M+H]+ at m/z 1577.0082, 
1577.0137, respectively, for the same molecular formula of C80H134N15O17 (calc. 1577.0077, Δ 
+0.3 ppm, +3.8 ppm, respectively)  (Figures 18, 21). An HSQC overlay experiment as well as 
comparison of the 13C NMR chemical shift in amide carbonyl and α-carbon regions between 
isoKF and 3, 4 did not show significant differences (Figure 19). This could result from similar 
chemical shifts of added Val residue with D-Val13. However, additional methyl groups at δC 
18.29 and 19.75 in 3, δC 18.31 and 19.74 in 4 suggested the presence of one more Val residue 
(Figures 20, 22).  
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Figure 18 HRMS spectrum of D-Val14-isoKF (3) 
 
Figure 19 13C NMR spectra in carbonyl and α-carbon regions of isoKF (top), D-Val14-isoKF (3) 
(middle), and Val13-Val14-isoKF (4) (bottom) 
[M+H]+ 
isoKF+99 Da 
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Figure 20 13C NMR spectra (δC 14-22) of isoKF (top) and D-Val14-isoKF (3) (bottom) 
 
Figure 21 HRMS spectrum of Val13-Val14-isoKF (4) 
[M+H]+ 
isoKF+99 Da 
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Figure 22 13C NMR spectra (δC 16-22) of isoKF (top) and Val13-Val14-isoKF (4) (bottom) 
D-Leu14-isoKF (5), D-Pro14-isoKF (6), D-Phe14-isoKF (7), and 3,4-2F-D-Phe14-isoKF 
(8) provided a quasi-molecular ion [M+H]+ or [M+Na]+ signal corresponding to their molecular 
formula, respectively (Table 3; Figures 23, 25, 27, 30). Their HSQC overlay experiments with 
isoKF suggested an addition of one amino acid residue (Figures 24, 26, 29, 32). It was observed 
that in D-Phe14-isoKF (7) and 3,4-2F-D-Phe14-isoKF (8), carbon signals at δC 29.08, 29.17, 
32.42, 32.47, 33.34, 33.98 corresponding to C-2, C-3 and C-4 at both 4S- and 4R- MeHex shifted 
upfield (Figures 28, 31). This shielding effect due to the adjacent aromatic ring system 
confirmed the structures of 7 and 8.  
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Table 3 1H and 13C NMR data of additional amino acid residues of 5-8 a (δ in ppm, DMSO-d6)  
Compound HRMS Formula Amino acid Carbon δC, mult δC, mult  
D-Leu14-isoKF 
(5) 
1591.0335 C81H136N15O17 D-Leu 14 1 172.85, qC  
[M+H]+   2 51.45, CH 4.36, m 
    3 41.26, CH2 1.41, 1.48, m 
    4 24.96, CH 1.58, m 
    5 23.20, CH3 0.86, m 
    6 22.17, CH3 0.83, m 
D-Pro14-isoKF 
(6) 
1596.9690 C80H131N15NaO17 D-Pro 14 1 172.18, qC  
[M+Na]+   2 59.65, CH 4.49, m  
    3 31.85, CH2 2.00, 2.26, m 
    4 26.49, CH2 1.36, 1.51, m 
    5 46.48, CH2 3.38, 3.52, m 
D-Phe14-isoKF 
(7) 
1625.0131 C84H134N15O17 D-Phe 14 1 171.41, qC  
[M+H]+   2 54.10, CH 4.60, m 
    3 37.48, CH2 2.75, 3.05, m 
    4 138.67, qC  
    5,5' 129.56, CH 7.15, m 
    6,6' 128.29, CH 7.17, m 
    7 126.53, CH 7.20, m 
3,4-2F-D-Phe14-
isoKF (8) 
1660.9999 C81H132F2N15O17 3,4-2F-D-Phe 14 1 171.48, qC  
[M+H]+   2 54.09, CH 4.62, m 
   3 37.14, CH2 2.72, 2.98, m 
    4 136.24, qC  
    5 117.3, CH 7.26, m 
    6 149.46, qC  
    7 148.45, qC  
    8 118.58, CH 7.30, m 
    9 126.48, CH 7.07, m 
aAssignments based on 1H, 13C, and HSQC NMR (100/400 MHz) experiments at room temperature.  
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Figure 23 HRMS spectrum of D-Leu14-isoKF (5) 
 
Figure 24 HSQC spectra overlay of isoKF (green) and D-Leu14-isoKF (5) (red) in DMSO-d6 
[M+H]+ 
isoKF+113 Da 
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Figure 25 HRMS spectrum of D-Pro14-isoKF (6) 
 
Figure 26 HSQC spectra overlay of isoKF (green) and D-Pro14-isoKF 6 (red) in DMSO-d6 
[M+Na]+ 
isoKF+97 Da 
[M+H+Na]2+ 
[M+2Na]2+ 
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Figure 27 HRMS spectrum of D-Phe14-isoKF (7) 
 
Figure 28 13C NMR spectra (δC 120-142) of isoKF (top) and D-Phe14-isoKF (7) (bottom) in 
DMSO-d6 
[M+H]+ 
isoKF+147 Da 
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Figure 29 HSQC spectra overlay of isoKF (green) and D-Phe14-isoKF (7) (red) in DMSO-d6 
 
Figure 30 HRMS spectrum of 3,4-2F-D-Phe14-isoKF (8) 
[M+H]+ 
isoKF+183 Da 
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Figure 31 13C NMR spectrum of 3,4-2F-D-Phe14-isoKF (8) in DMSO-d6 
 
Figure 32 HSQC spectra overlay of isoKF (green) and 3,4-2F-D-Phe14-isoKF (8) (red) in 
DMSO-d6 
31 
 
For the first attempt of N-protection of KF, Fmoc-Cl in the presence of 0.25 eq. DMAP in 
DMF was used. However, carbamyl-KF (9) was the major product. 9 provided a quasi-molecular 
ion signal [M+Na]+ at m/z 1527.9134 for the molecular formula of C76H124N14NaO17 (calc. 
1527.9167, Δ -2.2 ppm), which was 28 Da more than KF (Figure 33). Comparison of 9 with KF 
in the amide carbonyl region implied that 9 has one more amide or ester carbonyl signal at δC 
161.38. Carbonyl groups of L-Orn8 and D-Pro9 in 9 had minor shifts demonstrating that the 
addition had occurred at the L-Orn8 residue (Figure 34). The HMBC spectrum of 9 displayed a 
correlation between the new carbonyl and methylene on L-Orn8 at δC 37.21. The 13C satellites of 
δH 7.95 in the HMBC spectrum suggested its HSQC correlation with the new carbonyl signal, 
thus confirming the formamide linkage at L-Orn8 (Figure 35). Partial hydrolysis of both KF and 
9 followed by the coupling reactions using the same approach as listed in Scheme 1 produced 
carbamyl-de-DV13-isoKF (10) and 4MeCap-de-D-Val13-isoKF (11). Compound 10 provided a 
quasi-molecular ion signal [M+Na]+ at m/z 1428.8409 for the molecular formula of 
C71H115N13NaO16 (calc. 1428.8482, Δ -5.1 ppm) (Figure 36). It also displayed a formamide 
carbonyl signal at δC 161.74 (Figure 37). Compound 11 provided a quasi-molecular ion signal 
[M+Na]+ at m/z 1512.9361 for the molecular formula of C77H127N13NaO16 (calc. 1512.9421, Δ -
3.9 ppm) (Figure 38). Its 13C NMR spectrum displayed that the formamide carbonyl was missing. 
Instead, an amide carbonyl at δC 172.66, one methine at δC 33.94, three methylenes at δC 33.93, 
33.45, and 29.12, two methyls at δC 19.29 and 11.60 were observed, indicating the presence of 
an additional 4-MeHex group at L-Orn8 (Figures 39-41). 
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Figure 33 HRMS spectrum of carbamyl-KF (9) 
 
 
Figure 34 13C NMR spectra (δC 158-176) of isoKF (green) and carbamyl-KF (9) (red) 
[M+Na]+ 
KF+28 Da 
[M+2Na]2+ 
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Figure 35 HMBC spectrum of carbamyl-KF (9) in DMSO-d6 
 
Figure 36 HRMS spectrum of carbamyl-de-D-Val13-isoKF (10) 
[M+Na]+ 
carbamyl-KF-99 Da 
[M+2Na]2+ 
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Figure 37 13C NMR spectrum of carbamyl-de-D-Val13-isoKF (10) in DMSO-d6 
 
Figure 38 HRMS spectrum of 4MeCap-de-D-Val13-isoKF (11) 
[M+Na]+ 
carbamyl-de-D-Val13-isoKF+84 Da 
[M+2Na]2+ 
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, 
Figure 39 13C NMR spectra (δC 160-176) of carbamyl-de-D-Val13-isoKF (10) (top) and 
4MeCap-de-D-Val13-isoKF (11) (bottom) in DMSO-d6 
 
Figure 40 13C NMR spectra (δC 11-35) of carbamyl-de-D-Val13-isoKF (10) (top) and 4MeCap-
de-D-Val13-isoKF (11) (bottom) in DMSO-d6 
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Figure 41 13C NMR spectrum of 4MeCap-de-D-Val13-isoKF (11) in DMSO-d6 
2.2 Modification of L-Thr12. Published SAR results showed that the hydroxy group of L-Thr12 
was not necessary for the activity. Additionally, the replacement of L-Thr12 into a nonpolar 
amino acid residue may increase the activity.27 Therefore, modifications by either fluorination or 
dehydration of L-Thr12 were performed using BAST. BAST and its older generation agent 
DAST are commonly used in fluorination and dehydration reactions of hydroxy group.38,39 
BAST is thermally stable and more capable to perform the reactions in a high yield.40 In the 
presence of fluorinating agents, the hydroxy group could attack the reagent at sulfur, thus 
eliminating hydrogen fluoride to form an alkoxyaminosulfur difluoride as an intermediate. 
Nucleophilic attack on different positions could generate possible products such as fluorinated 
and oxazoline through either SN1 or SN2 reactions. In some cases, the elimination could occur to 
produce an olefin under the anhydrous condition (Scheme 6). In the reaction attempted, only the 
olefin (Z)-Dhb12-KF (12) was detected (20% yield). It was reported that a trace amount of water 
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could help the release of HF, thus stabilizing the intermediate and promoting the fluorination.41 
However, no fluorinated product was observed even in the presence of traces of water. This 
could result from the steric hindrance of KF.  
 
Scheme 6 Possible reactions on L-Thr12 catalyzed by BAST 
(Z)-Dhb12-KF (12) provided quasi-molecular ion signals [M+H+Na]2+ at m/z 741.4714,  
[M+H]+ at m/z 1459.9350 for the molecular formula of C75H123N14O15 (calc. 1459.9287, Δ +4.3 
ppm) (Figure 42). Comparison of its 1H NMR spectrum with that of KF demonstrated the 
presence of an olefinic proton at δH 6.42 (q, J=6.9) (Figure 43). The HSQC overlay experiment 
showed that 12 lost a hydroxy group at L-Thr12, and the methyl group moved up filed to δC 
13.66, thus confirming the formation of a double bond between the α- and β- carbons at L-Thr12 
(Figure 44). The coupling constant of new olefinic proton determined the double bond is Z-
configured. 
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Figure 42 HRMS spectrum of (Z)-Dhb12-KF (12) 
 
Figure 43 1H NMR spectra of KFs (top) and (Z)-Dhb12-KF (12) (bottom) in DMSO-d6 
[M+H]+ 
KF-18 Da 
[M+H+Na]2+ 
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Figure 44 HSQC spectra overlay of KFs (green) and (Z)-Dhb12-KF (12) (red) in DMSO-d6 
2.3 Cyclization of Kahalalide G. An enzymatic stability study of KF demonstrated that the 
transformation of KF into kahalalide G (KG) by esterase could be one option for the inactivation 
of KF.42 It was hypothesized that an amide bond could be more stable than the ester bond in KF. 
Therefore, a coupling reaction of KG was performed to generate a new cyclic peptide as cyclo-
isoKG (13) and its isomer cyclo-KG (14) (Scheme 7).  
 
Scheme 7 Cyclization of kahalalide G 
Cyclo-isoKG (13) and cyclo-KG (14) provided a quasi-molecular ion [M+Na]+ at m/z 
1499.9186 or 1499.9141, respectively, for the same molecular formula as KF of 
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C75H124N14NaO16 (calc. 1499.9217, Δ -2.1 ppm or -5.1 ppm, respectively) (Figures 45, 49). 1H 
NMR spectra of 13 and 14 did not show difference. However, they shifted significantly in both 
amide-proton and α-proton regions when compared to KF (Figure 46). The HSQC overlay 
between KF and 13/14 (Figures 47, 50) showed that the β-proton of D-allo-Thr6 shifted upfield 
from δH 4.96 to δH 3.76 suggesting the presence of a free hydroxy group. The α-carbon of L-Orn 
8 shifted downfield from δC 51.65 to δC 53.34 suggesting the change of chemical environment. 
Additionally, the α-proton of L-Val1 and δ-protons of L-Orn8 shifted downfield from δH 3.85 to 
δH 4.26, δH 2.74 to δH 3.01 and 3.15, respectively. This deshielding effect indicated the 
formation of a new amide linkage between L-Val1 and L-Orn8. There were correlations between 
α-proton of L-Val1 and δ-protons of L-Orn8 observed in the NOESY spectrum, which confirmed 
the formation of a new cyclic peptide (Figure 48). Both carbon and proton chemical shifts of 
(Z)-Dhb2, L-Phe3, D-allo-Ile7, and D-Pro9 in 13/14 varied compared to KF (Table 4). The 
variance was attributed to the intramolecular interactions between amino acid residues in the new 
ring system. The difference between 13 and 14 was the signals in the methylene and methyl 
regions corresponding to the MeHex lipid chain. The HSQC overlay between KF, 13, and 14 
showed that geminal methyl groups at δC 22.5 were missing from 13, which suggested that 13 is 
the analogue with 4-MeHex residue. Carbon signals at δC 33.7, 33.1, 32.3, and 29.4 
corresponding to 4-MeHex residue were missing from 14, which confirmed that 14 is the 
molecule with 5-MeHex residue (Figure 50). 
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Table 4 Selected 1H and 13C NMR data of KF, 13 and 14a (δ in ppm, DMSO-d6) 
  KF 13 & 14 
Amino acid Carbon δC, mult. δH, mult.  δC, mult. δH, mult.  
L-Val1 1 169.82, qC (NH) 7.59  (NH) 7.33 
 2 60.46, CH 3.85, t 58.48, CH 4.17, m 
 3 29.92, CH 1.97, m 30.78, CH 1.78, m 
 4 19.19, CH3 0.81, m 19.65, CH3 0.83, m 
 5 18.63, CH3 0.83, m 18.69, CH3 0.85, m 
(Z)-Dhb2 1 163.66, qC (NH) 9.70   (NH) 9.31 
 2 130.54, CH 6.35, q  130.63, CH 6.43, q 
 3 130.27, qC    
 4 12.74, CH3 1.27, d  13.14, CH3 1.49, d 
L-Phe3 1 171.76, qC (NH) 8.55  (NH) 8.28 
 2 56.13, CH  4.42, bs 55.19, CH 4.55, bs 
 3 36.59, CH2  2.97, bs  38.41, CH2 2.83, 3.15, dd 
 4 137.26, qC  138.06, qC  
 5,5' 128.64, CH 7.25, m 128.58, CH 7.25, d 
 6,6' 129.67, CH 7.26, m 129.68, CH 7.26, t 
 7 126.96 7.20, m 126.85, CH 7.18, m  
L-Thr6 1 170.15, qC (NH) 7.64  (NH) 7.43 
 2 56.75, CH  4.52, m 57.97, CH 4.40, t 
 3 70.24, CH 4.96, m 68.98, CH 3.76, m 
 4 17.25, CH3 1.09, d 20.58, CH3 1.05, d 
D-allo-Ile7 1 171.45 (NH) 7.82   (NH) 7.32 
 2 56.15, CH 4.36, m 56.36, CH 4.24, m 
 3 38.50, CH 1.71, m 35.89, CH 1.92, m 
 4 14.93, CH3 0.76, m 14.79, CH3 0.74, m 
 5 26.19, CH2 1.01, 1.32, m 26.01, CH2 1.02, 1.29, m 
 6 11.87, CH3 0.81, m 11.74, CH3 0.80, m 
L-Orn8 1 172.70, qC (NH) 7.92  (NH) 7.29 
 2 51.65, CH 4.46, m 53.34, CH 4.11, m 
 3 30.55, CH2 1.96, m 30.04, CH2 1.76, m 
 4 23.84, CH2 1.49, m 23.58, CH2 1.47, m 
 5 38.95, CH2 2.74, bs 38.50, CH2 3.01, 3.15, bs 
D-Pro9 1 172.01, qC    
 2 59.86, CH 4.39, m 60.32, CH 4.26, m 
 3 29.96, CH2 1.78, 1.97, m 29.79, CH2 1.55, 1.72, m 
 4 25.14, CH2 1.79, 1.85, m 24.97, CH2 1.77, 1.93, m 
 5 47.67, CH2 3.54, 3.79, m 47.81, CH2 3.55, 3.80, m 
aAssignments based on 1H, 13C, HSQC, and NOESY NMR (100/400 MHz) experiments at room temperature.  
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Figure 45 HRMS spectrum of cyclo-isoKG (13) 
 
Figure 46 1H NMR spectra of KF (top), cyclo-isoKG (13) (middle) and cyclo-KG (14) (bottom) 
in DMSO-d6 
[M+Na]+ 
Same as KF 
[M+H+Na]2+ 
[M+2Na]2+ 
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Figure 47 HSQC spectra overlay of KF (green) and cyclo-isoKG (13) (red) in DMSO-d6  
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Figure 48 NOESY spectrum of cyclo-isoKG (13) in DMSO-d6 
 
Figure 49 HRMS spectrum of cyclo-KG (14) 
[M+Na]+ 
Same as KF 
[M+2Na]2+ 
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Figure 50 HSQC spectra overlay of KF (green) and cyclo-KG (14) (red) in DMSO-d6 
2.4 N-amidation Based on The Target Delivery Approach. Target delivery of cytotoxic 
molecules could help to release active compounds in cancer cells selectively, avoid its 
degradation, thus improving the therapeutic efficacy. Hypoxia in tumor tissues leads to tumor 
progression by adaptive responses of tumor cells including enhanced migration of endothelial 
cells and therapy resistance, which results in poor prognosis and patient outcomes.43 Cancer cells 
are known to express elevated levels of DT-diaphorase [NAD(P)H dehydrogenase] that catalyzes 
a two-electron reduction of quinones into hydroquinones. It is proposed that a benzoquinone 
derived KF analogue may be reduced by DT-diaphorase under hypoxia conditions, and release 
KF to inhibit tumor growth. Under normoxic conditions, benzoquinone reduction does not occur 
due to the reversible oxidation in the presence of oxygen (Scheme 8). Therefore, a benzoquinone 
derivative of KF (15) was synthesized starting from the formation of an NBS-modified 
benzoquinone acid, followed by synthesis of its succinimide ester by reacting with 1 eq. of 
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HOSu using THF in the presence of 2 eq. EDCI at 0 ℃ for 12 hr. The succinimide ester of a 
benzoquinone derivative then reacted with 1 eq. of KF using MeCN-DMSO (8:2) for 8 hr to 
yield benzoquinone-KF (15) (Scheme 9).  
 
Scheme 8 Activation of KF by DT-diaphorase in hypoxic cancer cells 
 
 
Scheme 9 Synthesis of benzoquinone-KF (15) 
Benzoquinone-KF (15) provided a quasi-molecular ion of [M+Na]+ at m/z 1732.0382 for 
the molecular formula of C89H140N14NaO19 (calc. 1732.0317, Δ +3.8 ppm) (Figure 51).  
Comparison of 1H NMR spectra of KF and 15 displayed that 15 has five additional methyl 
groups at δH 1.33, 1.92, 19.6, and 2.05 (Figure 52). The 13C NMR spectrum of 15 indicated the 
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presence of one benzoquinone, five methyls, one methylene, and one quaternary carbon (Table 
5). The proton signal of δ-C at L-Orn8 shifted downfield from δH 2.74 to δH 2.89. The addition 
of amide signals at δC 171.61, δH 7.82 were observed. The results indicated the formation of a 
new amide linkage of 15 at L-Orn8 residue (Figures 53, 54). There were correlations between 
the new amide proton, δ-protons of L-Orn8, and β-protons of the benzoquinone residue observed 
in the NOESY spectrum (Figure 55), which confirmed the structure of 15.  
Table 5 Additional 1H and 13C NMR signals of 15a (δ in ppm, DMSO-d6) 
Carbon δC, mult. δH, mult. Carbon δC, mult. δH, mult. 
1 171.61, qC (NH) 7.82, m   8 190.59, qC  
2 48.02, CH2 2.66, s   9 136.41, qC  
3 37.66, qC  10 135.69, qC  
4 28.42, CH3 1.33, s 11 187.22, qC  
5 28.42, CH3 1.33, s 12 14.06, CH3 2.05, s 
6 155.32, qC  13 13.15, CH3 1.96, s 
7 144.50, qC  14 12.07, CH3 1.92, s 
aAssignments based on 1H, 13C, and HSQC  NMR (100/400 MHz) experiments at room temperature.  
 
Figure 51 HRMS spectrum of benzoquinone-KF (15) 
[M+Na]+ 
KF+233 Da 
[M+2Na]2+ 
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Figure 52 1H NMR spectra of KF (top) and benzoquinone-KF (15) (bottom) in DMSO-d6 
 
Figure 53 13C NMR spectra (δC 110-200) of KF (top) and benzoquinone-KF (15) (bottom) in 
DMSO-d6 
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Figure 54 13C NMR spectra (δC 10-50) of KF (top) and benzoquinone-KF (15) (bottom) in 
DMSO-d6 
 
Figure 55 NOESY spectrum of benzoquinone-KF (15) in DMSO-d6 
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3. Materials and Methods 
3.1 General Experimental Procedures.  NMR spectra were recorded on a Bruker Avance 
DRX-400 spectrometer. The 1H and 13C NMR chemical shifts were reported in ppm. IR spectra 
were measured on a PerkinElmer Spectrum 100 FT-IR spectrometer. HPLC-ESI-TOF was 
performed on Bruker MicroTOF spectrometer in line with an Agilent 1100 Series HPLC system 
and G1316A DAD detector. Preparative HPLC was carried out on a Waters PrepLC system with 
a single wavelength detector. Phenomenex Luna C18 5 µm column (250 mm × 20.2 mm) was 
used. Optical rotations were measured on a JASCO DIP-370 polarimeter. The succinimide ester 
of bezoquinone derivative, 3-methyl-3-(2,3,5-trimethyl-1,4-benzoquinonyl)butanoic succinimide 
ester, was kindly provided by Dr. Seongbong Jo of the Department of Pharmaceutics, The 
University of Mississippi. All other reagents were purchased from Sigma-Aldrich.  
3.2 Elongation of Amino Acid Chain on KF (1-8).  4-Methylhexanoic acid (1 mmol) was 
dissolved in 25 mL anhydrous DCM, HOSu (1 eq.) and EDCI (2 eq.) were added. The mixture 
was stirred at room temperature for 1 d, water (25 mL) was then added. The mixture was 
extracted with EtOAc three times. The combined organic layers were evapored under vacuum. 
The resulting residue was purified by flash silica chromatography using hexanes-EtOAc (8:2). 
N-Boc protected amino acid (0.1 mmol) was dissolved in 3 mL anhydrous DMF, HOSu 
(1 eq.) and EDCI (2 eq.) were added. The mixture was stirred at room temperature for 2 d, and 
extracted with DCM-H2O (2:1) (3×10 mL). The combined organic layers were evapored under 
vacuum. The second amino acid (0.1mmol) was added and dissolved in 5mL DMSO. The 
mixture was stirred at room temperature for 1 or 2 d and the solvent was evaporated under 
vacuum. The product was purified using C18 glass open-tubular column with MeCN-H2O (1:1). 
Purified product was dissolved in TFA-H2O (1:1) and stirred at room temperature for 1 h. The 
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solution was concentrated in vacuum and purified using C18 glass open-tubular column with 
H2O to afford a dipeptide.    
Purified 4-methylhexanoic ester (0.05 mmol) and dipeptide (0.05 mmol) were dissolved 
in 2 mL DMSO. The mixture was stirred at room temperature for 1 d and the solvent was 
evaporated under vacuum. The product was purified by HPLC using a C18 5 µm column (250 
mm × 20.2 mm) with a gradient elution of MeCN-H2O from 20:80 to 80:20 at a flow rate of 8.0 
mL/min to afford the C-terminal fragment.  
KF (450 mg, 0.3 mmol) was dissolved in MeCN-DMSO (8:2) solution, Fmoc-OSu (1.5 
eq.) was slowly added. The reaction mixture was stirred at room temperature for 8 h and the 
solvent was evaporated under vacuum. The product was purified by HPLC using a C18 5 µm 
column (250 mm × 20.2 mm) with a gradient elution of MeCN-H2O in 0.05% HCOOH from 
50:50 to 100:0 at a flow rate of 8.0 mL/min to afford Fmoc-KF (90% yield). Fmoc-KF was 
dissolved in 6 M HCl-MeOH (1:2), and stirred under reflux at 70 ℃ for 12 h. The solvent was 
evaporated under vacuum and the product was purified by HPLC using a C18 5 µm column (250 
mm × 20.2 mm) with a gradient elution of MeCN-H2O in 0.05% HCOOH from 20:80 to 80:20 at 
a flow rate of 8.0 mL/min to afford the partial hydrolyzed Fmoc-KF (70% yield).  
Partial hydrolyzed Fmoc-KF (10mg, 6.7 μmol), synthesized C-terminal fragment (1.5 
eq.), EDCI (5 eq.) and HOBt (5 eq.) were dissolved in 2 mL anhydrous DMF. The mixture was 
stirred at room temperature for 2 d and the solvent was evaporated under vacuum. The product 
was purified by HPLC using a C18 5 µm column (250 mm × 20.2 mm) with a gradient elution of 
MeCN-H2O in 0.05% HCOOH from 50:50 to 100:0 at a flow rate of 8.0 mL/min (80% yield). 
The coupling product was deprotected using 10% piperidine in 1 mL DMSO at room 
temperature for 2 h and the solvent was evaporated under vacuum, followed by HPLC 
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purification using a C18 5 µm column (250 mm × 20.2 mm) with a gradient elution of MeCN-
H2O in 0.05% HCOOH from 20:80 to 80:20 at a flow rate of 8.0 mL/min to afford 1-8 (90% 
yield). 
1 (6.2 mg) was obtained as white amorphous powder. [α]25D   -14 (c 0.1, MeOH); UV λmax 
(MeOH) 205, 224 nm; IR neat (KBr) 3280 (s, br), 2964 (s), 2932 (s), 2877 (s), 1736 (s), 1632 (s), 
1514 (s), 1465 (s), 1383 (s), 1342 (s), 1227 (s), 1025 (s) cm-1; HRMS m/z calc. for 
C75H125N14O16 [M+H]+ 1477.9393, detected 1477.9453. 
2 (6.5 mg) was obtained as white amorphous powder. [α]25D   -32 (c 0.1, MeOH); UV 
(DAD) λmax (MeOH) 205, 224  nm; IR neat (KBr) 3280 (s, br), 2965 (s), 2932 (s), 2876 (s), 1736 
(s), 1633 (s), 1515 (s), 1464 (s), 1383 (s), 1341 (s), 1226 (s), 1024 (s) cm-1; HRMS m/z calc. for 
C70H115N13NaO15 [M+Na]+ 1400.8533, detected 1400.8471. 
3 (6.1 mg) was obtained as white amorphous powder. [α]25D   -16 (c 0.1, MeOH); UV 
(DAD) λmax (MeOH) 205, 224  nm; IR neat (KBr) 3280 (s, br), 2964 (s), 2932 (s), 2876 (s), 1736 
(s), 1633 (s), 1515 (s), 1464 (s), 1383 (s), 1342 (s), 1227 (s), 1025 (s) cm-1; HRMS m/z calc. for 
C80H134N15O17 [M+H]+ 1577.0077, detected 1577.0082. 
4 (6.4 mg) was obtained as white amorphous powder. [α]25D   -14 (c 0.1, MeOH); UV 
(DAD) λmax (MeOH) 205, 224  nm; IR neat (KBr) 3280 (s, br), 2964 (s), 2932 (s), 2876 (s), 1736 
(s), 1633 (s), 1515 (s), 1464 (s), 1383 (s), 1342 (s), 1227 (s), 1025 (s) cm-1; HRMS m/z calc. for 
C80H134N15O17 [M+H]+ 1577.0077, detected 1577.0137. 
5 (5.8 mg) was obtained as white amorphous powder. [α]25D   -30 (c 0.1, MeOH); UV 
(DAD) λmax (MeOH) 205, 224  nm; IR neat (KBr) 3281 (s, br), 2964 (s), 2932 (s), 2874 (s), 1736 
(s), 1633 (s), 1516 (s), 1462 (s), 1384 (s), 1343 (s), 1227 (s), 1024 (s) cm-1; HRMS m/z calc. for 
C81H136N15O17 [M+H]+ 1591.0233, detected 1591.0335. 
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6 (5.6 mg) was obtained as white amorphous powder. [α]25D   -16 (c 0.1, MeOH); UV 
(DAD) λmax (MeOH) 205, 224  nm; IR neat (KBr) 3281 (s, br), 2965 (s), 2932 (s), 2877 (s), 1736 
(s), 1633 (s), 1515 (s), 1464 (s), 1383 (s), 1342 (s), 1227 (s), 1025 (s) cm-1; HRMS m/z calc. for 
C80H131N15NaO17 [M+Na]+ 1596.9745, detected 1596.9690. 
7 (6.4 mg) was obtained as white amorphous powder. [α]25D   -22 (c 0.1, MeOH); UV 
(DAD) λmax (MeOH) 205, 224  nm; IR neat (KBr) 3284 (s, br), 2965 (s), 2932 (s), 2873 (s), 1736 
(s), 1633 (s), 1525 (s), 1454 (s), 1389 (s), 1344 (s), 1230 (s), 1024 (s) cm-1; HRMS m/z calc. for 
C84H134N15O17 [M+H]+ 1625.0077, detected 1625.0131. 
8 (6.2 mg) was obtained as white amorphous powder. [α]25D   -18 (c 0.1, MeOH); UV 
(DAD) λmax (MeOH) 208, 228  nm; IR neat (KBr) 3288 (s, br), 2965 (s), 2932 (s), 2877 (s), 1736 
(s), 1641 (s), 1521 (s), 1455 (s), 1389 (s), 1343 (s), 1280 (s), 1233 (s), 1026 (s) cm-1; HRMS m/z 
calc. for C84H132F2N15O17 [M+H]+ 1660.9888, detected 1660.9999. 
3.3 Formation of Compounds 9-11. KF (90 mg, 60 μmol) was dissolved in MeCN-DMSO (8:2) 
solution, Fmoc-Cl (1.5 eq.) and DMAP (0.25 eq.) were slowly added. The reaction mixture was 
stirred at room temperature for 8 h and the solvent was evaporated under vacuum. The product 
was purified by HPLC using a C18 5 µm column (250 mm × 20.2 mm) with a gradient elution of 
MeCN-H2O in 0.05% HCOOH from 50:50 to 100:0 at a flow rate of 8.0 mL/min to afford 9 (73 
mg) as white amorphous powder (80% yield).  [α]25D   -12 (c 0.1, MeOH); UV (DAD) λmax (MeOH) 
208, 228  nm; IR neat (KBr) 3278 (s, br), 2964 (s), 2932 (s), 2873 (s), 1738 (s), 1629 (s), 1520 
(s), 1463 (s), 1385 (s), 1229 (s), 1025 (s) cm-1; HRMS m/z calc. for C76H124N14NaO17 [M+Na]+ 
1527.9167, detected 1527.9134. 
Compound 9 (45 mg, 0.03 mmol) was dissolved in 6 M HCl-MeOH (1:2), and partial 
hydrolyzed using the same method provided above. Its hydrolyzed product was coupled to 4-
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methylhexanoic succinimide ester (1 eq.) using the same approach as described above to yield 10 
(22 mg) as white amorphous powder. [α]25D   -14 (c 0.1, MeOH); UV (DAD) λmax (MeOH) 205, 
224  nm; IR neat (KBr) 3276 (s, br), 2965 (s), 2932 (s), 2876 (s), 1736 (s), 1639 (s), 1520 (s), 
1455 (s), 1382 (s), 1227 (s), 1203 (s), 1025 (s) cm-1; HRMS m/z calc. for C71H115N13NaO16 
[M+Na]+ 1428.8482, detected 1428.8409. 
KF (15 mg, 0.01 mmol) was dissolved in 6 M HCl-MeOH (1:2), and partial hydrolyzed 
using the same method provided above. Its hydrolyzed product was coupled to 4-methylhexanoic 
succinimide ester (2 eq.) using the same approach as described above to yield 11 (8 mg) as white 
amorphous powder. [α]25D   -8 (c 0.1, MeOH); UV (DAD) λmax (MeOH) 205, 224  nm; IR neat 
(KBr) 3281 (s, br), 2964 (s), 2932 (s), 2873 (s), 1736 (s), 1629 (s), 1582 (s), 1454 (s), 1381 (s), 
1348 (s), 1227 (s), 1025 (s) cm-1; HRMS m/z calc. for C77H127N13NaO16 [M+Na]+ 1512.9421, 
detected 1512.9361. 
3.4 Dehydration of KF (12). KF (30mg, 0.02 mmol) was dissolved in 2 mL anhydrous DCM-
DMSO (9:1), BAST (4 eq.) was added. The reaction mixture was stirred at -78℃ for 2 h, and 
allowed to warm to room temperature for an additional 2 h. The solvent was evaporated under 
vacuum and purified by HPLC using a C18 5 µm column (250 mm × 20.2 mm) with a gradient 
elution of MeCN-H2O in 0.05% HCOOH from 20:80 to 80:20 at a flow rate of 8.0 mL/min to 
afford 12 (5.9 mg) as white amorphous powder. Yield 20%; [α]25D   -12 (c 0.1, MeOH); UV (DAD) 
λmax (MeOH) 205, 224  nm; IR neat (KBr) 3280 (s, br), 2964 (s), 2932 (s), 2877 (s), 1736 (s), 
1632 (s), 1514 (s), 1465 (s), 1383 (s), 1342 (s), 1227 (s), 1025 (s) cm-1; HRMS m/z calc. for 
C75H123N14O15 [M+H]+ 1459.9287, detected 1459.9350.       
3.5 Cyclization of KG (13, 14). KG (30 mg, 0.02 mmol), EDCI (2 eq.) and HOBt (2 eq.) were 
dissolved in 3 mL anhydrous DMF. The reaction mixture was stirred at room temperature for 2 d, 
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and the solvent was evaporated under vacuum. The product was purified by HPLC using a C18 5 
µm column (250 mm × 20.2 mm) with a gradient elution of MeCN-H2O in 0.05% HCOOH from 
20:80 to 80:20 at a flow rate of 8.0 mL/min to afford 13 and 14.  
13 (2.9 mg) was obtained as white amorphous powder. Yield 10%; [α]25D   +30 (c 0.1, 
MeOH); UV (DAD) λmax (MeOH) 205, 224  nm; IR neat (KBr) 3280 (s, br), 2964 (s), 2932 (s), 
2873 (s), 1629 (s), 1516 (s), 1455 (s), 1386 (s), 1227 (s), 1025 (s) cm-1; HRMS m/z calc. for 
C75H124N14NaO16 [M+Na]+ 1499.9217, detected 1499.9186. 
14 (3.2 mg) was obtained as white amorphous powder. Yield 11%; [α]25D   +24 (c 0.1, 
MeOH); UV (DAD) λmax (MeOH) 205, 224  nm; IR neat (KBr) 3280 (s, br), 2964 (s), 2932 (s), 
2873 (s), 1629 (s), 1515 (s), 1454 (s), 1385 (s), 1226 (s), 1025 (s) cm-1;  HRMS m/z calc. for 
C75H124N14NaO16 [M+Na]+ 1499.9217, detected 1499.9141. 
3.6 Amidation of KF (15). KF (45 mg, 30 μmol) was dissolved in 15 mL solution of MeCN-
DMSO (8:2), the benzoquinone derivative (1.5 eq.) was slowly added. The reaction mixture was 
stirred at room temperature for 8 h, and the solvent was evaporated under vacuum. The product 
was purified by HPLC using a C18 5 µm column (250 mm × 20.2 mm) with a gradient elution of 
MeCN-H2O in 0.05% HCOOH from 50:50 to 100:0 at a flow rate of 8.0 mL/min to afford 15 (42 
mg) as yellow amorphous powder. Yield 80%; [α]25D   -4 (c 0.1, MeOH); UV (DAD) λmax (MeOH) 
210, 234  nm; IR neat (KBr) 3286 (s, br), 2964 (s), 2936 (s), 2876 (s), 1736(s), 1633 (s), 1515 (s), 
1465 (s), 1373 (s), 1226 (s), 1021 (s) cm-1; HRMS m/z calc. for C89H140N14NaO19 [M+Na]+ 
1732.0317, detected 1732.0382. 
3.7 Antitumor Assay.  The cytotoxicity soft-agar based disc diffusion assay defines the 
differential cell killing among the 13 cell types examined. This unique and effective model was 
used to guide the discovery of novel molecular structures with anticancer potential. The screen 
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included 11 cell types: two leukemias (murine L1210 and human CCRF-CEM), eight solid 
tumors (murine Colon 38, human colon HCT116, human lung H125, human ovarian OVCAR5, 
Human breast MCF7, human prostate LNCaP, human pancreatic cancer PANC1 and human 
brain U251N), as well as two normal types, a murine and human normal cell (hematopoietic 
progenitor cell, CFU-GM).  Differential cytotoxicity was the endpoint with four possible positive 
outcomes: Murine solid tumor selectivity relative to leukemia, human solid tumor selectivity 
relative to leukemia; and, murine or human solid tumor selectivity relative to the normal cell. 
Murine L1210 and human CCRF-CEM were the reference tumors of the assay.   
Colon 38 gave a good monodispersed cell suspension with mechanical disruption from a 
murine tumor.  Colon 38 (approx. 1g) was cut into small fragments in 15 mL of Hank's Balanced 
Salt Solution (HBSS) over a 100-mesh sieve and gently forced through by the scissors with 
HBSS constantly perfusing the sieve. The material was drawn into and out of a 5 mL syringe 
without a needle to further disperse the cell clumps.  It was diluted and plated in 0.3% agarose in 
DMEM plus 10% heat-inactivated Bovine Calf Serum (BCS).  For plating of all of the cell types 
other than the normal CFU, the 60 mm plates were first prepared with a hard agar bottom layer 
(0.6% agar in RPMI-1640 plus 15% BCS). 
The human cancer cell lines were maintained in cell culture.  They were removed from 
their cultures by a trypsin-collagenase-DNAase cocktail. Their plating efficiencies were 
sufficiently high that 30,000 to 60,000 cells in 3 mL produce the targeted number of colonies 
(over 10,000 per plate) in the 60 mm plates.  This soft agar top layer (0.3% with the serum and 
media as above) plus the titrated tumor cells were poured into the plates and allowed to solidify. 
For CFU-GM, the femoral marrow of C57Bl/6 mice was flushed with MEM-alpha; 2 mL 
per femur. The cells are passed through an 18-gauge needle twice and the monodispersed 
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suspension counted.  A total of 1.5x106 cells were plated in 3 mL of 0.3% agar with the addition 
of 10% L-cell conditioned media, which provided colony stimulating factor, in MEM-alpha plus 
10% BCS. For human CFU-GM, the cells were obtained from Poietic Technologies, Inc. 
(Gaithersburg, MD) overnight and washed twice with PBS before being titered and added to the 
agar mixture. The same cell number, culture conditions and conditioning factors were used as 
with the murine marrow. 
A volume of 15 µL of each sample was dropped onto a 6.5 mm filter disc.  The disc was 
allowed to dry overnight and then placed close to the edge of the petri dish.  The plates were 
incubated for 7-10 days (depending upon the cell type) and examined by an inverted stereo-
microscope (10X) for measurement of the zone of inhibition measured from the edge of the filter 
disc to the beginning of normal-sized colony formation.  The diameter of the filter disc, 6.5 mm, 
was arbitrarily taken as 200 units. A difference in zones between solid tumor cells and either 
normal or leukemia cells of 250 units defines solid tumor selective compounds.  If the test 
material was excessively toxic at the first dosage, a range of dilutions of the agents (at either 1:4 
or 1:10 decrements) against the same tumors were retested. At some dilution, quantifiable 
cytotoxicity was invariably obtained.  The results were expressed as, for example, HCT-116∆CFU = 
350, which indicated that there is a 350 unit zone differential between human colon HCT-116 
and normal CFU-GM; such a differential (>250 units) was of a sufficient magnitude to proceed 
with further pharmacological studies.  
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1. Introduction 
Bryopsis and Elysia species generate a variety of depsipeptides with different activities. 
For example, kahalalide A shows inhibition against Mycobacterium tuberculosis; KF and isoKF 
show activities against solid tumor cell lines, HSV II, fungi, as well as leishmania; norkahalalide 
A (norKA) exerts inhibition of the Y1 receptor (Table 6). The MALDI-TOF mass imaging 
analysis of the tissue of the mollusk Elysia rufescens indicated the presence of kahalalide C 
[M+Na]+ at m/z 936, and KF [M+Na]+ at m/z 1500. Some new metabolites at m/z 761, 797, 747, 
and 770 were distributed on the different positions of the organism (Figure 56). To acquire KF 
as the starting material of its analogues, both E. rufescens and Bryopsis pennata were collected. 
During the isolation, new peptides were identified from E. rufescens using a chemical 
dereplication approach. Further purification afforded nine new and 10 known kahalalides. In this 
chapter, purification and structure elucidation of the new peptides are discussed. 
  
CHAPTER 2 
KAHALALIDES FROM THE MOLLUSK Elysia rufescens   
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Figure 56 MALDI imaging of the E. rufescens 
 
Table 6 Kahalalide family peptides 
 
Compounds  Mol wt  Mol formula  Activity  Reference 
kahalalide A  893.49  C46H67N7O11  Antituberculosis;  Antimalarial activity 12 
norKA 879.47 C46H65N7O11 Y1 receptor inhibition 44 
kahalalide B  877.46  C45H63N7O11  ---  12 
kahalalide C  913.47  C47H63N9O10  ---  12 
kahalalide D  595.35  C31H45N7O5  ---  12 
kahalalide E  835.52  C45H69N7O8  Anti HSV II  12 
kahalalide F 
isoKF 
1476.93 C75H124N14O16  
Anticancer in vitro and in vivo against solid tumor cell 
lines; Anti HSV II;  Antifungal activity 12, 11 
5-OHKF 1492.93 C75H124N14O17 Moderate antimalarial activity 44 
kahalalide G  1494.94  C75H126N14O17  ---  12 
kahalalide H  1110.58  C55H82N8O16  ---  45 
kahalalide J  1238.67  C61H94N10O17  ---  45 
kahalalide K  891.47  C46H65N7O11  ---  46 
kahalalide O  932.50  C48H68N8O11  ---  47 
kahalalide P  1317.72  C66H99N11O17  Moderate inhibition on HL-60 cancer cell lines 48 
kahalalide Q  1301.72  C66H99N11O16  Moderate inhibition on HL-60 cancer cell lines 48 
kahalalide R  1518.94  C77H126N14O17  
Anticancer activity against MCF7 human mammary 
carcinoma cell line  49 
kahalalide S  1534.94  C77H126N14O18  ---  49 
kahalalide R2 1462.92 C74H122N14O16 --- 50 
kahalalide S2 1490.95 C76H126N14O16 --- 50 
kahalalide V 613.36 C31H47N7O6 --- 51 
kahalalide W 611.34 C31H45N7O6 --- 51 
kahalalide X 931.48 C47H65N9O11 --- 51 
kahalalide Y 875.48 C46H65N7O10 --- 51 
  
A: Epifluorescence image of a transverse 14 μm 
thick section across the middle of the E. 
rufescens at 590 nm; B-G: Epifluorescence (590 
nm) image overlaid by MALDI image at m/z 
761, 797, 936, 747, 770, 1500 indicating the 
localization of compounds; H: Epifluorescence 
(590 nm) image overlaid by MALDI image at 
m/z 770 (yellow) and 1500 (purple) showing the 
differential localization of the molecules. 
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2. Results and Discussion 
2.1 Dereplication. Dereplication approaches were used to improve the efficiency of new 
molecule identification. One of the typical features of peptides is that multiple charged ions, 
especially double charged ions [M+2H]2+ in small peptides can be detected by LC-MS (Figure 
57). In the dereplication of kahalalide peptides, the LC-MS signals with both double and single 
charged ions were scanned to quickly determine molecular weight. Determined molecular 
weights were searched using Marinlit which is the library for all known marine natural products 
(Figure 58). If the mass was not identified via this route, the peptide could be considered new 
and worth pursuing for further isolation and biological evaluation.  
 
Figure 57 An example of a double charged ion in KF 
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Figure 58 An example of marine product searching on Marinlit 
2.2 MALDI-Imaging on E. rufescens. The snail sample was thawed, precut, and embedded in 
1´ Dulbecco's PBS and placed in the cryostat at -20 ℃. Once the tissue and embedding block had 
frozen completely, 10- to 20-mm-thick coronal sections were cut and mounted onto a 
semithawed MALDI plate. The plate was desiccated at 38 ℃ for 10 min. The MALDI plate 
containing the snail tissue slices was imaged on a Zeiss Axioskop. Two sets of images were 
collected within the same region of the sponge tissue slice at ´400 (Image B: Zeiss filter set #14, 
emission 590 nm+; Image C: Zeiss filter set #2, emission 420 nm+). After gathering 
photomicrographs of the samples using a Nikon digital camera (2 megapixels), a matrix 
composed of 35 mg/mL α-cyanohydroxycinnamic acid, 35 mg/mL DHB, 78% MeCN, and 0.1% 
TFA was coated onto the MALDI plate by using an airbrush (www.paascheairbrush.com). The 
Bruker MSP 96 anchor target plate containing sample and matrix was then placed in an empty 
Petri dish until the sample was analyzed. A photomicrograph of the sample to be imaged by mass 
spectrometry was loaded onto the flexImaging command window. Three teach points were 
selected to align the background image with the sample target plate. After the target plate 
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calibration was complete, the AutoXecute command was used to analyze the samples: 350-2,000 
m/z window, reflector mode, positive ion mode, 100-mV electronic gain, and real-time smooth 
off. The instrument was calibrated externally by using a digest of BSA as a standard. In the 
resulting spectra, different colors were designated to the different masses allowing the 
visualization of their respective distribution in the rastering window. 
2.3 Extraction and Isolation. An EtOH extract of E. rufescens was subjected to silica gel 
vacuum-liquid chromatography followed by the fractionation on an HP-20 column. The LC-MS 
data of each fraction showed that the MeOH-H2O (90:10) and 100% MeOH fractions mainly 
contained peptides. The two fractions were subjected to open column chromatography on C18, 
followed by preparative HPLC (Phenomenex C18 column 21.2 × 250 mm) at a flow rate of 8 
mL/min or HPLC (Phenomenex C8 column 10.0 × 250 mm) at a flow rate of 2.5 mL/min to yield 
10 known peptides kahalalide D (16), kahalalide A (21), kahalalide B (22), kahalalide H (23), 
kahalalide O (24), kahalalide G (28), kahalalide R2 (31), kahalalide F (32), kahalalide P (33), 5-
OHKF (34), and nine new peptides (17-20, 25-27, 29, 30), among which five peptides (17, 20, 
25-27) were determined based on HRMS and 1D, 2D NMR spectra, while the structures of 
remaining four peptides could not be assigned due to their trace amounts (Figure 59). It was 
noticed that new metabolites at m/z 761, 797, 747, and 770 detected using MALDI imaging were 
not isolated. There are several possibilities. Firstly, the metabolites are instable and degraded 
during the purification procedure. Secondly, those metabolites are not peptides. Hence, they were 
not localized when using the dereplication approach.   
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Figure 59 Structures of new kahalalides 
 
2.4 Structure Elucidation.  
HydroKA (17) (1.2 mg, yield 0.00012%) was obtained as white amorphous powder. 
HRMS provided quasi-molecular signals [M+2Na]2+ at m/z 478.7487, [M+H]+ at m/z 934.4843, 
and [M+Na]+ at m/z 956.4696 (Figure 60) indicating the molecule is a sodium carboxylate for a 
molecular formula of C46H68N7Na2O12 (calc. 956.4721, Δ -2.6 ppm). The 1H, 13C, and HMBC 
NMR spectra (Figure 61-64) displayed seven amide proton signals at δH 7.74-8.12, as well as 
seven amide carbonyls at δC 170.12, 170.16, 171.47, 171.98, 172.28, 172.34, and 175.99, 
 64 
 
indicating the presence of seven amino acid residues. An additional carbonyl at δC 172.36 
suggested the presence of an ester bond. The 1H and 13C NMR spectra also displayed 10 
aromatic protons at δH 7.16-7.24, and six pairs of aromatic carbons at δC 126.65-138.31, 
demonstrating the presence of two Phe residues. The methylene group at δC 61.90 suggested the 
presence of one Ser residue. Two methine groups at δC 66.99 suggested the presence of two Thr 
residues (Table 7). The assignment of amino acid residues of 17 and their correlation were 
identified using an HMBC experiment (Figure 64). Correlations between the NH (δH 7.82) of 
Ser 1 and the carbonyl (δC 170.16) of Thr2, the NH (δH 7.66) of Thr2 and the carbonyl (δC 
172.34) of Leu3, the NH (δH 8.00) of Leu3 and the carbonyl (δC 171.47) of Phe4, the NH (δH 
7.96) of Phe4 and the carbonyl (δC 172.36) of Leu5, the NH (δH 7.72) of Leu5 and the carbonyl 
(δC 170.12) of Thr6, the NH (δH 7.76) of Thr6 and the carbonyl (δC 171.98) of Phe7, as well as 
the NH (δH 8.01) of Phe7 and the carbonyl (δC 175.99) of the 2-methylbutric acid residue, were 
observed (Figure 65). The specific rotation [α]25D   of 17 (c 0.1, MeOH) is 0. This could be 
attributed to the sodium carboxylate. The presence of sodium may influence the intramolecular 
interactions such as the H-bond formation, thus allowing sp3 carbons on amino acid residues to 
rotate freely. Marfey’s analysis revealed that Ser1, Thr2, Thr6 of 17 have the L- configurations, 
while Leu3, Phe4, Leu5, and Phe7 of 17 have the D- configurations (Figure 66). 
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Table 7 1H and 13C NMR data of hydroKA (17)a (δ in ppm, DMSO-d6) 
 Carbon δC, mult δH, mult. J (Hz)  Carbon δC, mult δH, mult. J (Hz) 
Ser1 1 172.28, qC (NH) 7.82 d 7.7 Leu5 1 172.36, qC (NH) 7.72, d 7.8 
 2 55.11, CH 4.36, m   2 52.09, CH 4.36, m  
 
3 61.90, CH2 
3.73, dd 11.1, 3.6  3 41.30, CH2 1.52, 1.41, m  
 3.64, dd 10.9, 4.5  4 24.57, CH 1.57, m  
Thr2 1 170.16, qC (NH) 7.66, d 8.4  5 23.50, CH3 0.87, m  
 2 58.48, CH 4.15, m   6 23.44, CH3 0.87, m  
 3 66.99, CH 3.92, m  Thr6 1 170.12, qC (NH) 7.76, d 7.8 
 4 19.74, CH3 0.91, m   2 57.90, CH 4.28, m  
Leu3 1 172.34, qC (NH) 8.00,d 8.0  3 66.99, CH 3.97, m  
 2 51.91, CH 4.26, m   4 19.59, CH3 1.02, d 6.3 
 3 41.23, CH2 1.52, 1.41, m  Phe7 1 171.98, qC (NH) 8.01, d 7.7 
 4 24.33, CH 1.51, m   2 54.64, CH 4.60, m  
 5 22.02, CH3 0.82, m   3 37.67, CH2 3.07, 2.84, m  
 6 21.93, CH3 0.82, m   4 138.31, qC   
Phe4 1 171.47, qC (NH) 7.96, d 8.3  5,5' 129.53, CH 7.24, m  
 2 54.64, CH 4.60, m   6,6' 128.44, CH 7.26, m  
 3 37.66, CH2 3.07, 2.82, m   7 126.65, CH 7.17, m  
 4 138.31, qC   2Mebut  1 175.99, qC   
 5,5' 129.58, CH 7.24, m  
 
 
2 41.49, CH 2.19, m  
 6,6' 128.50, CH 7.26, m  3 27.07, CH2 1.36, 1.22, m  
 7 126.65, CH 7.17, m  4 17.87, CH3 0.93, d 6.8 
     5 11.86, CH3 0.59, t 7.4 
aAssignments based on 1H, 13C, HSQC and HMBC NMR (100/400 MHz) experiments at room temperature.  
 
 
 
Figure 60 HRMS spectrum of hydroKA (17) 
[M+H]+ 
[M+Na]+ 
[M+H+Na]2+ 
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Figure 61  1H NMR spectrum of hydroKA (17) in DMSO-d6 
 
 
Figure 62 13C NMR spectrum of hydroKA (17) in DMSO-d6 
 
 67 
 
 
 
Figure 63 HSQC spectrum of hydroKA (17) in DMSO-d6 
 
  
Figure 64 HMBC spectrum of hydroKA (17) in DMSO-d6 
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Figure 65 HMBC correlations of hydroKA (17)  
 
 
 
 
Figure 66 Marfey’s analysis of hydroKA (17)  
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18 (800 μg, 0.00008%) was obtained as light yellow solid and LC-MS provided quasi-
molecular signals [M+2H]2+ at m/z 427.3, [M+H]+ at m/z 853.6 (Figure 67). The HSQC NMR 
spectrum showed 18 was not pure (Figure 68). Future work on this new peptide will focus on the 
amino acid sequence analysis using FTMS.  
 
 
Figure 67 MS spectrum of 18 
 
19 (400 μg, 0.00004%) was obtained as light yellow amorphous powder and MS 
spectrum provided quasi-molecular signals [M+2H]2+ at m/z 462.3, [M+H]+ at m/z 923.5 (Figure 
69). However, the NMR spectra could not be acquired due to limited amount. Future FTMS 
analysis will be needed to assign the peptide sequence as well. 
 
[M+H]+ 
[M+2H]2+ 
 70 
 
 
 
Figure 68 HSQC spectrum of 18 in DMSO-d6 
 
 
 
Figure 69 MS spectrum of 19 
 
[M+H]+ 
[M+2H]2+ 
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7-OH-KH (20) (1.1 mg, yield 0.00011%) was obtained as colorless amorphous solid. 
HRMS provided a quasi-molecular signal [M+Na]+ at m/z 1149.5712 for a molecular formula of 
C55H82N8NaO17 (calc. 1149.5690, Δ 1.9 ppm) (Figure 70). Based on HRMS data, the mass of 
20 is 16 daltons more than that of kahalalide H, which suggested that the structure could consist 
of one more hydroxy group than kahalalide H. Therefore, an HSQC overlay experiment was 
utilized to compare these two molecules. As a result, one carbon at δC 38.90 corresponding to the 
C-8 at 3-OH-9-MeDec residue of kahalalide H shifted down field to δC 47.03. The other four 
carbons of 3-OH-9-MeDec residue at δC 25.53, 29.83, 27.85, and 27.30 were replaced by signals 
at δC 21.87, 38.24, 68.25, and 24.27 in 20, respectively, indicating the presence of one more 
hydroxy group. Based on the 13C NMR chemical shifts, the lipid chain of 20 was determined as 
3,7-dihydroxy-9-methyldecane (Table 8, Figures 71, 72).  
The relative configuration of 4-OH-Pro4 was determined using NOESY data (Figure 73). 
There was no NOE correlation between the α-protons of Val5 and 4-OH-Pro4 observed, 
indicating that the 4-OH-Pro4 was trans- conformation. The specific rotation [α]25D   of 20 (c 0.10, 
MeOH) is +40, which is similar to that of kahalalide H [+39, (c 0.45, MeOH)]. Moreover, an 
HSQC overlay experiment displayed that all the other amino acid residue signals overlapped 
well, suggesting that the absolute configuration of the amino acid residues of 20 could be the 
same as those of kahalalide H. Marfey’s analysis of 20 confirmed that Leu2, Val5, and Asp8 are 
the D- configured, while Ser3, trans-4-OH-Pro4, and Ser6 are the L- configured, which are the 
same as those of kahalalide H. Both D- and L- Phe were observed in the Marfey’s analysis. 
Considering that the optical rotation and HSQC data of 20 are closed to those of kahalalide H, 
the Phe residues could be L-Phe1 and D-Phe7 (Figure 74).  
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Figure 70 HRMS spectrum of 7-OH-KH (20) 
 
 
 
Figure 71 1H NMR spectrum of 7-OH-KH (20) in DMSO-d6  
[M+Na]+ 
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Figure 72 HSQC spectra of kahalalide H (green) and 7-OH-KH (20) (red) in DMSO-d6 
 
 
 
Figure 73 NOESY correlations of trans-4-OH-Pro in 7-OH-KH (20) in DMSO-d6 
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Table 8 1H and 13C NMR data of 20 and 27a (δ in ppm, DMSO-d6) 
  20 27 
Carbon δC, mult δH, mult. J (Hz) δC, mult δH, mult. J (Hz) 
 Phe1 1 173.47, qC (NH) 7.86, d 7.9 173.47, qC (NH) 7.86, d 7.9 
 2 54.61, CH 4.44, m  54.61, CH 4.44, m  
 3 37.43, CH2 3.02,dd ;2.79, m  13.6, 4.3 37.43, CH2 3.02,dd; 2.79, m 13.6, 4.3 
  4 138.11, qC   138.11, qC   
 5,5’ 129.65, CH 7.20, m  129.65, CH 7.20, m  
 6,6’ 128.49, CH 7.26, m  128.49, CH 7.26, m  
 7 126.73, CH 7.19, m  126.73, CH 7.19, m  
 Leu2 1 170.99, qC (NH) 7.65, d 8.2 170.99, qC (NH) 7.65, d 8.2 
 2 51.33, CH 4.28, m  51.33, CH 4.28, m  
 3 41.43, CH2 1.27, bs  41.43, CH2 1.27, bs  
 4 24.40, CH 1.36, m  24.40, CH 1.36, m  
 5 23.43, CH3 0.83, m  23.43, CH3 0.83, m  
 6 21.57, CH3 0.79, m  21.57, CH3 0.79, m  
 Ser3 1 170.02, qC (NH) 7.89, m  170.02, qC (NH) 7.89, m  
 2 55.97, CH 4.31, m  55.97, CH 4.31, m  
 3 62.23, CH2 3.58, m  62.23, CH2 3.58, m  
OH-Pro4 1 171.29, qC   171.29, qC   
or Pro4 2 59.30, CH 4.36, m  60.99, CH 4.33, m  
 3 37.99, CH2 1.89, 2.01, m  29.78, CH2 1.83, m  
 4 69.01, CH 4.31, m  24.68, CH2 1.83, m  
 5 55.74, CH2 3.71, 3.45, m  47.58, CH2 3.52, 3.66, m  
Val5 1 172.02, qC (NH) 7.95, m  172.02, qC (NH) 7.95, m  
 2 55.69, CH 4.37, m  55.69, CH 4.34, m  
 3 30.45, CH 2.01, m  30.45, CH 2.01, m  
 4 20.09, CH3 0.83, m  20.09, CH3 0.83, m  
 5 18.19, CH3 0.82, m  18.19, CH3 0.82, m  
Ser6 1 170.22, qC (NH) 7.93, m  170.22, qC (NH) 7.93, m  
 2 55.82, CH 4.21, m  55.82, CH 4.21, m  
 3 62.00, CH2 3.58, m  62.00, CH2 3.58, m  
Phe7 1 170.20, qC (NH) 8.25, d 7.4 170.20, qC (NH) 8.25 7.4 
 2 54.06, CH 4.53, m  54.06, CH 4.53, m  
 3 37.31, CH2 3.07,dd; 2.84, m 13.7, 4.6 37.31, CH2 3.07,dd ;2.84, m  13.7, 4.6 
 4 138.00, qC   138.00, qC   
 5,5' 129.65, CH 7.20, m  129.65, CH 7.20, m  
 6,6' 128.47, CH 7.26, m  128.47, CH 7.26, m  
 7 126.68, CH 7.19, m  126.68, CH 7.19, m  
Asp8 1 172.28, qC (NH) 8.23, d 8.12 172.28, qC (NH) 8.23, d 8.12 
 2 50.03, CH 4.53, m  50.03, CH 4.53, m  
 3 36.34, CH2 
2.62, dd 
2.36, dd 
17.1, 5.6 
16.8, 8.4 36.34, CH2 
2.36, dd 
2.62, dd 
17.1, 5.6 
16.8, 8.4 
 4 171.93, qC   171.93, qC   
3-OH-9MeDec 
or 3,7-dihydroxy 
-9MeDec 
1 172.33, qC   172.33, qC   
2 43.86, CH2 2.20, d 6.1 43.86, CH2 2.20, d 6.1 
3 68.17, CH 3.82, bs  68.17, CH 3.82, bs  
4 37.90, CH2 1.96, m  37.90, CH2 1.96, m  
 5 21.87, CH2 1.38, m  25.53, CH2 1.33, m  
 6 38.24, CH2 1.30, m  29.83, CH2 1.26, bs  
 7 68.25, CH 3.44, m  27.85, CH2 1.51, m  
 8 47.03, CH2 1.20, m  38.90, CH2 1.15, bs  
 9 24.27, CH 1.75, m  27.30, CH 1.24, m  
 10, 11 22.98, CH3 0.84, m  22.98, CH3 0.84, m  
aAssignments based on 1H, 13C, and HSQC NMR (100/400 MHz) experiments at room temperature.  
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Figure 74 Marfey’s analysis of 7-OHKH (20) 
 
25 (10mg, yield 0.001%) possibly was a δ-lactam synthetase catalyzed kahalalide F 
degraded peptide (laskide). It was obtained as white amorphous powder and HRMS provided 
quasi-molecular signals [2M+Na]+ at m/z 1465.8257 and [M+Na]+ at m/z 744.4629 for a 
molecular formula of C36H63N7NaO8 (calc. 744.4630, Δ -0.1 ppm) (Figure 75). The 1H, 13C, 
and HMBC NMR spectra displayed six amide protons at δH 7.58-8.08, eight carbonyls at δC 
170.06, 170.14, 170.24, 171.09, 171.53, 172.94 and 173.18, indicating the presence of at least six 
amino acid residues (Figure 76-79). The methine group at δC 66.68 suggested the presence of 
one Thr residue (Table 9). The signals at δC 33.42, 33.97, 32.42, 29.26, and 11.59 in HSQC 
presented less intensity, suggesting the presence of a 4-MeHex isomer (Figure 78). The amino 
acid residues and their sequence of 25 were determined using HMBC experiment. Correlation 
between the NH (δH 7.55) of 3-aminopiperidin-2-one and its carbonyl (δC 170.06) indicating the 
formation of a lactam. There was no NOESY correlation between the α-protons of Pro2 and Val3 
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observed. Moreover, the Δδβγ (differential value of 13C chemical shift of β- and γ- carbons in Pro) 
is 5.04 ppm, which is < 8 ppm, suggested the trans- conformation of Pro2.52   The absolute 
configuration analysis of 25 using Marfey’s analysis demonstrated that 25 contains L-Thr, trans-
D-Pro, L-Orn, D-Val, and L-Val residues (Figure 80). The absolute configurations of Val3, Val4, 
and Val6 could not be determined. However, considering 25 is a degraded product of KF, the 
configuration of the Val residues could be proposed as D-Val3, L-Val4, and D-Val6.    
 
 
Figure 75 HRMS spectrum of laskide (25) 
 
  
[M+Na]+ 
[2M+Na]+ 
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Table 9 1H and 13C NMR data of laskide (25)a (δ in ppm, DMSO-d6) 
 Carbon δC, mult δH, mult. J (Hz)  Carbon δC, mult δH, mult. J (Hz) 
3-amino 
piperidine 
-2-one 
1 170.06, qC (NH) 7.82, d 7.6 Thr 5 1 171.09, qC (NH) 7.79, d 8.6 
2 49.65, CH 4.05, m   2 58.22, CH 4.26, m  
3 21.21, CH2 1.75, m   3 66.68, CH 4.01, m  
  4 27.88, CH2 1.99, m   4 19.88, CH3 1.02, d 6.3 
 5 41.35, CH2 3.12  Val 6 1 171.93, qC (NH) 7.87, d 9.2 
   (NH) 7.55,bs    second (NH) 7.85, d 9.1 
Pro2 1 170.14, qC    2 58.50, CH 4.23, m  
  2 59.88, CH 4.36, m    3 30.53, CH 2.02, m  
 3 29.74, CH2 2.01, 1.82, m   4 19.69, CH3 0.83, m  
 4 24.70, CH2 1.91, 1.81, m   5 19.69, CH3 0.83, m  
 5 47.48, CH2 3.72, 3.59, m  5-
MeHex 
  
1 173.18, qC   
Val3 1 171.53, qC (NH) 7.59, d 8.8 2 35.74, CH2 2.17, m  
 2 57.89, CH 4.29, m  3 23.61, CH2 1.51, m  
  3 31.16, CH 2.02, m   4 38.46, CH2 1.13, m  
 4 18.08, CH3 0.84, m   5 27.66, CH 1.54, m  
 5 18.08, CH3 0.84, m   6 22.89, CH3 0.84, m  
Val4 1 170.24, qC (NH) 8.06, d  8.6  7 22.85, CH3 0.84, m  
 2 56.11,CH 4.34, m  4-
MeHex 
  
1 172.94, qC   
  3 30.21, CH 2.02, m  2 33.26, CH2 2.19, m  
 4 18.66, CH3 0.84, m  3 32.42, CH2 1.54, 1.29, m  
 5 18.79, CH3 0.84, m   4 33.97, CH 1.30, m  
      5 29.26, CH2 1.29, m  
      6 19.17, CH3 0.80, m  
      7 11.59, CH3 0.83, m  
aAssignments based on 1H, 13C, HSQC and HMBC NMR (100/400 MHz) experiments at room temperature.  
 
 
Figure 76 1H NMR spectrum of laskide (25) in DMSO-d6 
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Figure 77 13C NMR spectrum of laskide (25) in DMSO-d6 
 
 
 
Figure 78 HSQC spectrum of laskide (25) in DMSO-d6 
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Figure 79 HMBC correlations of laskide (25) in DMSO-d6 
 
 
 
 
Figure 80 Marfey’s analysis of laskide (25) 
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HydroKB methyl ester (26) (20mg, yield 0.002%) was obtained as white amorphous 
powder. HRMS provided quasi-molecular signals [M+2Na]2+ at m/z 477.7753, [M+Na]+ at m/z 
933.4805 for a molecular formula of C46H67N7NaO12 (calc. 933.4818, Δ -1.4 ppm) (Figure 81). 
The 1H, 13C, and HMBC NMR spectra displayed six amide protons at δH 6.61-7.71, eight 
carbonyls at δC 170.01, 171.76, 172.77, 171.74, 171.82, 172.33, 174.63 and 174.80, indicating 
the presence of at least six amino acid residues (Figures 82-84). Moreover, carbons at δC 174.80, 
31.88, 33.94, 28.99, 18.77 and 11.06 displayed less intensity in the 13C NMR spectrum, 
demonstrating the presence of a 4-MeHex isomer. The HMBC and NOESY correlations revealed 
that 26 has the same amino acid sequence as kahalalide B12 (Table 10). The only difference is 
that the ester was hydrolyzed, and an additional methyl group was present in 26 at δC 52.33. It 
was clearly observed that the new methyl group had an HMBC correlation with the carbonyl (δC 
175.99) of Gly1, and NOE correlations with the α-protons (δH 3.83, 4.13) of Gly1, thus 
determining that 26 is a methyl ester at Gly1 (Figure 85). There was no NOE correlation 
between the α-protons of Pro3 and Leu4 observed. Additionally, the Δδβγ value of Pro3 is 4.47 
ppm (< 8 ppm), indicating the Pro3 is trans- conformation. The specific rotation [α]25D   of 26 (c 
0.1, MeOH) is 0. This could be attributed to an acyclic peptide chain and the presence of a 
methyl ester that allow sp3 carbons at amino acid residues to rotate freely. Marfey’s analysis 
revealed that 26 shares the same absolute configuration as kahalalide B, which is L-Thr2, trans-
L-Pro3, D-Leu4, L-Phe5, D-Ser6, and L-Tyr7 (Figure 86). 
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Table 10 1H and 13C NMR data of hydroKB methyl ester (26) a (δ in ppm, CDCl3) 
 Carbon δC, mult δH, mult. J (Hz)  Carbon δC, mult δH, mult. J (Hz) 
GlyOMe1 1 171.01, qC (NH) 7.63, m   Ser6 1 171.82, qC (NH) 7.68, m  
2 41.27, CH2 3.83, dd 17.5, 4.1  2 55.44, CH 4.37, m  
  4.13, dd 17.2, 4.9  3 62.47, CH 3.40, d  8.7 
3 52.33, CH3 3.63, s     4.05, d 9.6 
Thr2 1 171.01, qC (NH) 7.15, m  Try7 1 172.33, qC (NH) 6.61,bs  
 2 59.49, CH 4.33, m   2 55.74, CH 4.55, m  
 3 66.66, CH 4.42, m   3 36.94, CH2 2.88, dd  8.2, 4.7 
 4 19.98, CH3 1.23, d 5.3    3.06, m  
Pro3 1 171.76, qC     4 127.06, qC   
 2 61.22, CH 4.55, m   5,5’ 130.14, CH 7.03, d 7.6 
 3 28.99, CH2 2.32, 2.05, bs   
 
5-
MeHex  
6,6’ 116.76, CH 6.76, d 7.5 
 4 24.52, CH2 2.00, bs  7 155.91, qC   
 5 47.52, CH2 3.98, 3.49, bs  1 174.63, qC   
Leu4 1 172.77, qC (NH) 7.35, bs  2 36.16, CH2 2.10, t 7.2 
  2 50.02, CH 4.49, m   3 23.19, CH2 1.49, m  
 3 39.84, CH2 1.49, 1.36, m   4 38.28, CH2 1.06, m  
 4 24.49, CH 1.42, m   5 27.71, CH 1.42, m  
 5 23.21, CH3 0.89, d 5.0  
 
 4-
MeHex 
6 22.37, CH3 0.78, m  
 6 21.75, CH3 0.85, d 5.1 7 22.40, CH3 0.78, m  
Phe5 1 171.74, qC (NH) 7.71, bs  1 174.80, qC   
 2 54.40, CH 4.69, m  2 33.71, CH2 2.12, m  
 3 36.50, CH2 2.97, dd  13.6, 6.2  3 31.88, CH2 1.54, 1.33, m  
   3.21, dd 13.1, 7.3  4 33.94, CH 2.13, m  
 4 137.09, qC    5 28.99, CH2 1.07, m  
 5,5' 129.12, CH 7.17, m   6 18.77, CH3 0.77, m  
 6,6' 128.37, CH 7.23, m   7 11.06, CH3 0.75, m  
 7 126.64, CH 7.17, m       
aAssignments based on 1H, 13C, HSQC and HMBC NMR (100/400 MHz) experiments at room temperature. 
  
 
Figure 81 HRMS spectrum of hydroKB methyl ester (26) 
 
[M+Na]+ 
[M+2Na]2+ 
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Figure 82 1H NMR spectrum of hydroKB methyl ester (26) in CDCl3 
 
 
 
Figure 83 13C NMR spectrum of hydroKB methyl ester (26) in CDCl3 
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Figure 84 HMBC correlations of hydroKB methyl ester (26) in CDCl3  
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Figure 85 The key NOESY correlations of hydroKB methyl ester (26) in CDCl3 
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Figure 86 Marfey’s analysis of dehydroKB methyl ester (26) 
DehydroxyKH (27) (1.2mg, yield 0.00012%) was obtained as light yellow amorphous 
powder and HRMS provided quasi-molecular signals [M+H+Na]2+ at m/z 559.2990, [M+Na]+ at 
m/z 1117.5728 for a molecular formula of C55H82N8NaO15 (calc. 1117.5792, Δ -5.7 ppm) 
(Figure 87). The mass of 27 is 16 dalton less than kahalalide H, which suggested that 27 has one 
less hydroxy group than kahalalide H. The HSQC overlay with kahalalide H revealed that the α-
carbon of OH-Pro4 shifted slightly from δC 59.30 to δC 60.99. The other three carbon signals on 
OH-Pro4 at δC 37.99, 69.01, 55.74 shifted upfield to δC 29.78, 24.68, 47.58, respectively (Figure 
88, 89). This provided evidence that the OH-Pro4 is replaced by a Pro residue in compound 27 
(Table 8). The specific rotation [α]25D   of 27 (c 0.1, MeOH) is +32, which is close to that of 
kahalalide H. Moreover, the HSQC overlay experiment displayed that all the other amino acid 
residues signal overlapped well, indicating that the absolute configurations of the amino acid 
residues of 27 are the same as those of kahalalide H. The Δδβγ value of Pro4 is 5.1 ppm (< 8 
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ppm), suggesting its trans- conformation. Marfey’s analysis of 27 revealed that Leu2, Val5, and 
Asp8 are D- configured, and Ser3, trans-Pro4, Ser6 are L- configured. Although both D- and L- 
Phe were observed in 27, considering a similar optical rotation value and HSQC data to 
kahalalide H, L-Phe1 and D-Phe7 could be proposed (Figure 90). 
 
 
Figure 87 HRMS spectrum of dehydroxyKH (27) 
 
[M+Na]+ 
[M+H+Na]2+ 
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Figure 88 1H NMR spectrum of dehydroxyKH (27) in DMSO-d6 
 
 
 
 
Figure 89 HSQC spectra of kahalalide H (green) and dehydroxyKH (27) (red) in DMSO-d6 
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Figure 90 Marfey’s analysis of dehydroxyKH (27) 
 
29 (1 mg, yield 0.0001%) was obtained as light yellow amorphous powder. The LC-MS 
provided quasi-molecular signals [M+2H]2+ at m/z 901.0, [M+H]+ at m/z 1801.0 (Figure 91). 
The 1H NMR spectrum suggested the presence of 10 amide protons in 29 (Figure 92). However, 
the other NMR spectra could not be acquired due to limited amount. Future work will focus on 
the amino acid sequencing analysis using FTMS analysis to assign the structure. 
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Figure 91 MS spectrum of 29 
 
 
 
Figure 92 1H NMR spectrum of 29 in DMSO-d6 
 
[M+H]+ 
[M+2H]2+ 
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30 (300 μg, yield 0.00003%) was obtained as white amorphous powder and LC-MS 
provided a quasi-molecular [M+2H]2+ signal at m/z 893.0 (Figure 93). The mass suggested that 
30 could have one less hydroxy group than 29. However, the NMR spectra could not be acquired 
due to limited amount. Further FTMS analysis of amino acid sequence will be needed to assign 
the structure. 
 
 
Figure 93 MS spectrum of 30 
 
3 Materials and Methods 
3.1 General Experimental Procedures.  NMR spectra were recorded on a Bruker Avance 
DRX-400 spectrometer. The 1H and 13C NMR chemical shifts were reported in ppm. The 
MALDI imaging was performed on the MALDI MS (Bruker microflex fitted with flexImaging 
2.0 software) in positive mode, with 100-mm raster intervals in XY and approximately 35-62% 
laser power. HPLC-ESI-TOF was performed on Bruker MicroTOF in line with an Agilent 1100 
Series HPLC system and G1316A DAD detector. Phenomenex Luna C8 5 µm column (150 mm 
[M+2H]2+ 
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× 4.6 mm) was used with a gradient elution of MeOH in 0.05% HCOOH at a flow rate of 0.6 
mL/min. Preparative HPLC was carried out on a Waters PrepLC system with a single 
wavelength detector. Diaion HP-20 and sephadex LH-20 resins were purchased from Sigma.  
3.2 Sample Collection. Samples were collected from the waters of Kahala Bay near Black Point, 
Oahu, during March, April and May of 2003. The collected samples were identical to voucher 
specimen #9507019 deposited at the Suntory Institute for Bioorganic Research, Osaka, Japan.  
3.3 Sample Preparation. A dry weight of E. rufescens (1 kg) was blended, and the powder was 
extracted with EtOH for 1 hr in a sonicator. This process was repeated 5 times. The extracts were 
dried for further isolation. 
3.4 Compound Isolation. The extract (300 g) was fractionated on a silica flash column with a 
gradient solvent system of hexanes-EtOAc (100:0, 50:50, 0:100) and EtOAc-MeOH (50:50, 
0:100). EtOAc-MeOH fractions were found to contain peptides, and these two fractions were 
further eluted on HP-20 with MeOH-H2O (50:50, 60:40, 80:20, 90:10, 100:0). The LC-MS data 
for each fraction showed that the MeOH-H2O (90:10) and 100% MeOH fractions mainly 
contained the peptides. MeOH-H2O (90:10) fraction was subjected to C18 glass open-tubular 
column with an isocratic solvent system of MeOH-H2O (90:10), followed by preparative HPLC 
(Phenomenex C18 column 21.2 × 250 mm) at a flow rate of 8 mL/min or HPLC (Phenomenex C8 
column 10.0 × 250 mm) at a flow rate of 2.5 mL/min with a gradient system of MeCN-H2O 
(50:50-80:20) to afford kahalalide D (16). The 100% MeOH fraction was subjected to C18 glass 
open-tubular column with a gradient solvent system of MeOH-H2O (70:30-100:0) to acquire 
four sub-fractions. Sub-fraction 1 was purified by preparative HPLC (Phenomenex C18 column 
21.2 × 250 mm) at a flow rate of 8 mL/min with a gradient system of MeCN-H2O (50:50-80:20) 
to afford four new peptides (17-20). Sub-fraction 2 was purified using the same condition as sub-
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fraction 1 to afford kahalalide A (21), kahalalide B (22), kahalalide H (23), kahalalide O (24), 
and three new peptides 25-27. Sub-fraction 3 was purified by preparative HPLC (Phenomenex 
C18 column 21.2 × 250 mm) at a flow rate of 8 mL/min with a gradient system of MeCN-H2O 
(60:40-90:10) to afford kahalalide G (28), and two new peptides 29, 30. Sub-fraction 4 was 
purified by preparative HPLC (Phenomenex C18 column 21.2 × 250 mm) at a flow rate of 8 
mL/min or HPLC (Phenomenex C8 column 10.0 × 250 mm) at flow rate of 2.5 mL/min with a 
gradient system of MeCN-H2O (70:30-100:0) to afford kahalalide R2 (31), kahalalide F (32), 
kahalalide P (33), and 5-OHKF (34) (Scheme 10). 
 
Scheme 10 Isolation scheme of kahalalides from E. rufescens 
 
17 (1.2 mg) was obtained as white amorphous powder. [α]25D   0 (c 0.1, MeOH); UV λmax 
(MeOH) 204  nm; IR neat (KBr) 3286 (s, br), 2958 (s), 2873 (s), 1744 (s), 1638 (s), 1519 (s), 
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1209 (s), 1025 (s) cm-1; HRMS m/z calc. for C46H68N7Na2O12 [M+Na]+ 956.4721, detected 
956.4696. 
20 (1.1 mg) was obtained as colorless amorphous solid. [α]25D   +40 (c 0.1, MeOH); UV 
λmax (MeOH) 210 nm; IR neat (KBr) 3298 (s, br), 2956 (s), 2930 (s), 2869 (s), 1722 (s), 1645 (s), 
1544 (s), 1440 (s), 1232 (s), 1025 (s) cm-1; HRMS m/z calc. for C55H82N8NaO17 [M+Na]+ 
1149.5696, detected 1149.5712. 
25 (10 mg) was obtained as white amorphous powder. [α]25D   +42 (c 0.1, MeOH); UV λmax 
(MeOH) 195 nm; IR neat (KBr) 3282 (s, br), 2960 (s), 2877 (s), 1627 (s), 1534 (s), 1025 (s) cm-1; 
HRMS m/z calc. for C36H63N7NaO8 [M+Na]+ 744.4636, detected 744.4629. 
26 (20 mg) was obtained as white amorphous powder. [α]25D   0.0 (c 0.1, MeOH); UV λmax 
(MeOH) 204 nm; IR neat (KBr) 3285 (s, br), 2956 (s), 2873 (s), 1742 (s), 1632 (s), 1514 (s), 
1438 (s), 1207 (s), 1025 (s) cm-1; HRMS m/z calc. for C46H67N7NaO12 [M+Na]+ 933.4745, 
detected 933.4805. 
27 (1.2 mg) was obtained as colorless amorphous solid. [α]25D   +32 (c 0.1, MeOH); UV 
λmax (MeOH) 210 nm; IR neat (KBr) 3298 (s, br), 2956 (s), 2929 (s), 2869 (s), 1722 (s), 1643 (s), 
1544 (s), 1441 (s), 1231 (s), 1025 (s) cm-1; HRMS m/z calc. for C55H82N8NaO15 [M+Na]+ 
1117.5797, detected 1117.5728. 
3.5 Marfey’s Analysis of New Peptides. Marfey’s reaction is the most commonly used method 
to separate the enantiomers by introducing an additional stereogenic center, thus determining 
their absolute configuration (Scheme 11). Peptides (0.5 μmol) were hydrolyzed using 1 mL of 6 
M HCl in a sealed reaction vial at 100 ºC for 20 h. Traces of HCl was removed under vacuum. 
The resulting hydrolysate and amino acid standards were derivatized with 200 μL of 1% FDAA 
in acetone and 40 μL of 1 M NaHCO3. The mixtures were heated at 40ºC for 1 h. The solution 
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was cooled to room temperature, neutralized with 20 μL of 2M HCl, and evaporated to dryness. 
LC-MS analysis of FDAA-derivatized hydrolyzates and standard FDAA-derivatized amino acids 
were carried out using C8 (4.6 × 150 mm column) with a linear gradient of H2O (0.05% 
HCOOH)-MeOH (0.05% HCOOH) 60:40 to 10:90 in 75 min at 0.6 mL/min. The absolute 
configuration of amino acid residues was determined by comparing the retention time with the 
standard FDAA-derivatized amino acids. The extracted ions corresponding to amino acid FDAA 
derivatives were listed in Table 11. It was noticed that Orn contains two free amine groups, the 
major derivative was the addition of FDAA on both amine groups in the molecule. 
NO2
O2N
F
H
N
NH2
O
H2N
OH
O
AA
NO2
O2N
HN
H
N
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O OH  
Scheme 11 The mechanism of Marfey’s reaction  
 
Table 11 Extracted ions of amino acid FDAA derivatives
Amino acid [M+H]+ Amino acid [M+H]+ 
Asp 386.2 allo-Thr 372.2 
Leu 384.1 Tyr 434.2 
Orn 637.2 Pro 368.1 
Phe 418.2 OH-Pro 384.2 
Ser 358.1 Val 370.2 
Thr 372.2   
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1. Introduction 
Since 1960, the NCI has been dedicated to the discovery of anticancer drug leads from 
natural sources. The Natural Products Branch of the NCI Developmental Therapeutics Program 
collected plants and marine organisms from around the world. During the period of 1986-1999, 
more than 50,000 plant samples and 10,000 marine organisms were collected from over 25 
countries.53 Each organism was extracted using DCM-MeOH (50:50), followed by H2O. The 
extracts were stored in a natural product repository at -20 ℃.53 All the extracts were prescreened 
in selected tumor cell lines at a rate of 20,000 samples yearly.53,54 With bioassay-guided isolation, 
active molecules could be considered for further evaluation using 60 human tumor cell lines, 
including lung, colon, melanoma, prostate, ovarian, breast and kidney. About 2% of screened 
compounds with promising potency and selectivity would be recommended for in vivo assays, 
such as hollow fiber assay and xenografts.55 If the candidate is selected for the next step 
development, NCI will provide larger-scale production, initiate preclinical studies such as 
collecting short and long term toxicological data, and schedule early stage clinical trials.55  Our 
group has a long-term collaboration with the NCI. More than 80 extracts have been evaluated 
from the NCI repository. In this chapter, screening and isolation of extracts from marine 
organisms provided by the NCI repository are discussed.   
CHAPTER 3 
ANTICANCER LEADS FROM THE NCI REPOSITORY 
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2. Results and Discussion 
2.1 Primary Screening. At the first stage, 27 extracts from the NCI repository were fractionated 
using standard procedure listed in the “Materials and Methods” section. All the subfractions were 
sent to Dr. Fred Valeriote’s group at Wayne State University for prescreening in murine 
lymphoma L1210, colon 38, hematopoietic CFU-GM, as well as human colon HCT116, NSCLC 
H125, T-cell lymphoma CEM cell lines. As a result, 20 extracts were dropped due to the reduced 
potency or limited amount of active metabolites; four fractions were potent against several cell 
lines, particularly H125; three extracts showed potency, however, the materials were not 
provided by NCI (Table 12). Four active extracts were selected for further purification. 
Table 12 Current status of extracts from the NCI repository 
Sample Amount Organism Status  
C021197-T/6 1g Cystodytes fuscus Three known compounds isolated 
C004690 12g Phakellia sp. Five known compounds isolated  
C023087-X/6 2g Phakellia cavernosa Three known compounds isolated 
C012610-L/6 1g Didemnum rubeum  One known compound isolated 
C023069-180 4g Hyrtios erecta  Dropped due to limited amount of active metabolites 
C022471-176 2g Hyrtios sp. Dropped due to limited amount of active metabolites 
C004440 20mg Adolphia sp. Dropped without selective fraction 
C011316 20mg Nemanthus sp. Dropped without selective fraction 
C004024 20mg Sclerothamnopsis sp. Dropped without selective fraction 
C002136 20mg Unknown Dropped without selective fraction 
C002394 20mg Unknown Dropped without selective fraction 
C017508 20mg Unknown Dropped without selective fraction 
C017022 20mg Barbatia sp. Dropped without selective fraction 
C001119 20mg Batzella sp. Dropped without selective fraction 
C017114 20mg Dorypleres sp. Dropped without selective fraction 
C016326-Y/6 3g Eudistoma sp. Dropped without selective fraction 
C009472 20mg Pchyclavularia sp. Dropped without selective fraction 
C021336 20mg Stephanoscyphus sp. Dropped without selective fraction 
C014402 20mg Theonella sp. Dropped without selective fraction 
C003658 20mg Unknown Dropped without selective fraction 
C003878 20mg Unknown Dropped without selective fraction 
C006332 20mg Unknown Dropped without selective fraction 
C011574 20mg Unknown Dropped without selective fraction 
C017702 20mg Unknown Dropped without selective fraction 
C011264 20mg Halichondria sp. Sample not provided 
C013676 20mg Halichondria sp. Sample not provided 
C014398 20mg Halichondria sp. Sample not provided 
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2.2 Identification of Active Compounds. Purification of the four potent extracts yielded 12 
known compounds (35-46). 
2.2.1 C021197. C021197 is the extract of the ascidian Cystodytes fuscus collected at -10 meters 
from Aore Island located in the Republic of Vanuatu (Figure 94). Primary activity displayed that 
silica EtOAc, EtOAc-MeOH (75:25, 50:50) fractions were potent against H125 and CEM cell 
lines. Further purification of active fractions on preparative HPLC yielded three compounds (35-
37). The three compounds provided quasi-molecular signals [M+H]+ at m/z 358.1, 388.1, 431.1, 
respectively. Odd molecular weights of 35 and 36 suggested that they are nitrogen containing 
metabolites. The 1H NMR chemical shifts of 35 in the regions of δH 7.0-9.5 and δH 5.58 revealed 
the presence of an aromatic system and olefin protons. Two vicinal methylenes at δH 3.32 and 
3.82, as well as two methyls at δH 1.89 and 2.14 
were observed (Figure 95). Compound 36 has one 
more methyl group at δH 3.52 when compared to 35, 
suggesting the presence of one O-methyl group. 
Aromatic protons and vicinal methylene protons of 
37 shifted upfield when compared to 35, indicating a 
change of the ring system. Searching the molecular 
mass using Marinlit and the comparison of acquired 1H NMR spectra with published data 
determined these three compounds to be pyridoacridine alkaloids cystodytin A (35), cystodytin F 
(36), and shermilamine C (37) (Figure 96).56,57,58 The optical rotation of cystodytin F (36) is 0, 
indicating  it is racemic. 
 
 
Figure 94 The ascidian Cystodytes fuscus 
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Figure 95 1H NMR spectrum of cystodytin A (35) in CDCl3 
 
 
 
Figure 96 Structures of 35-37 isolated from Cystodytes fuscus 
Cystodytin A (35) and cystodytin F (36) showed cytotoxicity against L1210 with IC50 
values of 0.24 and 0.068 µg/mL, respectively.56,57 Shermilamine C (37) showed inhibition of 
topoisomerase II catalytic activity of IC50 at 138 µM.58 The cytotoxicity soft-agar based disc 
diffusion assay revealed cystodytin F (36) exerts inhibition of CFU-GM, HCT116, H125, and 
U251N (Table 13).  
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Table 13 Disc diffusion assay data for compound 35-37 
 
Sample Concentration  (μg/mL) 
Inhibition zone units 
CFU-GM HCT116 H125 U251N 
DMSO  0 0 0 0 
cystodytin A (35) 600 50 250 300 300 
cystodytin F (36) 300 375 550 450 400 
shermilamine (37) 1200 150 200 300 250 
2.2.2 C004690. C004690 is the extract of the sponge Phakellia sp. Primary activity displayed 
that the MeOH fraction from a silica column or the H2O fraction from a C18 column was potent 
against H125. The extract (12 g) was eluted on C18 glass open-tubular column using a gradient 
of H2O-MeOH to generate nine subfractions. LC-MS analysis of the subfractions revealed that 
H2O-MeOH (50:50, 40:60, 30:70) fractions contained brominated metabolites. Further 
purification on a preparative HPLC C18 column afforded five pure compounds (38-42). The 
compounds provided quasi-molecular signals [M+H]+ at m/z 327.1, 188.9, 357.1, 355.1, and 
341.1, respectively. A mass ratio at M:[M+2] (1:1) was observed in all molecules, suggesting the 
presence of one bromine in the molecules. The 1H NMR chemical shifts of 42 in the δH 6.0-7.5 
region indicated the presence of an aromatic system. The 13C NMR spectrum showed two 
carbonyls at δC 158.2 and 159.1 suggesting the presence of two amides or esters (Figures 97, 98). 
One N-methyl at δH 2.6 was observed. The 1H and 13C NMR spectra of 38, 40, and 41 are similar 
to those of 42. Compound 38 has one N-methyl group less than 42. Compound 41 has one more 
O-methyl at δH 3.0 than 42. One carbon signal of 40 shifted from δC 65.5 to 89.1 when 
compared to 42, indicating the presence of a hydroxy group. Compared to these four compounds, 
only two aromatic protons and amide protons were observed in 39. Marinlit searching and 
comparison of acquired 1H and 13C NMR spectra with published compounds confirmed the 
molecules are agelastatin D (38), 5-bromo-1H-pyrrole-2-carboxamide (39), agelastatin C (40), 
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agelastatin E (41), and agelastatin A (42) (Figure 99).59,60 The absolute configuration was 
determined by measuring the optical rotation values and comparing with published data.  
 
Figure 97 1H NMR spectrum of agelastatin A (42) in DMSO-d6  
 
Figure 98 13C NMR spectrum of agelastatin A (42) in DMSO-d6 
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Figure 100 The sponge Phakellia cavernosa 
 
 
Figure 99 Structures of 38-42 isolated from Phakellia sp. 
Agelastatin (42) was reported to be the most active compound in the agelastatin family. It 
was first isolated from the sponge Agelas dendromorpha.61 42 displayed an inhibition on GSK-
3β.61 It is totoxic against L1210 with an IC50 of 0.033 μg/mL, which is competitive to that of 
doxorubicin.62 More than that, it showed the selectivity against human cervix carcinoma KB cell 
line with an IC50 of 0.075 μg/mL.62 Compounds 38-42 have been sent to Wayne State for the 
evaluation using other cancer cell lines.    
2.2.3 C023087.  C023087 is the extract of the sponge Phakellia cavernosa (Acanthella 
cavernosa) collected at -20 meters from Guam (Figure 100). Primary activity result displayed 
that the hexanes-EtOAc (50:50) fraction from a silica column was active against the H125 and 
CEM cell lines. Further purification on a 
preparative HPLC C18 column (21.2 × 250 mm) 
or C8 (10.0 × 250 mm) yielded three pure 
compounds (43-45). The compounds provided 
quasi-molecular signals [M+H]+ at m/z 384.2, 
411.2, and 402.3, respectively. Odd molecular 
weights of 43 and 45 demonstrated that they are nitrogen containing compounds. 43 has no UV 
absorption, while 44 and 45 have weak absorption at λ 210 nm. The 1H and 13C NMR spectra of 
43 displayed a proton at δH 4.99 and carbons in the region of δC 60-90, indicating they are 
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adjacent to oxygens. Carbons at δC 152.1, 152.8, and 156.7 suggested the presence of isocyano 
carbons. However, due to the limited sample size, insufficient pulsing, and the broadness of the 
signals, the response of isocynao carbons was limited (Figures 101, 102). Compound 44 
displayed a mass ratio of 3:1 at M:[M+2], suggesting the presence of a chlorine in the molecule. 
Mass searching in Marinlit and comparison of acquired 1H NMR spectra with published 
compounds confirmed the compounds are kalihinol F (43), 10-formamidokalihinol A (44), and 
10-formamidokalihinol F (45) (Figure 103).63,64   
 
Figure 101 1H NMR spectrum of kalihinol F (43) in CD3OD  
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Figure 102 13C NMR spectrum of kalihinol F (43) in CD3OD 
 
 
 
Figure 103 Structures of 43-45 isolated from Phakellia cavernosa 
2.2.4 C012610. C012610 is the extract of the ascidian Didemnum rubeum collected at -10 meters 
from Ngerkuul in the Republic of Palau (Figure 104). The primary activity result of its fractions 
showed the silica EtOAc-MeOH (50:50) fraction was active against the H125 cell line. Further 
purification on sephadex LH-20 using DCM-MeOH (1:1), followed by a preparative HPLC C18 
column (21.2 × 250 mm) yielded compound (46). The molecule gave a quasi-molecular signal 
[M+H]+ at m/z 403.9. An odd molecular weight provided the evidence that it is nitrogen 
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Figure 104 The ascidian Didemnum rubeum 
containing compound. Proton and carbon signals at δH 7.8, δC 136.7, 140.1, 158.3 indicated the 
presence of an aromatic ring. An additional two 
aromatic carbons at δC 90.1 were observed, which 
was due to a shielding effect caused by the iodine. 
The 1H NMR spectrum displayed a methyl signal at 
δH 3.81, indicating the presence of a methoxy 
group (Figures 105, 106). Marinlit searching and 
comparison of acquired 1H and 13C NMR spectra with published data confirmed that 46 is 3,5-
diiodo-4-methoxyphenethylamine (Figure 107).65 
 
Figure 105 1H NMR spectrum of 3,5-diiodo-4-methoxyphenethylamine (46) in CD3OD 
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Figure 106 13C NMR spectrum of 3,5-diiodo-4-methoxyphenethylamine (46) in CD3OD 
 
NH2
H3CO
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Figure 107 The structure of 3,5-diiodo-4-methoxyphenethylamine (46)  
3. Materials and Methods 
3.1 General Experimental Procedures.  NMR spectra were recorded on a Bruker Avance 
DRX-400 spectrometer. The 1H and 13C NMR chemical shifts were reported in ppm. HPLC-ESI-
TOF was performed on Bruker MicroTOF in line with an Agilent 1100 Series HPLC system and 
G1316A DAD detector. Phenomenex Luna C8 5 µm column (150 mm × 4.6 mm) was used with 
a gradient elution of MeOH with 0.05% HCOOH at a flow rate of 0.6 mL/min. Preparative 
HPLC was carried out on a Waters PrepLC system with a single wavelength detector. C18 and 
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sephadex LH-20 resins were purchased from Sigma-Aldrich. Optical rotations were measured on 
a JASCO DIP-370 polarimeter. 
3.2 Screening of Active extracts. A standard approach for the screening of NCI extracts was 
developed by our group. First, 20mg of extract is divided into four 5 mg fractions. Then 5 mg 
material is eluted on the silica, C18, sephadex LH-20, and amino cartridges, respectively 
(Scheme 12). All the fractions were sent to Wayne State University for bioassay. Once the 
activity was confirmed for the fractions, the isolation of potent extracts was performed utilizing 
the best separation material based on the assay data. 
 
Scheme 12 A standard approach for the screening of NCI extracts 
3.3 Compound Isolation.   
3.3.1 C021197. The crude extract (1 g) was subjected to VLC on a silica gel column eluting with 
a stepwise gradient solvent of hexanes−EtOAc (100:0, 75:25, 50:50, 25:75, 0:100), and 
EtOAc−MeOH (75:25, 50:50, 25:75, 0:100), to yield nine fractions. Fr5-7 showing activity were 
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chromatographed on a preparative HPLC C5 column (21.2 × 250 mm); C8 column (10.0 × 250 
mm using a gradient of MeOH-H2O (0.05% HCOOH) (20:80-80:20) to afford 35 (1.5mg), 36 
(1.8mg), and 37 (2.0mg). 
3.3.2 C004690. The crude extract (12 g) was subjected to C18 glass open-tubular column eluting 
with a gradient solvent of H2O-MeOH (95:5, 90:10, 75:25, 60:40, 50:50, 40:60, 30:70, 20:80, 
10:90, 0:100). LC-MS data displayed that Fr5-7 contain brominated metabolites. Fr5 was 
chromatographed on a preparative HPLC C18 column (21.2 × 250 mm) using a gradient of 
MeCN-H2O (10:90−50:50) to afford 38 (4.8 mg) and 39 (20 mg). Fr 6 and Fr 7 were 
chromatographed on a preparative HPLC C18 column (21.2 × 250 mm) using a gradient of 
MeCN-H2O (20:80-70:30) to afford 40 (27 mg), 41 (5 mg), and 42 (150 mg). 
3.3.3 C023087. The crude extract (1 g) was subjected to VLC on a silica gel column eluting with 
a stepwise gradient solvent of hexanes−EtOAc (100:0, 75:25, 50:50, 0:100), and EtOAc−MeOH 
(50:50, 0:100), to yield six fractions. The active Fr3 was subjected on a preparative HPLC C8 
column (21.2 × 250 mm) or C8 (10.0 × 250 mm) using a gradient of MeCN-H2O (30:70 - 100:0) 
to yield 43 (1.0 mg), 44 (0.8 mg), and 45 (0.8 mg). 
3.3.4 C012610. The crude extract (1 g) was subjected to VLC on a silica gel column eluting with 
a stepwise gradient solvent of hexanes−EtOAc (100:0, 50:50, 0:100), and EtOAc−MeOH (50:50, 
0:100), to yield five fractions. Active Fr4 was eluted on sephadex LH-20 using DCM-MeOH 
(50:50), followed by a preparative HPLC C8 column (21.2 × 250 mm) or C8 (10.0 × 250 mm) 
using a gradient of MeCN-H2O (20:80 - 90:10) to yield 46 (1.0 mg). 
3.4 Antitumor Assay. The cytotoxicity soft-agar based disc diffusion assay was described in 
Chapter 1. 
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1. Introduction 
Foodborne diseases have long been a major concern to public health. The WHO reports 
that there are approximately 76 million cases of foodborne illnesses annually in the U.S., and 
cost approximately $35 billion each year in treatment, prevention, and lost productivity.66 
Foodborne diseases are involved in high levels of morbidity and mortality, especially among 
infants, children, elderly, and the immunocompromised. With the growing challenges of 
foodborne diseases, innovative, economical, and effective controls are needed to inhibit the 
spread and prevent outbreaks of infectious diseases. Improving microbiological quality and 
safety of food is one of the most important points in this effort.  
Foodborne diseases can be caused by either infections or intoxications.67 Infections may 
be caused by bacteria, fungi, viruses, or parasites.68 Intoxications can be acquired by 
microorganism toxins or other poisonous chemical substances found in certain plants or 
animals.67 It is estimated that bacterial pathogens are responsible for more than 60% of 
foodborne diseases. According to the CDC, the most common bacterial pathogens leading to 
foodborne illnesses are Campylobacter, Salmonella, and Escherichia coli O157:H7.69 In addition, 
CHAPTER 4 
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bacterial toxins produced by Staphylococcus, Clostridium, Bacillus, and Vibrio result in 
foodborne disease outbreaks.67,68,69  
There are many approaches to deal with the microbiological safety of food. Except for 
quality assessments and controls during harvesting, processing, packaging, storage, and shipping, 
treating food with preservatives is another major approach. Debates on the safety of commonly 
used synthetic antimicrobial preservatives are ongoing. Compared to artificial presertivatives, 
natural ones could be safer and more readily degradable. Moreover, large-scale biosynthesis of 
target substances is economical, environmentally benign and achievable. Currently, only two 
antibiotics, the lantibiotic nisin and the bacteriocin, pediocin PA1 produced by lactic acid 
bacteria,70,71 and some essential oils are used as legal food preservatives. Thus, identification of 
new natural products as antimicrobial preservatives is required.  Marine microbes represent an 
unprecedented natural source for biologically active compounds. Many marine microbes belong 
to the same genera as terrestrial bacteria that are known producers of bioactive molecules. Many 
metabolites have been reported as drug-like molecules; however, molecules to be used as food 
preservatives have a different set of requirements than those that are destined for use as 
therapeutic agents. Metabolic stability is one of the major differences. A potential therapeutic 
product needs to be relatively stable to a variety of metabolic factors, but immediate degradation 
of a food additive to inactive molecules upon consumption is desirable. Therefore, discovery of 
antimicrobial substances from marine microorganisms is an appealing approach to reduce 
foodborne diseases.  
Marine microbes are capable of producing distinct secondary metabolite profiles based 
on their need for defense, competition or a number of other environmental factors.72 The most 
common approach for discovery of bioactive secondary metabolites from microbes is to screen 
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microbes for unique biological activities. However, a major challenge to this approach is the 
cultivation of microbes under laboratory conditions. Even under the best of circumstances, these 
experiments fail to emulate environmental conditions such as competition, diverse nutrient 
sources, and extreme temperature variations. The result is an artificial environment for producing 
secondary metabolites which may cause the silencing of certain genetic pathways since the 
secondary metabolites they produce are non-essential for survival. To address this problem, 
strategies of using epigenetic modifiers were utilized to activate the silent gene pathways. Under 
specific stresses, microbes can respond to stimuli, thus increasing the yield of certain secondary 
metabolites or producing new metabolites. Cichewicz’s research group identified several new 
metabolites by treating the fungus Cladosporium cladosporioides with histone deacetylase or 
DNA methyltransferase inhibitors.73 This study provided evidence that the ecological responses 
could be attributed to the chemical activation of gene expression corresponding to the secondary 
metabolite biosynthetic gene clusters. Fenical’s research group also reported an increased 
production of emericellamides A and B when co-culturing the fungus Emericella sp. with an 
actinomycete Salinispora arenicola.74 In this case, biochemical communication between 
microorganisms represents more complicated interactions in microbial communities.  
In 2009, marine sediment microbes were collected from the Texas Gulf Coast. Based on 
general antimicrobial and antimalarial activities screening of their extracts, 17 antibiotic 
producing microbes were identified. From one of the microbes, YPD1C, which was 
characterized as Pseudomonas aeruginosa, 15 known compounds including two derivatives of 
phenazine (47, 48), six 2-alkyl-4-quinolones (49-54), and seven rhamnolipids (55-61) were 
isolated (Figure 108). This isolation allowed us to understand the metabolic profile of 
biologically active secondary metabolites from P. aeruginosa, and using this as a basis for 
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comparison, we were able to identify the differences in metabolite production when treating P. 
aeruginosa with different modifiers and external stimuli. In the world of bacteria, stimuli can 
change gene expression by affecting DNA methylation,75 transcription initiation,76 quorum 
sensing,77 kinase signaling,78 or carbon and nitrogen metabolism.79 In this chapter, isolation of 
antibiotics from P. aeruginosa and impacts on their production in P. aeruginosa are discussed 
using modifiers including kinase inhibitors manzamine A, kahalalide F, and sceptrin, a cell 
transport regulator ilimaquinone; adjustment to growth factors such as carbon sources and 
temperature or co-culturing with four other antibiotic producing microbes (YPD1A, YPD1D, 
YPD5A, and YPD5C) also collected from the Gulf of Mexico in the Fall of 2009. Interestingly, 
an improvement of antibiotic production was observed in a mix microbial community with the 
presence of the chemical modifier sceptrin. 
 
 
Figure 108 Structures of isolated antimicrobial agents from P. aeruginosa 
2. Results and Discussion 
2.1 Active Compounds from Fermentation of P. aeruginosa. The active fraction was 
subjected to VLC on silica gel. A disc diffusion assay revealed fractions Fr3, Fr4 (hexanes-
 113 
 
EtOAc 50:50, 25:75) and Fr6 EtOAc-MeOH 75:25 have activity against Bacillus cereus (Figure 
109). The LC-MS and 1H NMR screening of Fr3 and Fr4 revealed signals consistent with 
aromatic rings. The odd molecular weight m/z signals suggested the presence of alkaloids. 
Further purification was performed using HPLC leading to the isolation of two known active 
compounds, 1-phenazinecarboxamide (47) and 1-phenazinecarboxylic acid (48).  
Fr6 was eluted using sephadex LH-20 with DCM-MeOH (50:50) to give 10 sub-fractions, 
in which Fr6-4, Fr6-6 and Fr6-7 were active using a B. cereus disc diffusion assay. Fr6-4 was 
further purified by HPLC, yielding six pure compounds. LC-MS data of compound 6-4-7-6 gave 
quasi-molecular ions at m/z 244.2 [M+H]+, 266.2 [M+Na]+, 487.4 [2M+H]+, and 509.3 
[2M+Na]+, which implied the molecule contains an odd number of nitrogens. The 1H and 13C 
NMR chemical shifts of the molecule from δH 6.25 to δH 8.22, and δC 107.4 to δC 179.2, 
suggested that it is a quinolone derivate. The 1H NMR signals from δH 0.8 to δH 1.9 indicated 
that the molecule contains an aliphatic chain (Figures 110, 111). Based on the key HMBC 
correlations and comparison with known compounds in SciFinder database using a partial 
structure, it was determined to be the known compound 2-heptyl-4(1H)-quinolone (49). The 
structures of the remaining five compounds were identified as 1-hydroxy-2-heptyl-4-quinolone 
(50), 2-octyl-4(1H)-quinolone (51), 2-nonyl-4(1H)-quinolone (52), 2-(2-nonenyl)-4(1H)-
quinolone (53), and 2-(1-nonenyl)-4(1H)-quinolone (54) by the LC-MS and HMQC overlay 
experiments. 
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Figure 109 Bioassay result of active fractions on Bacillus cereus 
 
Figure 110 1H NMR spectrum of 2-heptyl-4(1H)-quinolone (49) in CD3OD 
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Figure 111 13C NMR of 2-heptyl-4(1H)-quinolone (49) in CD3OD 
The isolation of Fr6-6 and Fr6-7 was conducted using a CR8R (250mm×10mm, 5um) 
column to yield seven pure compounds. The P1PH NMR chemical shifts of compound 6-6-8-5-4 
from δRHR 3.2 to δRHR 4.2 suggested the presence of a sugar moiety. The P13 PC NMR spectrum showed 
the characteristic signals for rhamnose at δRCR 99.26, 74.13, 72.53, 71.20, 70.97, and 16.51. The P1 PH 
NMR signals below δRHR 1.7 indicated the presence of an aliphatic chain (Figures 112, 113). Its 
negative-ion mode LC-MS data gave quasi-molecular ions at m/z 503.3 [M-H] P־P and 1007.1 [2M-
H] P־P. The fragment ion at m/z 333.2 indicated the loss of a terminal fatty acid unit (CR10RHR20ROR2R). 
The identity of the sugar and lipid moieties of these seven compounds and their interconnection 
by HMBC correlations determined they are known rhamnolipids: Rha-CR10R-CR10R (55), Rha-Rha-
CR10R-CR10R (56), Rha-Rha-CR10R-CR12:1R (57), Rha-Rha-CR10R-CR12R (58), Rha-CR10R-CR12:1R (59), Rha-CR10R-CR12R 
(60), Rha-CR8R-CR10R (61). Two D-rhamnose and two α-hydroxy fatty acid moieties were identified 
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by comparing characteristic spin systems from the 1D and 2D 1H COSY spectra and specific 
rotation values to the published data.80,81  
 
Figure 112 1H NMR spectrum of Rha-C10-C10 (55) in CD3OD  
 
Figure 113 13C NMR spectrum of Rha-C10-C10 (55) in CD3OD 
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2.2 Activities.  1-Phenazinecarboxamide (47), 1-phenazinecarboxylic acid (48), Rha-Rha-C10-
C12:1 (57) and Rha-Rha-C10-C12 (58) showed antifungal activity against Cryptococcus 
neoformans with IC50 values of 6.99, 1.30, 15.67, and 5.82 μg/mL, respectively; Rha-C10-C12:1 
(59) and Rha-C10-C12 (60) showed antibacterial activity against Staphylococcus aureus with IC50 
19.88, 5.70 μg/mL, against MRS with IC50 at 18.89, 12.33 μg/mL, respectively; 47 and 2-(1-
nonenyl)-4(1H)-quinolone (54) also displayed activity against Mycobacterium intracellulare 
with IC50 at 17.48, 20.00 μg/mL, respectively. In addition, 2-nonyl-4(1H)-quinolone (52) and 54 
show antimalarial activity with IC50 at 0.13, 0.26 μg/mL in D6 strain, and 0.14, 0.36 μg/mL in 
W2 strain of Plasmodium falciparum, respectively. 1-Hydroxy-2-heptyl-4-quinolone (50), 2-
octyl-4(1H)-quinolone (51) and 2-(2-nonenyl)-4(1H)-quinolone (53) were not tested for 
activities due to the low yields. 
2-Nonyl-4(1H)-quinolone (52) and 2-(1-nonenyl)-4(1H)-quinolone (54) showed potent 
antimalarial activity both in D6 and W2 strains of P. falciparum, which was first reported in this 
paper. Moreover, they have no cytotoxicity against Vero cells. 1-Hydroxy-2-dodecyl-4-
quinolone82 and 3-substituted 2-methyl-4(1H)-quinolones83 exhibited antimalarial activity by 
inhibiting type II NADH dehydrogenases.82 QSAR studies on 4(1H)-quinolones provided 
evidence that both the aromatic ring and aliphatic group are essential for the activity.84 Since 
mammalian cells possess type I instead of type II NADH dehydrogenases,82 this class of 4(1H)-
quinolones could be potential drug leads in treating malaria. 
2.3 Identification of Microorganisms. BLAST analysis demonstrated YPD1C is 99% identical 
to Pseudomonas aeruginosa. YPD1A and YPD1D were determined to be two Bacillus sp., 
YPD5A and YPD5C were two Pseudomonas sp..  
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2.4 Activities of Pseudomonas Extracts Treated with Different Factors. P. aeruginosa 
(YPD1C) was cultured with different carbon and nitrogen sources, regulators and co-cultured 
with the four other antibiotic producing microbes, YPD1A, YPD1D, YPD5A, and YPD5C. 
Considering the extensive number of experiments required to test all of these factors 
independently, an orthogonal design was used to minimize sample size. Each sample was 
duplicated (Table 14).  
Table 14 Orthogonal design of treatments on P. aeruginosa (n=2) 
Carbon Source   
(400 mg/50 mL) 
Nitrogen Source 
(400 mg/50 mL) 
Regulator            
(1 µM) 
Temperature 
(°C)  Days Microorganism 
Glucose  NH4Cl Sceptrin  25 2 YPD1C 
Sodium Acetate Urea --- 25 5 YPD1C+1D 
Oil Mix NaNO3   Kahalalide F  25 8 YPD1C+5A 
Starch NaNO2   Ilimaquinone  25 11 YPD1C+1A 
Citric Acid Peptone Manzamine A  25 14 YPD1C+5C 
Citric Acid Urea Ilimaquinone  30 2 YPD1C+5A 
Glucose  NaNO3   Manzamine A 30 5 YPD1C+1A 
Sodium Acetate NaNO2   Sceptrin 30 8 YPD1C+5C 
Oil Mix Peptone --- 30 11 YPD1C 
Starch NH4Cl Kahalalide F  30 14 YPD1C+1D 
Starch NaNO3   --- 35 2 YPD1C+5C 
Citric Acid NaNO2   Kahalalide F  35 5 YPD1C 
Glucose  Peptone Ilimaquinone  35 8 YPD1C+1D 
Sodium Acetate NH4Cl Manzamine A   35 11 YPD1C+5A 
Oil Mix Urea Sceptrin 1uM  35 14 YPD1C+1A 
Oil Mix NaNO2   Manzamine A  40 2 YPD1C+1D 
Starch Peptone Sceptrin  40 5 YPD1C+5A 
Citric Acid NH4Cl --- 40 8 YPD1C+1A 
Glucose  Urea Kahalalide F  40 11 YPD1C+5C 
Sodium Acetate NaNO3   Ilimaquinone  40 14 YPD1C 
Sodium Acetate Peptone Kahalalide F  45 2 YPD1C+1A 
Oil Mix NH4Cl Ilimaquinone  45 5 YPD1C+5C 
Starch Urea Manzamine A  45 8 YPD1C 
Citric Acid NaNO3   Sceptrin  45 11 YPD1C+1D 
Glucose  NaNO2   --- 45 14 YPD1C+5A 
YPD medium Sceptrin --- --- --- 
YPD medium Ilimaquinone --- --- --- 
YPD medium Kahalalide F --- --- --- 
YPD medium Manzamine A --- --- --- 
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Extract activity was normalized by comparison with the activity of the regulator control 
in each bioassay, thus providing an accurate assessment. The direct sum in an orthogonal design 
was used to determine the best conditions for each modifying factor. As a result, the best 
conditions to produce antimicrobial compounds are oil mix (50% corn oil, 50% olive oil) as the 
carbon source, peptone as a nitrogen source, and incubation at 30°C for 11 days (Table 15). 
However, only antifungal activity displayed an increase when compared to positive control. 
Interestingly, when treating YPD1C with sceptrin and co-culturing with YPD5A, an increase of 
antifungal activity against C. neoformans, antibacterial activity against S. aureus and MRS, and 
antimalarial activity were observed.  
To further determine the significance of sceptrin and YPD5A on antibiotic production 
from P. aeruginosa, a second batch of experiments was designed using YPD media, at 30°C and 
250 rpm for 7 days, different concentrations of sceptrin, and with/without YPD5A. OD600 values 
were measured to test viability of the microbe in each condition. Antimicrobial and antimalarial 
activities were tested for all the extracts. (Table 16) The activity data (T1-T6) was analyzed 
using the analysis of variance (ANOVA). As a result, the activities showed significant 
differences between all the treatments (P<0.01). To further determine which treatment was 
responsible for the major difference, a Dunnett’s test was applied by comparison of treatment 
groups (T2-T6) with a positive control group (T1).  There were no significance differences 
observed (P>0.05) between the groups singly treated with sceptrin or co-culturing (T2-T4). 
However, when treating sceptrin and co-culturing with YPD5A, a significant enhancement of all 
the activities was observed (T5, P<0.05; T6, P<0.01; Figures 114, 115). The antimicrobial 
activities of YPD5A (T7-T9) decreased significantly when adding 5 μM sceptrin (T9, P<0.05). 
Meanwhile, the OD600 value of T9 dropped more than five times to the same level as media 
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controls. It is unclear if this decline is due to a bacteriostatic or a bacteriocidal effect; however, at 
1 µM there is no effect on growth. This lack of growth would also result in lack of antibiotic 
production. 
Table 15 Orthogonal direct sum of activities in different culture conditions 
  C. glabrata C. neoformans S. aureus MRS E. coli Malaria 
Carbon 
Source 
Glucose  0  12  6  20  27  84  
Sodium 
Acetate 0  11  3  1  2  9  
Oil Mix 0  80  57  60  54  164  
Starch 23  10  14  18  13  90  
Citric Acid 37  11  12  21  22  86  
Nitrogen 
Source 
NH4Cl 6  23  2  4  13  1  
NaNO3   10  9  2  13  3  1  
Peptone 44  74  69  85  75  255  
Urea 0  3  9  10  23  172  
NaNO2   0  14  11  9  5  4  
Regulator 
Sceptrin  33  3  21  36  7  175  
Manzamine A 21  8  6  4  12  4  
Ilimaquinone  0  29  4  22  48  168  
Kahalalide F  0  2  12  8  3  0  
--- 6  81  49  51  49  86  
Temp. 
25 21  13  1  3  8  5  
30 0  72  51  51  56  172  
35 0  9  24  36  31  166  
40 29  13  13  18  6  89  
45 10  18  3  13  18  1  
Days 
2 0  1  2  0  12  85  
5 23  17  26  25  7  94  
8 6  19  5  23  45  88  
11 10  78  51  62  49  83  
14 21  8  9  10  6  83  
Co-culture 
YPD1C 0  72  61  57  52  83  
YPD1C+1A 6  20  12  13  13  83  
YPD1C+1D 10  8  4  30  30  87  
YPD1C+5C 21  16  1  3  11  5  
YPD1C+5A 23  7  15  17  12  175  
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Table 16 Antimicrobial and antimalarial activities of YPD1C with epigenetic regulation (n=3) 
 Media Temp. (°C) Days 
Sceptrin 
(µM) Microorganism OD600 
Antifungal  
(% Inh.) 
Antibacterial (% Inh.) 
Antimalarial  
(IC50, µM) 
C. neoformans S. aureus MRS D6 W2 
C1 YPD --- --- --- --- 0.60±0.004 7.72±0.96 8.98±1.04 9.17±1.16 ND ND 
C2 YPD --- --- 5 --- 0.63±0.006 9.15±0.58 8.04±0.88 8.71±1.74 ND ND 
T1 YPD 30 7 --- YPD1C 4.11±0.008 18.1±4.62 55.2±5.25 57.6±3.84 7.25±0.78 9.15±1.20 
T2 YPD 30 7 1 YPD1C 4.28±0.017 18.8±8.81 44.8±11.8 51.7±12.8 5.95±0.21 8.45±1.48 
T3 YPD 30 7 5 YPD1C 4.30±0.072 24.4±6.89 38.3±8.29 41.4±9.27 5.43±1.25 6.80±2.09 
T4 YPD 30 7 --- YPD1C+5A 3.56±0.061 6.45±1.36 6.39±2.82 15.1±4.63 ND ND 
T5 YPD 30 7 1 YPD1C+5A 3.95±0.066 45.1±12.6 65.6±16.2 81.9±13.1 2.80±1.17 3.41±0.86 
T6 YPD 30 7 5 YPD1C+5A 4.12±0.005 63.5±4.43 94.1±2.49 94.3±4.00 0.89±0.10 1.10±0.14 
T7 YPD 30 7 --- YPD5A 3.59±0.147 13.4±1.89 11.4±2.12 17.5±1.92 ND ND 
T8 YPD 30 7 1 YPD5A 3.59±0.101 11.7±5.46 8.43±3.50 15.3±1.40 ND ND 
T9 YPD 30 7 5 YPD5A 0.678±0.026 7.21±3.04 3.35±1.02 7.10±2.53 ND ND 
ND: IC50 was not tested in the secondary assay, which due to a limited inhibition (< 10%) observed in the primary assay.
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 *: P<0.05; **: P<0.01 
Figure 114 Antimicrobial activities of YPD1C extracts with different treatments 
 
ND: IC50 was not tested due to less than 10% of inhibition in the primary assay  
 *: P<0.05; **: P<0.01 
Figure 115 Antimalarial activity of YPD1C extracts with different treatments 
 
The total ion chromatograms (TICs) of YPD5A extracts (T7-T9) displayed different 
profiles than those of YPD1C extracts (Figure 116). Comparison of the extracted ion 
chromatograms (EICs) between extracts of YPD5A and YPD1C confirmed that YPD5A does not 
produce the same active metabolites as YPD1C. The fingerprints of groups T1, T5, and T6 were 
compared. The TICs showed an increase in production, especially of phenazines (Rt 10-15 min) 
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and quinolones (Rt 18-26 min) (Figure 117).  To further determine the variation of each class of 
metabolites, EICs were compared by extracting ions at m/z=224, 225, 244, 260, 270, 272 
(Figure 118), and 651, 505, 677, 679, 531, and 533 (Figure 119) that correspond to 1-
phenazinecarboxamide (47) and 1-phenazinecarboxylic acid (48), 2-heptyl-4(1H)-quinolone (49), 
1-hydroxy-2-heptyl-4-quinolone (50), 2-(2-nonenyl)-4(1H)-quinolone (53), 2-(1-nonenyl)-
4(1H)-quinolone (54), 2-nonyl-4(1H)-quinolone (52),  Rha-Rha-C10-C10 (56), Rha-C10-C10 (55), 
Rha-Rha-C10-C12:1 (57), Rha-Rha-C10-C12 (58), Rha-C10-C12:1 (59), and Rha-C10-C12 (60). It 
was noticed that the yields of 47, 48, 49, 50, 52, 54, 57, 58, and 60 increased in T5 and T6. 
Moreover, a new signal which could be another 2-alkyl-4-quinolone with m/z 298 was observed 
in a high intensity. Based on the MS data and retention time, it could contain two more 
methylenes than 53 or 54. According to the activities, 47, 48, 57, and 58 were responsible for the 
antifungal activity, 47, 54, and 60 for the antibacterial activity, and 52 and 54 for the antimalarial 
activity. The fingerprint comparison of T1, T5 and T6 complemented the observed bioactivity 
and our statistical analysis. 
 
 
Figure 116 TIC comparison of T7-T9 
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Figure 117 TIC comparison of T1, T5-T6 
 
 
 
Figure 118 Quinolones EIC comparison of T1, T5-T6 
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Figure 119 Rhamnolipids EIC comparison of T1, T5-T6 
2.5 Role of Yeast Extract in Media. The antimicrobial activity of all the extracts indicated that 
the best conditions to produce antimicrobial compounds was oil mix (50% corn oil, 50% olive oil) 
as the carbon source, and peptone as the nitrogen source. However, antibiotic production under 
these conditions was far less than that of YPD medium. YPD consists of yeast extract, peptone, 
and dextrose, among which only yeast extract was not added during the media modifications. 
Hence, it was considered that yeast extract played a key role in the high yield of antibiotic 
production. Yeast extract is a processed product by removing the yeast cell wall. It may contain 
various cell contents of yeast including small RNAs. There was evidence that small RNAs in the 
yeast extract containing media could change bacterial protein profiles, thus influencing bacterial 
adaption.85 Yeast extract serves not only as nutrient in growth media, but a stimulus to P. 
aeruginosa. It is reasonable that yeast extract induced antibiotic production in P. aeruginosa as a 
modifier. 
2.6 Roles of Regulators. Manzamine A has been identified as a potent GSK-3β inhibitor.86 
Kahalalide F was shown to down-regulate the ErbB3 receptor and inhibit Akt signaling.18 Both 
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of these compounds are cytotoxic. When the regulator controls were tested, manzamine A and 
kahalalide F displayed inhibition of all microbes. Cultures treated with manzamine A and 
kahalalide F lacked growth during fermentation, indicating that the compounds were cytotoxic to 
the bacteria.  
Sceptrin has diverse activities including antifungal, antibacterial, and antihistaminic. It is 
an inhibitor of somatostatin and cell motility.87 Based on our experimental data, the addition of 
sceptrin does not have a significant influence on P. aeruginosa. However, it does affect the 
vitality of another Pseudomonas species, YPD5A. The fingerprint comparison of T7-T9 
suggested the yields of some metabolites were improved when YPD5A was treated with 5 μM 
sceptrin (Figure 116). These could be degradation products of sceptrin or other metabolites 
released from YPD5A, which indicated that YPD5A is able to trigger a series of responses under 
stress conditions.  
2.7 Mixed Fermentation 
Usually, microbes within the same genus are able to consume the same nutrients for their 
survival. When co-culturing, there is potential competition for nutrients.88,89 In our experiment, 
another Pseudomonas sp., YPD5A, was co-cultured with YPD1C. A comparison of activities as 
well as OD600 values between T1 and T4 suggested the vitality of both YPD1C and YPD5A 
were weakened after co-culturing. This could be proposed that some YPD1C died from an 
insufficient nutrient, or YPD5A released quorum sensing (QS) molecules to down-regulate the 
antibiotics produced from YPD1C. 
Chemical communication between microbes can induce a series of interactions between 
species. In the experiment, another Pseudomonas species YPD5A was co-cultured with P. 
aeruginosa, YPD1C. The data indicates that the antibiotic production of YPD1C singly treated 
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with sceptrin or co-cultured with YPD5A is not sufficient to equal that of culturing all three 
components together. We have also established that the concentration used in this co-culture is 
sufficient to inhibit growth of YPD5A. This suggests several possible outcomes when co-
culturing YPD1C with YPD5A. One option is that YPD5A releases a signaling molecule when 
exposed to 5 µM sceptrin and this molecule induces production of secondary metabolites in 
YPD1C. Another option is a much more complex cross-talk mechanism between the two stains 
involving a combination of QS molecules and sceptrin or derivatives thereof. Quinolones have 
been implicated in QS regulation.90 An increase in OD600 as well as quinolone concentration 
implied a relationship between the antibiotic production of the species and microbial competition 
between species.  
3. Materials and Methods 
3.1 General Experimental Procedures.  NMR spectra were recorded on a Bruker Avance 
DRX-400 spectrometer. The 1H and 13C NMR chemical shifts were reported in ppm. HPLC-ESI-
TOF was performed on a Bruker MicroTOF in line with an Agilent 1100 Series HPLC system 
and G1316A DAD detector. A Phenomenex Luna C18 5 µm column (150 mm × 4.6 mm) was 
used with a gradient elution of MeCN in 0.05% HCOOH at a flow rate of 0.6 mL/min. 
Preparative HPLC was carried out on a Waters PrepLC system with a single wavelength detector. 
Sephadex LH-20 and Diaion HP-20 were purchased from Sigma. Sephadex LH-20 was applied 
in an isocratic solvent system of MeOH-H2O (75:25), unless otherwise stated. Optical rotations 
were measured on a JASCO DIP-370 polarimeter. OD values were measured on a Varian Cary 
50 Bio UV/visible spectrophothmeter. 
3.2 Microbial Collection and Isolation.  On October 24, 2009, sediment collection was made in 
the tributary leading into West Galveston Bay (N29 13.349º W95 12.992º). Sediment was 
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collected from the bay floor using a petite ponar grabber and transferred to a sterile 50 mL 
conical tube.  The volume of collected sediment was diluted with sterile filtered artificial sea 
water (2% Instant Ocean) to approximately 1.5 times the original volume.  The sediment was 
mixed by agitation and heat shocked at 55℃ for eight minutes.  The sample was allowed to rest 
until the sediment had settled.  Volumes of 150 and 300 µL of supernatant were placed on Yeast 
Peptone Dextrose (YPD) (10/20/20 g/L) media with 50 µg/mL of ampicillin.  The plate was left 
at room temperature until colonies appeared.  Once colonies grew, individual colonies were 
chosen and streaked onto secondary plates containing no antibiotics, but still supplemented with 
2% Instant Ocean.  Microbes were again grown at room temperature until colonies appeared.  
Using these plates, pure colonies were isolated and glycerol stocked at -80℃ for preservation 
and large scale growth.   
All organisms used for the antimicrobial assays were obtained from the American Type 
Culture Collection (Manassas, VA) and included the fungi Candida albicans ATCC 90028, C. 
glabrata ATCC 90030, C. krusei ATCC 6258, Cryptococcus neoformans ATCC 90113, and 
Aspergillus fumigatus ATCC 204305 and the bacteria Staphylococcus aureus ATCC 29213, 
methicillin-resistant S. aureus ATCC 33591 (MRS), Escherichia coli ATCC 35218, 
Pseudomonas aeruginosa ATCC 27853, and Mycobacterium intracellulare ATCC 23068. 
3.3 16S rRNA. YPD-1A, YPD-1C, YPD-1D, YPD-5A, and YPD-5C were grown in 
supplemented YPD media at 30°C and 200 rpm overnight. DNA was isolated using an MoBio 
Ultrapure DNA purification system and following the manufacturer’s instructions. 16s DNA was 
amplified by PCR using the published 17f and 1492r universal bacteria 16s primers. The 
resulting amplified DNA was cloned into the pCR2.1 vector using a topoTA (Invitrogen) ligation 
kit. Plasmids were purified and subsequently sequenced using the T7 and M13 sites in pCR2.1. 
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BLAST analysis was conducted by comparison of acquired sequences of five microorganisms 
with database.   
3.4 Large Scale Growth and Extraction.  Eight cultures of the isolate (500 mL) were grown 
using YPD media supplemented with 2% Instant Ocean mix in 2.5 L Fernbach flasks incubated 
at 30℃  and 250 rpm for 7 days.  The cultures were first sonicated for 20 min and then 
centrifuged for 10 min at 3600 rpm in 250 mL portions.  The supernatant was decanted into a 
flask and the cell pellet was discarded.  Approximately 160 mL of HP-20 resin was added to the 
supernatant.  The flask was placed in the incubator and left overnight at 30℃ and 250 rpm. 
The HP-20 resin was extracted with a Buchner funnel, and the media was discarded.  The 
HP-20 was then washed with 1 L of EtOH followed by 500 mL of EtOAc.  The extracts were 
dried under vacuum, and the samples were assayed to assess biological activity. 
3.5 Compound Isolation.  The EtOH extract of YPD1C cultures (20 g) were loaded onto an HP-
20 column and eluted with 100% H2O, H2O-MeOH (75:25, 50:50, 25:75), 100% MeOH, and 
MeOH-EtOAc (50:50). The last two fractions and EtOAc extract of YPD1C culture (2 g) 
acquired from the large scale extraction previously were combined.  Further purifications were 
conducted on a silica flash column and eluted with hexanes-EtOAc (100:0, 75:25, 50:50, 25:75, 
0:100), EtOAc-MeOH (75:25, 50:50; 25:75, 0:100), and MeOH-H2O (50:50). Purifications of 
Fr3 and Fr4 were performed by HPLC on C5 (250 mm×20.2 mm, 5 µm) or C8 (250 mm×10 mm, 
5 µm) columns using a gradient of MeOH with 0.05% HCOOH-H2O with 0.05% HCOOH (from 
20:80 to 100:0). Fr6 was eluted from sephadex LH-20 with DCM-MeOH (50:50) and followed 
by HPLC on C5 (250 mm×20.2 mm, 5 µm), C8 (250 mm×20.2 mm, 5 µm), or C8 (250 mm×10 
mm, 5 µm) column using gradient of MeOH with 0.05% HCOOH-H2O with 0.05% HCOOH 
(from 20:80 to 100:0) or MeCN-H2O (from 28:72 to 100:0).  
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3.6 Antimicrobial Assay.  All organisms were tested using modified versions of the CLSI 
methods. Optical density was used to monitor growth for all organisms excluding M. 
intracellulare and A. fumigatus.91,92 Media supplemented with 5% Alamar Blue™ (BioSource 
International, Camarillo, CA) is utilized for growth detection of M. intracellulare,93,94 and A. 
fumigatus.95 Samples are serially-diluted in 20% DMSO/saline and transferred (10 µL) in 
duplicate to 96 well flat bottom microplates.  Inocula are prepared by correcting the OD630 of 
microbe suspensions in incubation broth [RPMI 1640/0.2% dextrose/0.03% glutamine/MOPS at 
pH 6.0 (Cellgro) for Candida spp., Sabouraud Dextrose for C. neoformans, cation-adjusted 
Mueller-Hinton (Difco) at pH 7.3 for Staphylococcus spp., E. coli, and P. aeruginosa, 5% 
Alamar Blue™ (BioSource International, Camarillo, CA) in Middlebrook 7H9 broth with OADC 
enrichment, pH = 7.0 for M. intracellulare, and 5% Alamar Blue™/RPMI 1640 broth (0.2% 
dextrose, 0.03% glutamine, buffered with 0.165M MOPS at pH 7.0) for A. fumigatus to afford an 
assay volume of 200 µL and final target inocula of: Candida spp. and C. neoformans.: 1.5 × 103, 
M. intracellulare: 2.0 ×106, Staphylococcus spp., E. coli, P. aeruginosa: 5.0 × 105 CFU/mL, 
and A. fumigatus: 2.7 × 104 CFU/mL. Final sample test concentrations are 1% of the DMSO 
stock concentration. Drug controls [ciprofloxacin (ICN Biomedicals, Ohio) for bacteria and 
amphotericin B (ICN Biomedicals, Ohio) for fungi] are included in each assay.  All organisms 
are read at either 530 nm using the Biotek Powerwave XS plate reader (Bio-Tek Instruments, 
Vermont) or 544ex/590em, (M. intracellulare, A. fumigatus) using the Polarstar Galaxy Plate 
Reader (BMG LabTechnologies, Germany) prior to and after incubation: Candida spp. at 35℃ 
for 46-50 h, Staphylococcus spp., E. coli, and P. aeruginosa at 35℃ for 16-20 h, C. neoformans  
at 35℃ for 70-74 h, A. fumigatus at 35℃ for 46-50 h, and M. intracellulare at 37℃ and 10% 
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CO2 for 70-74 h.  IC50s were calculated using XLfit 4.2 software (IDBS, Alameda, CA) using fit 
model 201.  
3.7 Antimalarial Activity.  Antimalarial activity was determined in vitro against chloroquine 
sensitive (D6, Sierra Leone) and resistant (W2, Indo China) strains of Plasmodium falciparum by 
measuring plasmodial LDH activity. Chloroquine and artemisinin were used as the positive 
controls. Test compounds were dissolved in DMSO (2 mg/mL). A 200 μL suspension of P. 
falciparum culture (2% parasitemia and 2% hematocrit in RPMI 1640 medium supplemented 
with 10% human serum and 60 µg/mL amikacin) was added to the 96-well plate containing 10 
μL of serially diluted samples. The plate was flushed with a gas mixture of 90% N2, 5% O2, and 
5% CO2 and incubated at 37 ºC for 72 h in a modular incubation chamber. Plasmodial LDH 
activity was determined by using MalstatTM reagent (Flow Inc., Portland, OR).96 The incubation 
mixture (20 μL) was mixed with 100 μL of the MalstatTM reagent and incubated for 30 min. A 
1:1 mixture of NBT/PES (20 µL, Sigma, St. Louis, MO) were then added and the plate was 
further incubated for 1 h in dark. The reaction was stopped by adding 100 μL of a 5% acetic acid 
solution. The plate was read at 650 nm. The in vitro cytotoxicity to mammalian cells (Vero cells) 
was also tested to determine the selectivity index of antimalarial activity of compounds. Cells 
were seeded at a density of 25,000 cells/well and incubated for 24 h. Serially diluted samples 
were added and incubated for 48 h. The number of viable cells was determined by Neutral Red 
assay.97 Doxorubicin was used as a positive control. IC50 values were obtained from dose 
response curves. 
3.8 Disc Diffusion Assay (DDA).   DDA provides a rapid, reliable method to screen fractions 
during purification. Considering it is one of the microbes that are responsible for the foodborne 
disease outbreak, and easy to grow, B. cereus was applied to DDA. A concentration limitation 
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experiment was performed with each active extract to determine the minimal amount needed to 
observe a zone of inhibition. Once this limit was established, this amount of each column 
fraction was added to a six mm filter paper disc. B. cereus cells (250 µL) were suspended in 
water and then plated onto antibiotic medium 2 (Difco) to form a bacterial lawn on the plate. The 
disc were added to the plate with a control of 50 µg of kanamycin and allowed to grow at 30℃ 
overnight. Activity was determined as a clear zone of inhibition. 
3.9 Treatments of YPD1C. YPD1C was cultured at different temperatures with different carbon 
and nitrogen sources, regulators and co-cultured with the four other antibiotic producing 
microbes (YPD1A, YPD1D, YPD5A, and YPD5C). The experimental design is shown in Table 
13. Cultures of the YPD1C isolate (50 mL) were grown using different media supplemented with 
2% Instant Ocean mix in 250 mL flasks incubated at 15-45°C and 250 rpm for 3-7 days.  P. 
aeruginosa grown in YPD media at 30°C and 250 rpm for 7 days was used as a positive control, 
while four regulators prepared in YPD media, respectively, were used as negative controls. All 
the cultures were sonicated for 20 min and centrifuged for 10 min at 3600 rpm. The supernatant 
was extracted with EtOAc (3×100 mL). The organic layers were combined for further bioassays 
and fingerprint analysis.  
3.10 Fingerprint Setup of Each Extract.  Filtered extracts were diluted with MeOH, and eluted 
on a C8 column (4.6 mm×250 mm, 5 μm) using a gradient of MeOH (with 0.05% HCOOH)– 
H2O (with 0.05% HCOOH) from 40:60 to 100:0 over 45 minutes at a flow rate of 0.6 mL/min. 
Fingerprints were acquired using a TOF-MS detector on the positive mode. A fingerprint of each 
extract was compared. 
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1. Introduction 
Tuberculosis (TB), caused by mycobacteria, especially Mycobacterium tuberculosis 
(Mtb), was responsible for 8.8 million incident cases and 1.4 million deaths in 2010.98 With the 
wide spread of the human immunodeficiency virus (HIV-1), cases of HIV-associated TB have 
become a major concern.99 Although TB is one of the oldest human diseases, it is still a 
significant health problem worldwide due to the lack of effective treatments. The primary 
limitations of current TB treatments include drug-resistance of Mtb by altering environmental 
signaling100 and the prevalent long-term latent infections which can persist in the human host 
with the capability to reactivate.101 In recent years multidrug-resistant TB and extensively drug-
resistant TB have emerged. With these challenges, there is an urgent medical need for new drugs 
to overcome drug resistance and dormancy. Since the 1990s a number of new chemotherapeutic 
agents to control Mtb have entered clinical trials including cell wall, RNA, malate, ATP and 
protein synthesis inhibitors, as well as proton pump and DNA gyrase inhibitors.102 No protein 
kinase inhibitors have entered clinical trials or been approved for treating TB thus far, though 
some are being investigated for this purpose. 
Phosphorylation by kinases is known to regulate signal transduction pathways in cells 
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and kinases play critical roles in cell growth, metabolism, differentiation and apoptosis. In the 
past two decades, many research groups have been developing kinase inhibitors and 23 kinase 
inhibitors have been approved for clinical use,103,104,105,106 some of which are proteins including 
trastuzumab, cetuximab, panitumumab, ranibizumab, bevacizumab, and pegaptanib. The 
remaining inhibitors are small molecules (Table 17), including the tyrosine kinase inhibitor 
imatinib (Gleevec/Glivec registered by Novartis) which was the first small-molecule kinase 
inhibitor used as a targeted therapy to treat chronic myeloid leukemia (CML) and gastrointestinal 
stromal tumors (GIST).107 In May 2001, the FDA made an exception and approved imatinib in 
less than three months. It was described as a “new hope for cancer”. The exploration of imatinib 
not only disclosed the prelude of targeted cancer therapy, but promoted the development of a 
new class of kinase inhibitors.  
Table 17 Approved small-molecule protein kinase inhibitors 
Year of 
Approval 
Name 
(Brand Name) Structure Target Clinical use  
1999 
Rapamycin/ 
Sirolimus 
(Rapamune) 
N
O
O
OH
O
OH
OO
O
O
O
O
O
HO
 
mTOR serine/ 
threonine kinase 
(STK) 
Immunosuppressant 
2001 
Imatinib 
(Gleevec, USA) 
(Glivec, Europe) 
 
Tyrosine kinase 
(TK) 
Chronic myelogenous leukemia 
(CML), gastrointestinal stromal 
tumors (GISTs) 
2003 Gefitinib (Iressa) 
 
EGFR TK 
Advanced or metastatic non-
small cell lung cancer 
(NSCLC) 
2004 Erlotinib (Tarceva) 
 
EGFR TK NSCLC,  Pancreatic cancer 
2005 Sorafenib (Nexavar) 
 
EGFR TK/ 
Raf STK 
Renal cell carcinoma (RCC), 
Advanced primary liver cancer 
N
N
HN
HN
N
N
N
O
O
N O
O N
N
HN
F
Cl
N
N
HN C
C
H
O
O
O
O
NH
N
O
H
N
H
N
Cl
CF3O
O
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2006 Sunitinib (Sutent) 
 
Multi-targeted 
TKs 
RCC, 
imatinib-resistant GIST  
2006 Dasatinib (Sprycel) 
 
Bcr/Abl,  
Src TKs  
Chronic myelogenous leukemia 
(CML), Philiadelphia 
chromosome -positive acute 
lymphoblastic leukemia (Ph+ 
ALL) 
2007 Lapatinib (Tykerb) 
 
Glycogen 
synthase kinase 
(GSK) 
HER2-positive Breast cancer 
2007 Temsirolimus (Torisel) 
N
O
O
O
O
OH
OO
O
O
O
O
O
HO
O
OH
OH
 
mTOR STK RCC 
2007 Nilotinib (Tasigna) 
 
Tyrosine kinase Drug-resistant CML 
2009 Pazopanib (Votrient) 
 
VEGFR, 
PDGFR TKs 
RCC 
Soft tumor sarcoma 
2009 
Everolimus 
(Zortress, USA) 
(Certican, Europe) 
N
O
O
O
O
OH
OO
O
O
O
O
O
HO
OH
 
mTOR STK Advanced kidney cancer Immunosuppressant 
2011 Vandetanib (Caprelsa) 
 
VEGFR,  
EGFR TKs 
Metastatic medullary  
thyroid cancer 
N
H
N
HF
NH N
O
O
Cl
O
H
N S
N
N
H
N
N N N
OH
N
N
O
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S
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Cl
O
F
O
O
N
N
N
HN
NH
N
N
F3C
O
NH
S
NH2
O O
N N
N N
N
N
O
O
N
N
HN
F Br
  
136 
 
2011 Crizotinib (Xalkori) 
 
ALK,  
ROS1 TKs Metastatic NSCLS 
2011 Vemurafenib (Zelboraf) 
 
B-Raf STK Late-stage melanoma 
2011 Ruxolitinib (Jakafi) 
 
Janus TK Intermediate or high-risk myelofibrosis 
2012 Axitinib (Inlyta) 
 
VEGFR, 
c-Kit TKs Metastatic RCC 
With the whole genome sequence of the Mtb strain H37Rv having been completed,108 it 
helped to reveal the kinases in Mtb. In Mtb, prokaryotic two-component systems and eukaryotic-
like serine/threonine protein kinases are used to transmit signals and control complex processes. 
Other kinases acting on small molecules take part in biochemical reactions including small 
molecule degradation, energy metabolism, central intermediary metabolism, amino acid 
biosynthesis, nucleotide biosynthesis, and serving as cofactors and carriers of these reactions. 
With many crystal structures of Mtb kinases completed, it is now possible to explore the 
potential of Mtb kinase inhibitors. Based on the kinase inhibitor scaffolds, various types of 
candidates, more than 26,000 in total, against the whole bacterium have been screened. Several 
classes of compounds, such as 2-acylaminothiophenes, 2-aminobenzothiazoles,  benzopyran-2-
ones, and 1,3,4-oxadiazoles displayed a significant inhibition on Mtb growth (Figure 120).109 
Many research groups have designed and screened inhibitors targeting specific kinases. In this 
review, we summarized the classification, function, crystal structures of kinases in Mtb, as well 
as Mtb kinase inhibitor design. SciFinder Scholar, Pubmed, Google Scholar, and protein data 
bank (PDB) are the major searching utilities used to finish the review.  
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Figure 120 Scaffolds of Mtb growth inhibitors 
2. Histidine Kinases in Two-Component Systems 
The primary environmental signal transduction pathways in prokaryotes feature two-
component systems (TCS) which include a sensor histidine kinase (HK) and a response regulator 
(RR).110 An external or internal stimulus can lead to the transfer of a phosphoryl group from 
adenosine triphosphate (ATP) to a conserved histidine of HK. Right after the phosphorylation, 
the histidine kinase catalyses the transfer of the phosphate group from the phosphorylated 
histidine residue to the receiver domain on an aspartate residue of the RR. The RR mediates an 
appropriate response, mainly by activating transcription.111  
Mtb has 14 sensor HKs and 16 RRs to form 12 HK/RR pairs and RR orphans,108,112 
Microbial HKs shares five conserved motifs denoted as the H-box, N-box, G1-box, F-box and 
G2-box.113 Depending upon the conservation of amino acids in and around the H-box, bacterial 
HKs are classified into five different types, types I-IV and CheA.113 All Mtb HKs belong to 
either Type IA (MtrB, MprB, PrrB, PhoR, KdpD, SenX3, TcrY, TrcS and Rv601c/Rv600c) or 
Type III (DevS, DevT, PdtaS and NarS).113 Members of Mtb HKs that belong to Type IA have 
four orthodox type motifs, the N-Box, G1-Box, F-Box and G2-Box, referred to as the catalytic 
ATP (CA) binding domain,114 while those belonging to Type III have unorthodox type motifs, 
where one or more motifs are missing (the F-box and part of the G2-box are missing in the 
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amino acid sequences of DevS, DevT, PdtaS and NarS) or they are otherwise different from the 
orthodox type.  
A typical HK is composed of three domains: the sensor, dimerization and catalytic 
domains. The sensor domain, which can be of different types, senses the external/internal signal 
[e.g. cyclic GMP binding-Adenyl cyclase-FhlA (GAF) domain of DevS and DosT115,116; 
osmosensitive K+ channel sensor domain of KdpD117; Per-Arnt-Sim (PAS) domain of SenX3118 
and PdtaS119]. Since the functional form of the HKs is a dimer, HKs dimerize using a 
dimerization domain. The dimerization domain is composed of two helices, the first of which 
houses the H-box whose conserved histidine gets phosphorylated during phosphotransfer. The 
catalytic domain is composed of four motifs, the N-box, G1-box, F-box and G2-box. This 
domain catalyzes the transfer of a phosphate from ATP to the conserved histidine in the H-
box.114,120 Several pairs of HK/RR of Mtb have been studied to date. However the only crystal 
structures available are for the sensor domain (GAF domain) of DosS and DosT, and for the CA 
domain of PrrB.  
The DosS(DevS)/DosT/DosR system controls the Mtb dormancy regulon. DosS and 
DosR deletion mutants of Mtb showed a growth defect in mouse and guinea pig models, 
suggesting that these proteins are required for full virulence.121 DosS and DosT are HKs that 
transduce signals on to the response regulator DosR by phosphotransfer.122 The activation of 
DosS and DosT is controlled by the heme binding of O2, nitrogen monoxide (NO), or carbon 
monoxide (CO).123,124 Both DosS and DosT are essential. They play different roles in oxygen 
sensing. DosT is more important at the early stage of hypoxic conditions, it induces the DosR 
regulon with its DosS, then the predominance is switched to DosS when O2 is limited.125 Hence, 
DosS was reported to serve as a redox sensor, which is activated when the Met(Fe3+) form under 
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the rapid oxidation by O2 is reduced to the Fe2+ form;124,126 while DosT is a hypoxia sensor, 
autophosphorylation activity of which will increase when it is deoxygenated.124  However, the 
most recent study indicated that in vivo, DosS is more preferably a hypoxia sensor, since DosS is 
active in the ferrous unligated form, and turned off upon oxygen binding to the ferrous 
complex.127 These conflicting results have been replenished by that DosS serves as an oxygen 
sensor at off switch, and redox sensor at on switch.128 The N-terminal input domains of the DosS 
and DosT sensors have been shown to contain two GAF domains. The first GAF domain (GAF-
A) contains the residue which coordinates the heme iron.126,115 The C-terminal domain is 
responsible for autophosphorylation and phosphotransfer to DosR.115 It has been determined that 
His149 in the DosS GAF-A domain,115 and His147 in the DosT GAF-A domain,116 which is at 
the same position as His149 in a sequence alignment of DosT with DosS, are the residues which 
coordinated the heme iron. Tyr171 in DosS127 and Tyr169 in DosT116 play a key role in the 
ligand-binding site. The Tyr forms a stacking interaction with heme, and its hydroxy group 
provides a H-bond to stabilize oxygen-binding to the heme iron.116,129 The complementary 
functionality of DosS and DosT is related to the structural difference in their GAF-A domain. 
The Glu87 side chain of DosS and the corresponding residues of DosT respond to functionality 
conversion between DosS and DosT.130, 131 
MtrA, an RR of the two complement system MtrB/MtrA, was reported to be essential for 
the viability of bacteria.132,133 However, unlike other two-component systems requiring both an 
RR and its cognate HK, MtrB was found not to be essential for the growth of Mtb in vitro. It has 
been shown that levels of phosphorylated and non-phosphorylated MtrA are tightly regulated in 
virulent Mtb, hence factors interfering with this regulation may limit proliferation.134 
MprB/MprA is a stress responsive signal-transducing pair mainly by activating a sigma 
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factor SigE.135,136 MprB/MprA also display a dual regulation with TrcS/TrcR on a β-propeller 
protein Rv1057 which could stabilize the envelope.137 MprA, the RR, is required for the 
maintenance of persistence.138 MprA can be phosphorylated by either MprB or by a small, 
nonprotein phosphodonor like acetyl phosphate.139 Residues His249 of MprB, which is the key 
histidine of the H-box that has been shown to be phosphorylated for several bacterial HKs, and 
Asp48 in His-MrpA have been proven to be important not only in MprB/MprA activity in vitro, 
but also for biological function in vivo.139 
PdtaR was determined to be a phosphorylation dependent transcriptional antitermination 
regulator. Later on, it was confirmed to be activated by the protein Rv3220c with Mg2+ as a 
cofactor after autophosphorylation.119 Rv3220c, which has also been called PdtaS, possesses four 
domains with GAF-PAS-HisKA (histidine kinase domain)-HATpase. The sequence and structure 
of C-terminal HisKA and HATPas, together with in vitro phosphorylation assays defined it to be 
the cognate HK of PdtaR.119 The N-terminal GAF-PAS domains form a dimer with PAS-PAS, 
GAF-GAF, and PAS-GAF interfaces. The PAS domain is responsible to transmit signals to the 
HisKA. A flexible inter-domain linker between GAF and PAS could regulate the orientation of 
two domains to change the conformation of the dimer, thus affecting the dimerization of 
HisKA .140   
The PrrB/PrrA system is important in adaption to the intracellular environment, and 
essential for the viability of Mtb.141,142 They are transiently required in the early stages for 
intracellular multiplication in mouse macrophages, indicating their role in the infection.143 The 
C-terminal domain of PrrB includes an HAMP linker (H domain), H-box domain, and CA 
domain.144 Nowak et al. described solution structures of PrrBHDC and PrrBDC, and a high-
resolution crystal structure of PrrBC.145 The phosphorylation assay in the presence of Mg2+ 
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showed PrrBHDC is active for both autophosphorylation and phosphotransfer. The solution 
structure of PrrBHDC is dimeric, and the CA domain is closer to the dimerization domain than 
what is observed in the model development using the dimerization domain of CheA, in the 
crystal structure of PrrB and in the crystal structure of CheA. The crystal structure of the CA 
domain of PrrB does not have a bound ligand (ATP), while the residues around the ATP binding 
site partially occupy the putative ATP binding site as deduced from the structure of PhoQ bound 
to ADPNP and Mg2+. The PrrB-dependent RR PrrA belongs to the OmpR/PhoB family and its 
crystal structure have been described.146  
The Rv0600c(HK1)/Rv0601c(HK2)/TcrA system is different from traditional two 
component systems. It is composed of three proteins, two HKs, HK1 (Rv0600c) and HK2 
(Rv0601c), that together phosphorylate a single RR TcrA.147 The function of this three-protein 
system is still unclear. However, HK2 can be upregulated in the presence of an antibiotic, 
tetrahydrolipstatin, suggesting its role in metabolism of small molecules.148 HK1 contains the CA 
domain (with N-, G1-, F- and G2-boxes), while HK2 possesses a histidine containing H-box. 
Together, HK1/HK2 forms a complete HK. HK2 forms a dimer. HK1 phosphorylates His131 
on HK2, then HK2 transfers the phosphoryl group to the conserved Asp residue on TrcA.149,150 
Homology modeling and subsequent docking of HK1 and HK2 has shown that Arg64, Arg73, 
Asp81, Gly118, and Arg134 of HK1 form hydrogen bonds with Glu43, Glu145, Arg134, Arg17, 
and Trp103 of HK2. 147, 149  
TrcS, a HK, and TrcR, a RR, constitute another two-complement system of Mtb. 
Autophosphorylation of TrcS needs Mn2+ or Ca2+ as a cofactor, and a phosphoryl group is 
presumed to be transferred from His287 to Asp82 in the N-terminal receiver domain of TrcR.151 
As the genes of TrcS and TrcR are expressed during the log phase of growth in the broth culture 
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and initial stages of infection in macrophages transiently, they may play a role in the intracellular 
adaptation, although the possibility of their role in extracellular replication and at the end of the 
latency period or initiation of reactivation stage cannot be ignored.152   
The PhoR/PhoP system is related to complex lipids biosynthesis and Mtb virulence. A 
PhoR/PhoP knock-out mutant of Mtb results in a deficiency in polyketide-derived lipids, such as 
sulfolipid (SL), diacyltrehaloses (DAT), and polyacyltrehaloses (PAT), which play roles in 
virulence.153, 154 However, only PhoP, the RR, but not HK PhoR, has been proven to be required 
for the biosynthesis of polyketide-derived lipids.153 In addition to synthesis of lipids, PhoP is 
involved in regulation of hypoxia response through DosR crosstalking, stress response, 
respiratory metabolism, secretion of T-cell antigen EAST-6,155 and specific T-cell 
recognition.155,156 More recently, there is evidence that PhoP is a key regulator of Mtb, and its 
mutants can be used as live vaccines to treate Mtb.157 The structure and binding site of PhoP have 
been discussed in some other studies.158,159,160 ,161 
The SenX3/RegX3 system, in which His167 and Asp52 are the sites for phosphorylation 
and phosphotransfer, respectively, is required for Mtb virulence.162,118 Based on the model of 
SenX3/RegX3 regulating phosphate-dependent gene expression in M. smegmatis, SenX3 carries 
out autophosphorylation, phosphotransfer onto RegX3 when inorganic phosphate (Pi) 
concentration is limited.163 SenX3, as an HK, has a PAS-similar domain which is related to 
oxygen or redox sensing. When compared with a modeled PAS domain, it lacks two helices in its 
N-terminal region which makes the structure more open and easier to target.118 However, RegX3 
is reported to be able to acquire phosphate from another phosphodonor than SenX3, though the 
phosphodonor is still unknown.163  
KdpD/KdpE is reported to regulate kdpFABC expression in bacteria, which encodes for 
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K+-translocating P-type ATPase.164 In Mtb, the N-terminal domain of the HK KdpD interacts 
with the membrane lipoproteins LprF and LprJ, and its C-terminal domain forms a ternary 
complex with N-KdpD/LprF and N-KdpD/LprJ. This protein complex regulates the expression 
of kdpFABC, controlled by RR KdpE.165 
Other two complement systems, NarS/NarL and TcrY/TcrX, are not well characterized. 
Parish et al. constructed mutants of TcrY/TcrX and NarL.133 Infection with mutant NarL in SCID 
mice showed no difference relative to the wild-type strain, while infection with mutant 
TcrY/TcrX showed hypervirulence. Their functions are still not known.  
3. Serine/Threonine Protein Kinases of Mtb 
Mtb does not have many two-component regulatory systems when compared with other 
prokaryotes (e.g. E. coli has 25 orthodox sensory kinases and 32 RRs).166 This deficiency is 
replenished by eukaryotic-like serine/threonine protein kinases (STPKs). The Mtb genome 
contains 11 STPKs named PknA, PknB, and PknD-PknL.108 Two (PknG and PknL) out of 11 are 
soluble proteins, while the others are membrane bound.167 Based on sequence analysis, the 
receptor-like (membrane bound) STPKs are divided into three groups PknA/B/L, PknD/E/H, and 
PknF/I/J. The two soluble kinases do not cluster with others.168,169,170 The N-terminal domains of 
the receptor-like STPKs connect through a single transmembrane helix to one or more C-
terminal domains that serve as signal sensors. The kinase domain is intracellular while the sensor 
domain is extracellular. STPKs are involved in many functions, such as cell division,171 
membrane transport,172 amino acid uptake,173 and transcription.174 The STPKs of Mtb have been 
extensively reviewed. A bioinformatics analysis and overall view of STPK family members of 
mycobacterium has been reviewed in several publications,167,168,175,176,177 and a comprehensive 
view of substrates of STPKs have been given by Chao et al.178 
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A transposon insertion experiment has shown that PknA is one of the three STPKs (PknA, 
PknB and PknG) required for growth in culture, indicating its role in proper function of Mtb. 
PknA is predominantly expressed in the exponential growth phase in experiments performed in 
culture. Since a partial depletion of PknA results in narrower and elongated cells, it was 
suggested to be involved in regulation of cell shape and in cell division in Mtb.179 PknA 
phosphorylates mtFabH, beta-ketoacyl-ACP synthase III, which is involved in mycolic acid 
biosynthesis;180 mMurD, mycobacterial UDP-N-acetylmuramoyl-L-alanine: D-glutamate-ligase, 
which is involved in peptidoglycan biosynthesis;181 Wag31, which is involved in regulation of 
cell shape and cell wall synthesis;179,182,183 mFtsZ, which is involved in septum formation during 
cell division;184 EmbR, which is further required for the transcriptional regulation of embCAB 
operon involved in cell wall arabinosyltransferases;185 Rv1422, a conserved protein of unknown 
function;179 KasA, KasB, and mtFabD, three type II fatty acid synthase (FAS-II) components;186 
and Ser/Thr phosphatase.187 Recombinant PknA was reported to be phosphorylated at seven sites 
in the intracellular domain.188 Although PknA has shown to be important for mycobacterium 
survival, no efforts have been reported for developing PknA inhibitors. 
As for PknA, a transposon insertion experiment highlighted the importance of PknB in 
the regulation of cell shape and in cell division in Mtb.179 K-252-b, a natural indolecarbazole 
protein kinase inhibitor which inhibits PknB in vitro, inhibited growth of slow- and fast-growing 
mycobacterial strains. Overexpression of Mtb PknB in M. smegmatis led to a two-fold increase 
in resistance to inhibitor K-252-b, revealing PknB as a target of inhibitor K-252-b.189 This 
observation further demonstrated the importance of PknB in Mtb survival. The substrates of 
PknB include PBPA, a penicillin binding protein which is involved in cell division;190 Forkhead-
Associated (FHA) domain-containing proteins, such as Rv0020c and Rv1747 (demonstrated in 
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vitro);191,192,193 GarA (Rv1827),194 EmbR,184 and Rv0019c,195 which are responsible for cell cycle 
regulation, protein degradation, DNA damage response, and signal transduction;196 polyketide-
associated protein PapA5;195 Wag31;179,182,183 Rv1422, a conserved protein of unknown function 
(demonstrated in vivo); 179 SigH, a sigma factor which is a regulator of transcription of several 
genes during stress and RshA, an anti sigma factor, which negatively regulates SigH in vivo;197 
and N-acetylglucosamine-1-phosphate uridyltransferase (GluM), which is involved in the 
biosynthesis of peptidoglycan.198 
There have been some efforts to understand the structural basis of the function, 
autophosphorylation and interactions with inhibitors for PknB. The structure of PknB was solved 
in the presence of an ATP analogue,199,200 with ATP competitive inhibitors mitoxantrone201 and 
KT5720 in complex with a mutant PknB,202 providing valuable resources for protein structure-
based drug discovery efforts. The X-ray structures of PknB highlighted its remarkable 
similarities with protein kinases of eukaryotic origin.199 The kinase domain of PknB consists of 
N- and C- lobes that bracket the ATP binding site (Figure 121A). In this structure, PknB takes on 
the closed conformation which results from the movement of the hinge region between the N- 
and C-lobes.199 The autophosphorylation of PknB is thought to depend on activation of the 
kinase domain by N-lobe dimerization203 and mediation of substrate recognition by the G-helix 
in the C-lobe.202 Moreover, the extracytoplasmic penicillin binding proteins and serine/threonine 
kinase (PASTA) domain serves as a sensor for signaling molecules. The ligand-dependent 
dimerization of the PknB-PASTA domain promotes cell growth by binding to the exogenous 
peptidoglycan fragment.204,205 
Considering the importance of PknB for Mtb survival, drug discovery efforts have been 
initiated. Nine hundred and seventy compounds from a protein kinase inhibitor library (Vichem’s 
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Nested Chemical Library, NCL) were tested for PknB inhibitory activity in vitro206 and a few 
compounds with submicromolar inhibitory activity were identified. For further effort to explore 
potentially useful agents, a docking model was setup to screen 19033 compounds, among which 
VI-15662 and VI-17494 showed a dual inhibition on PknB and PknG, while VI-12177 displayed 
a promising activity with an IC50 of 88 nM207 (Figure 121B).  Recently, more than 50,000 
compounds including 45,000 commercial available and 6,400 synthetic molecules were screened 
using “kinase Glo” assay kit. Aminopyrimidine compounds MRT67127, MRT67153, and 
MRT67150 displayed the best activity thus far with an IC50 of 53, 56, and 55 nM, respectively.208 
An SAR investigation on the aminopyrimidine analogues revealed that the induction of a basic 
amine side chain facilitated the binding affinity, while the replacement of the pyrazole head 
group with pyridine could improve the selectivity.209  
 
Figure 121 (A) Overall structure of the catalytic domain of PknB in complex with a nucleotide 
triphosphate analogue; (B) Inhibitors of PknB 
The figure was reprinted from reference 199 with the permission of the American Society for Biochemistry and 
Molecular Biology 
Similar to PknA and PknB, PknL might be involved in cell division as well.168  The study 
of the protein-protein interactions (PPI) network of Mtb provided the evidence that PknL 
interacts with two cell division protein, FtsE and FtsH.210 It is reported to phosphorylate a DNA-
binding protein, Rv2175c, of which the structure was determined by NMR methods.211 The 
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Thr173 and Thr175 residues which correspond to Thr171 and Thr173 in PknB have been proven 
to be phosphorylation sites in the activation loop.212 This indicates that PknL’s phosphorylation 
mode is similar to that of PknB. Rv2175c, KasA, KasB, and mtFabD186 as well as GroEL1213 are 
substrates of PknL.  
The exact in vivo function and importance of protein kinase PknD is not well 
characterized. Some preliminary studies have shown that the PknD knockout strain shows no 
attenuation in growth compared to wild type in mice.214 The latest research pointed out that 
PknD is crucial for invasion and virulence in central nervous system tuberculosis.215 As the gene 
of PknD is located next to the gene encoding phosphate transporter, it was suggested to be 
involved in phosphate transport.167 The unphosphorylated MtPknD kinase domain can be 
activated by dimerization through the N-lobe, which suggested a similar interface to that by 
which PknB regulates PknD.216 However, the rate of phosphate uptake in a PknD knockout was 
observed to be comparable to that of wild type.214 The putative substrates for PknD were shown 
to be MmpL7,217 which is involved in deposition of components of the cell wall; Rv0516c, a 
putative sigma factor;174 and the FHA-A domain of Rv1747,191 an ATP-binding cassette (ABC) 
transporter which is required by Mtb for infection (demonstrated in a murine model).218 The 
crystal structure of the MtPknD sensor domain has been determined. It forms a β-propeller with 
six blades that are arranged cyclically. The sensor domain mediates signaling by changing the 
quaternary structure of the intracellular kinase domain.219 
PknE showed an increased nitric oxide-mediated apoptosis of host macrophages.220,221 
However, this protein is not absolutely required for the Mtb in vitro220 or in a murine model.222 
The substrates of PknE include EmbR2, a homologue of EmbR, a transcription factor;223 the 
FHA domain of Rv1747,191 and GarA.194 The structure of apo-PknE has been solved. The PknE 
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kinase-domain forms a back-to-back dimer similar to that observed in the crystal structure of the 
PknB kinase-domain, supporting the idea of regulation of STPKs through dimerization.224 The 
regulation of kinase activity through dimer formation via this interface has been validated 
experimentally for PknD.216  
A deletion mutant of PknH showed enhanced survival and replication in murine models, 
especially during stages of chronic infection, compared to wild type and to a PknE deletion 
mutant, indicating the role of PknH in regulation of downstream pathways responsible for in 
vivo growth.222 PknH was reported to mediate phosphorylation of the FHA domain of the 
transcriptional regulatory protein EmbR;225 transcription factor Rv0681 and penicillin binding 
protein DacB1;226 and the hypoxia- and NO-inducible dormancy regulon DosR.227 The activity of 
PknH can be inhibited by staurosporine.228 Staurosporine (Figure 122), isolated from bacterium 
Streptomyces staurosporeus, is an ATP-competitive inhibitor of both tyrosine and 
serine/threonine protein kinases. It binds to many kinases with high affinity and lacks 
specificity,229 however, it could serve as a precursor of many new kinase-selective agents. 
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Figure 122 PknH inhibitor staurosporine 
PknF is able to regulate different stages of cell division.172 It also modulates 
phosphorylation of two FHA domains of the adjacent Rv1747,230,191 and an advanced study 
showed it down-regulates glucose transport.172 Considering that Rv1747 can serve as a substrate 
of PknD and PknE,191 and that another ABC transporter EmbR can be phosphorylated by 
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PknH,225 the PknF might be cross-regulated together with the cluster of PknD/PknE/PknH. In 
addition, like PknA/PknB/PknE, PknF phosphorylates the GroEL1 chaperone which plays an 
essential role in cytokine-dependent granulomatous response during Mtb infection.213  
Unlike other transmembrane domain-containing STPK, PknI is reported to be localized 
mainly in the cytosol, which indicates it might not be involved in host protein modification.231 
Similar to PknH, PknI serves as a downregulator during infection of Mtb both in vitro and in 
immunodeficient mice.231,232 The PknI mutant was shown to grow better under host mediated 
signals such as low pH and limited oxygen availability, suggesting its role in sensing the 
macrophage environment and slowing Mtb growth within the infected host.232 The substrates of 
PknI and the regulatory pathways initiated by PknI have not been characterized.   
Few studies have been completed on PknJ. PknJ is only present in Mtb among all 
sequenced mycobacterial species, which implies its specificity.168 In a PPI map, PknJ showed the 
ability to interact with FadE proteins suggesting it may be involved in fatty acid metabolism, 
which is similar to PknA/PknB/PknL.210 Thr168, Thr171, and Thr173 form the 
autophosphorylation sites of PknJ.233 PknJ is able to phosphorylate EmbR; methyltransferase 
MmaA4/Hma, which is responsible for mycolic acid biosynthesis; dipeptidase PepE, whose  
encoding gene is adjacent to PknJ;233 and pyruvate kinase A (MtPykA, Rv1617).234 
PknK is a member of a cluster of soluble kinases. It regulates the growth of Mtb during 
both the early and persistent stages of infection.235 The PPI network showed it to be like PknL, in 
that it interacts with FtsE and FtsH,210 and ABC transporters.210 Another recent study showed that 
a transcription factor VirS and four mycobacterial monooxygenase (mym) operon proteins, Mym, 
LipR, Rv3085, and Rv3088, are substrates of PknK. The PknK-induced phosphorylation on VirS 
promotes 2-3 fold mym promoter activity.236 Mutations on Lys55 and two threonines in the 
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activation loop, Thr178 and Thr180, result in a loss of phosphorylation, which demonstrates that 
these residues are necessary to the activity of PknK.236 Unlike for transmembrane STPKs, PknK 
is tied to the cell membranes by its PDZ domain or C-terminal domain in order to be able to 
function. 
Unlike most of STPKs, PknG lacks a critical arginine residue in the kinase-domain which 
plays a key role in the activation of kinase activity. Its autophosphorylation is conducted on six 
Thr residues near the N-terminus, however, the autophosphorylation is not necessary to activate 
PknG kinase activity.237 Instead, it is crucial for PknG to be able to inhibit phagosome-lysosome 
fusion,237,238 thus promoting Mtb survival in macrophages, which results from downregulation of 
protein kinase C-α controlled by PknG.239 In addition, PknG participates in glutamine and 
glutamate metabolism under stress conditions, thereby sustaining Mtb survival. 173,178 It is 
required for Mtb intrinsic antibiotic resistance to multiple antibiotics as well.240 The essential 
roles of PknG in maintaining Mtb virulence and resistance make it a potential target for 
antituberculosis drug design. 
Scherr et al. reported a crystal structure of PknG in complex with inhibitor AX20017 
(Figure 123A).241 PknG has three structural domains: the C-terminal contains a tetratricopeptide 
repeat (TPR) domain to mediate protein-protein interactions; the N-terminal moiety contains the 
rubredoxin domain that regulates PknG activity; the kinase domain is between the rubredoxin 
and TPR domains, and it adopts the typical two-lobed structure of eukaryotic protein 
kinases.241,242 PknG is able to phosphorylate GarA, and it is more active under oxidizing 
conditions.242 Unlike PknB and PknE which dimerize through the N-terminal domain, PknG 
dimerizes using the TPR domain. The AX20017 inhibitor (Figure 123B) has been determined to 
bind deep within a narrow pocket formed by the kinase lobes and a unique N-terminal peptide 
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segment of PknG.241 Inhibitor AX20017 was shown to be specific for PknG when tested against 
other Mtb kinases238 and a panel of 28 human protein kinases.241 Székely et al. screened 1000 
compounds to identify PknG inhibitors. As a result, AX20017 was confirmed to be a potent 
PknG inhibitor. Chemical modification of lead AX20017 led to identification of AX35510 with 
an IC50 of 200 nM, which was also found to be active in a macrophage assay.206 Based on these 
data, Hegymegi-Barakonyi et al. continued the optimization, and screened compounds against 
PknB, PknG, NAD kinase, and NAD synthetase as multiple targets with PknG as the primary 
one.207 As a result, eight analogues showed promising inhibition, and the most potent one with 
low toxicity was VI-16315 (Figure 123B) with an IC50 of 10 nM.   
       
Figure 123 (A) Crystal structure of PknG-AX20017 complex; (B) PknG inhibitors 
The figure was reprinted from reference 241 with the permission of the National Academy of Sciences, U.S.A 
4. Tyrosine Kinase of Mtb 
It was thought that protein tyrosine kinases (PTKs) only exist in eukaryotes. In the last 
two decades, however, PTKs have been identified in various strains of bacteria and recognized to 
play important roles in biosynthesis of polysaccharides,243,244 stress response,245 DNA 
metabolism,246 and antibiotic resistance.247 Bacterial PTKs have an external domain, trans-
membrane α-helices, and an intracellular catalytic domain with the ATP-binding Walker A and B 
motifs which are required for kinase activity. The end of the C-terminus possesses a Tyr-rich 
cluster that is responsible for multiple phosphorylation.248,249 
There was no PTK found in Mtb until the identification of the protein encoded by 
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Rv2232, named PtkA, which is able to use ATP or GTP as phosphate donors and functions as a 
PTK to phosphorylate protein tyrosine phosphatase PTPA.250 Although the roles of PtkA are still 
not clear, considering that PTPA is essential to maintain virulence in host macrophages,251 it 
could be a potential target for treatment of Mtb. 
5. Other Kinases of Mtb 
In addition to signal transduction, many other different types of kinases participate in the 
biochemical reactions of Mtb. Some of them were discussed in this review. Some others have not 
been well studied thus far (Table 18).  
Table 18 Some other not well studied kinases in Mtb 
Kinase Accession Characterization reference Structure 
Acetate kinase P63409 Whole genome --- 
Acetylglutamate kinase P0A4Y6 Whole genome 2AP9 
Galactokinase P96910 Whole genome --- 
Glycerol kinase O69664 Whole genome --- 
2-Amino-4-hydroxy-6-hydroxymethyldihydropteridine 
Pyrophosphokinase P64143 Whole genome --- 
6-Phosphofructokinase P65690 Whole genome --- 
Homoserine kinase P65224 Whole genome --- 
Ribose-phosphate pyrophosphokinase P65232 Whole genome --- 
Pyruvate kinase O06134 Whole genome --- 
Phosphoglycerate kinase P65700 Whole genome --- 
Phosphoenolpyruvate carboxykinase P65686 Whole genome --- 
Polyphosphate glucokinase Q59568 PMID:8617763 --- 
Inorganic polyphosphate/ATP- NAD kinase P0A5S6 PMID:11006082 --- 
Glutamate 5-kinase P71910 Whole genome --- 
Probable GTP pyrophosphokinase P66014 Whole genome --- 
Phosphomethylpyrimidine kinase P66913 Whole genome --- 
Ribokinase Q7D752 Whole genome --- 
Pyruvate, phosphate dikinase Q7D8T1 Whole genome --- 
Whole genome reference-PMID:12218036, 9634230 
5.1 Polyphosphate Kinase  
Inorganic polyphosphate (polyP) plays a number of critical roles in bacterial persistence, 
stress, and virulence. PolyP intracellular metabolism is regulated by the polyphosphate kinase 
(PPK) protein families. The enzyme PPK catalyses the reversible transfer of the terminal c-Pi of 
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ATP to form a long chain polyphosphate. The vulnerability of this gene was evaluated by 
antisense knockdown experiments in Mtb using an IPTG inducible mycobacterial vector.252 
Expression profiling studies demonstrated that down regulation of PPK causes a rapid bacterial 
cidality during the late growth phase. PPK thus seems to be a suitable antitubercular drug target. 
Recently, a class II MtPPK, MtPPK2 was biochemically characterized.253 The role of MtPPK2 is 
to catalyze polyP-dependent phosphorylation from ADP to ATP. To develop inhibitors of 
MtPPk2, high affinity DNA aptamers were screened. One G-quadruplex aptamer was highly 
selective to MtPPK2 with an IC50 at 39.3 ± 10 nM. The crystal structure of MtPPK2 is not 
characterized yet. However, based on the crystal structures of the Pseudomonas aeruginosa and 
Sinorhizobium meliloti PPKs, as well as a similar secondary structure of MtPPK2 as those 
proteins, it is proposed that the conserved Walker A (P-loop) and B motifs could be responsible 
for the polyphosphate binding.253    
5.2 4-Diphosphocytidyl-2-C-methyl-D-erythritol Kinase 
Isoprenoid precursors, which are a large group of natural products playing key roles in 
many biological pathways, can only be biosynthesized by the 2-C-methyl-D-erythritol 4-
phosphate pathway in Mtb.254 The 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase (IspE), 
which is an essential enzyme in the isoprenoid precursor biosynthesis pathway, catalyzes ATP-
dependent phosphorylation of 4-diphosphocytidyl-2-C-methyl-D-erythritol (CDP-ME) to 4-
diphosphocytidyl-2-C-methyl-D-erythritol-2-phosphate and plays a crucial role in Mtb survival. 
255,256 Therefore, IspE is an attractive and potential target for antimicrobial drug discovery. The 
MtIspE contains an N-terminal ATP binding domain and a C-terminal substrate binding domain. 
Three motifs creating the catalytic center are present in the MtIspE. Motif A participates in the 
formation of substrate binding site, motif B is the P-loop, and motif C stabilizes the 
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conformations of motifs A and B.257 ADP, 4-diphosphocytidyl-2-C-methyl-D-erythritol (CDP-
ME) and an ATP analogue adenosine 5'-(β,γ-imino)triphosphate (AMP-PNP) were used as 
MtIspE substrates to study the binding sites. A π-π interaction between Tyr28 and Tyr158 at the 
substrate binding site was found to be crucial to stabilize the substrate. The same interaction was 
observed in E. coli between Tyr and Phe. In the ATP binding site, a glycine-rich loop formed 
seven H bonds with water to stabilize the phosphate.257 All the results provided an implication 
for MtIspE inhibitor design.   
5.3 Aspartokinase 
Aspartokinase (AsK) is responsible for the biosynthesis of 4-phospho-L-aspartate that 
involved in the metabolic pathway of lysine, threonine, methionine and isoleucine.258 Since an 
intermediate of the lysine biosynthesis from 4-phospho-L-aspartate, mesodiaminopimelate, is a 
major component of the bacterial cell wall, an inhibition on AsK could decrease the production 
of lysine, thus interfering with the formation of the bacterial cell wall.258 Due to its selectivity on 
the bacterial cell wall, AsK could be another potential target for the development of nontoxic 
inhibitors.  
All the AsKs that have been studied contain an N-terminal kinase domain, coming 
together with different number of regulatory ACT domains originally characterized in AsK, 
chorismate mutase, and TyrA (prehenate dehydrogenase).259 Depending on the protein-protein 
interaction in the regulatory domain, AsKs are classified into three types. Type I and II are 
homo-dimeric. Each monomer contains two or four ACT domains. Type III is hetero-tetrameric 
(α2β2-). Each α- or β- subunit contains two ACT domains.259 The MtAsK belongs to type III 
AsK. Its N-terminal α-subunit forms the catalytic domain, and its two β-subunits as well as C-
terminal α-subunits form the regulatory domain.260,261 Molecular docking studies with natural 
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substrates, products and feedback inhibitors are in agreement with the published data and showed 
that ACT domains play an important role in binding to ligands.258 An enzymatic assay revealed 
an inhibition of MtAsK activity when it bond to threonine. The residues Asp274, Gln298, Ile126, 
Asn125, Thr59, Ile61, Ala30, Ala31, Gly28, and Val124 could be responsible for the formation 
of the binding pocket.261 Based on the docking conformations, a pharmacophore model can be 
developed by probing the common features of ligands. 
5.4 Nucleoside Kinases 
Nucleoside kinases form a family which includes adenosine kinase (AK), guanosine 
kinase (GK), cytidine kinase (CK), thymidine kinase (TK), and uridine kinase (UK). Only AK of 
Mtb has been studied so far. 
AK, which belongs to the phosphofructokinase B (PfkB) family of carbohydrate kinases, 
is responsible for the phosphorylation of adenosine (Ado) to adenosine monophosphate (AMP) 
by using ATP as cofactor. AK was not found in bacteria until it was identified and characterized 
in Mtb by Long et al.262 MtAK is a dimer, while human AK is a monomer. Their overall 
structures are similar when comparing apo-MtAK to the human AK·(Ado)2 complex.263 However, 
the Ado binding pocket of MtAK is quite different from that of human AK.263 Moreover, only 24% 
of its sequence is identical to the known AKs, and it is structurally and biochemically unique 
from other known AKs, including having higher optimum pH profile, lower pI, quaternary 
structure as a dimer, no stimulation by inorganic phosphate (Pi), and different specificities of 
substrate and phosphate donor.262 These aspects suggest that AK inhibitors against Mtb might 
have high selectivity versus human AK. This hypothesis has been confirmed by Gupta’s group. 
When treating MtAK with some non-nucleoside inhibitors of HsAK, the inhibition was 
attenuated from the micromolar range to 1 mM. The same tendency was found for their substrate 
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specificity.264 Some Ado analogues such as 2-methyl-Ado and fluorinated 3-deaza-Ado 
analogues (Figure 124) are proinhibitors of Mtb, which can be activated and become toxic to 
mycobacteria by phosphorylation. 2-Methyl-Ado shows a moderate inhibition on Mtb with a 95% 
MIC of 3 μg/mL,265 while 2-fluoro-3-deaza-Ado and 2,3-difluoro-3-deaza-Ado are much better 
substrates for MtAK than for human AK with specific activity of 63 and 81 nmol/mg/min, 
respectively.266 More modifications to the adenine moiety were produced (Figure 124).267,268 As 
a result, the most potent inhibitors are N1-benzyl-Ado, 6-cyclopentyloxypurine riboside, and 7-
iodo-7-deaza-Ado with Ki of 0.19, 0.15, and 0.21 μM, respectively. Since MtAK preferred the β-
D-ribofuranosyl conformation or modifications that closely resembled this conformation, the 
modifications on the ribofuranosyl moiety have been studied as well.269 Twenty-eight of the 63 
compounds showed inhibition. The most potent inhibitor is 5'-amino-5'-deoxy-Ado with a Ki of 
0.8 μM, which was shown to have an ATP-competitive mode of inhibition.  
 
Figure 124 MtAK inhibitors 
5.5 Nucleoside-Phosphate Kinases 
Nucleoside-phosphate kinases are a family of nucleoside monophosphate (NMP) kinases 
(NMPK), including adenylate kinase (ADK), guanosine monophosphate kinase (GMPK), 
cytidylate kinase (cytidine monophosphate kinase, CMPK), thymidylate kinase (thymidine 
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monophosphate kinase, TMPK), uridylate kinase (uridine monophosphate kinase, UMPK) which 
catalyze ATP dependent phosphorylation of NMP/dNMP to NDP/dNDP, and all nucleotide 
diphosphate kinases (NdKs). 
5.5.1 Nucleoside Monophosphate Kinases (NMPKs) 
NMPKs catalyze the phosphorylation of NMP/dNMP to NDP/dNDP. They consist of 
CORE, LID, and NMP-binding domains. ADKs were grouped into long variants of bacteria, 
yeast and mitochondria, and short variants of eukaryote cytosolic enzymes, differing in the 
length of amino acids in the LID domain. Later on, some ADKs of bacteria including Mtb have 
been grouped into a new subfamily called short bacterial forms.270 The crystal structure of 
MtADK showed that the overall structure is similar to the other ADKs, while the LID only 
contains 10 residues.271 There were obvious conformational differences when comparing free 
and complexed ADK structures.270,271 In addition, unlike for ADKs from either eukaryotes or 
other bacteria, MtADK has low catalytic activity, which results in low growth and low survival 
under nutritionally deprived conditions.270  
Hible et al. reported the crystal structures of apo, GMP-bound, and GDP-bound 
GMPK.272 Some properties of MtGMPK are significantly different from those of other GMPKs. 
The MtGMPK has an open domain conformation no matter if it is in the apo state or binding to 
GMP or GDP, while conformations of other GMPKs closed when they bound to either substrate. 
The GMP binding site of MtGMPK has unique interactions relative to other GMPKs. For 
example, it lacks a conserved Tyr81, which binds with α-phosphate of GMP in other GMPKs like 
GMPK of mouse. The corresponding residue to Tyr81 in MtGMPK is Ser99 which cannot form a 
hydrogen bond with the α-phosphate of GMP due to its shorter side chain, and instead interacts 
with water in the binding site. The length and sequence of the MtGMPK β5/β6 loop are also 
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distinct, which provides a unique binding pocket. The specificity in structure could be helpful for 
drug design. A typical GMPK structure from Mtb is shown in Figure 125. 
 
Figure 125 Crystal structure of reduced GMPK-GMP in Mtb 
The CORE domain is in green, the LID domain is in yellow, and the GMP domain is in blue. 
Reprinted from reference 272 with the permission of John Wiley & Sons, Inc. 
In the genome of H37Rv strain, Rv1712 is identified as a putative cmk gene, and it has 
been confirmed to function as a CMPK.273 CMPK is involved in the biosynthesis of pyrimidine 
ribonucleotide. No crystal structure of MtCMPK is available, but a homology model based on 
E.coli CMPK was made and refined using molecular dynamics.274 E. coli CMPK contains a short 
LID domain and an insertion of 40 amino acid residues in its NMP-binding domain, which 
makes it different from other NMP kinases.273 MtCMPK shares many common features with 
E.coli CMPKs, which could be used to guide design of inhibitors specific for MtCMPK. The 
LID and NMP-binding domains and also the phosphate donor site have low motion in the CMP-
bound form compared to in the unbound CMPK suggesting that CMP-binding is responsible for 
stabilizing the protein. Moreover, the mode of action of MtCMPK is similar to that of shikimate 
kinase in Mtb.274  
The TMPKs have been grouped into type I and type II TMPKs. For type I, mostly found 
in eukaryotes, the active-site arginine residues are in the P-loop, while for type II, usually found 
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in bacteria, those Args are in the LID. However, MtTMPK does not belong to either type, since 
arginine residues from both the P-loop and LID can be involved in catalyzing phosphoryl 
transfer.275,276 Also, the Mg2+ ion located in the TMP-binding site is unique, since no Mg2+ was 
observed in TMPK of yeast or E. coli, and the Mg2+ in TMPK of human is far from the binding 
site.275 3'-Azido-3'-deoxythymidine 5'-O-monophosphate (AZTMP) is an MtTMPK inhibitor, 
which can explain the importance of Mg2+ in MtTMPK, since its mechanism of action may 
involve its azido group preventing Mg2+ ion binding.277 Moreover, the sequence of amino acids 
in MtTMPK is only 22% identical to that of human TMPK.275 These factors make MtTMPK one 
of the best potential targets for the design of new antitubercular drugs.  
Many researchers have focused on screening of selective, competitive inhibitors of 
TMPK. Modifications of dTMP at 2'-, 3'-, 5'-, 5- positions displayed better affinities than those 
of nucleotides, and the inhibition of nucleosides was equal to those of their 5'-O-monosphate 
esters, which indicated that the ribose moiety is more important to maintain in the modified 
structures.278,279,280,281,282 Later, the 3D-pharmacophore sites of those 81 thymidine analogues 
using 4D-QSAR method were mapped.283 It was proposed that regions between the C-5' of the 
sugar ring and the nitrogen of the thiourea moiety can be good modification sites. 2',3'-bicyclic 
nucleosides284,285 and 5'-thiourea-substituted α-thymidine analogues286 were designed as TMPK 
inhibitors (Figure 126). The analogue which contains a 3-trifluoromethyl-4-chlorophenyl-
thiourea moiety showed a better activity with Ki of 0.6 μM and MIC50 of 6.25 μg/mL. 
Modifications to replace the ribose moiety with units, such as N1-(4-substituted-benzyl)-
pyrimidines287,288 and acyclic nucleoside analogues289,290 were synthesized as well (Figure 126). 
Some derivatives had low Ki between 0.27–0.93 μM. However, none of them displayed great 
inhibition of bacterial growth. Because of the unsatisfactory bioactivity of the thymidine-based 
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analogues, Siddiqi’s group searched for novel inhibitors by first developing a pharmacophore 
model, and using it to help in identifying potential inhibitors from the Maybridge database using 
protein structure-based virtual screening against MtTMPK.291 As a result, three compounds were 
identified (Figure 126) which showed promising inhibition with MIC of 3.12 μg/mL. In an effort 
to identify more potent and selective inhibitors of MtTMPK, a study of small peptide inhibitors 
as potential lead compounds was undertaken.292 Based on the crystal structures of MtTMPK and 
human TMPK complexed with AZTMP, respectively, a rational structure-based approach has 
been employed to design small peptides as MtTMPK inhibitors. By comparing their differential 
binding at the active site using in silico docking and selectivity analysis, a set of Trp- containing 
tripeptides, particularly Trp-Pro-Asp, was found to be most potent and selective for MtTMPK 
with Kd of 0.018 nM (compared to human TMPK with Kd of 0.43 μM).292 The inhibition of 
tripeptide is attractive enough as a drug candidate. As for the other peptide drugs,293 however, 
enzymatic unstability might cause less efficacy in vivo. Therefore, modifications on the 
tripeptide should be considered.    
 
Figure 126 TMPK inhibitors 
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MtUMPK (encoding gene pyrH) has been proven to be essential in Mtb.294 Considering 
the primary amino acid sequence and 3D structure of bacterial UMPKs are different from those 
of eukaryotes, the structure of UMPK is it also could be an attractive target.295 The structure of 
MtUMPK is homo-tetrameric. ATP and UMP serve as specific substrates of MtUMPK. It was 
suggested that Lys36, Asp166, Lys185, Phe191, and Asp221 are the key residues involved in 
ATP binding by comparing with E.coli UMPK. Using the same method, Gly77, Gly78, Arg82, 
Gly83, Asp97, Met158, and Leu169 were suggested to participate in the UMP binding.295 Based 
on the kinetic study, GTP exerts upregulation on MtUMPK. Opposite to GTP, UTP has 
noncompetitive inhibition towards MtUMPK. Two mechanisms were proposed for their 
regulation: GTP/UTP could bind onto the ATP binding site, or they possibly bind onto the third 
nucleotide-binding site, thus regulating MtUMPK.295 The hypothesis of an allosteric pocket was 
confirmed by the crystal structure of MtUMPK in complex with GTP.  The nucleotide binding 
only affects a small region with 30 residues. When GTP binding into the allosteric pocket, 
Pro139 plays a key role in the regulation of MtUMPK.296 The structural and functional 
characterization provided evidence for the inhibitor design. 
5.5.2 Nucleoside Diphosphate Kinase (NdK) 
NdK plays a key role in the maintenance of intracellular ratios of NTPs and dNTPs. 
Tiwari et al. reported autophosphorylation as well as phosphotransfer activities of MtNdK 
through structure-function analysis.297 Mutation studies showed that His53 plays a significant 
role in autophosphorylation. Furthermore, Tyr50 and Arg86 were found to maintain 
phosphotransfer capabilities.297  
5.6 Shikimate Kinase 
The shikimate pathway of Mtb is required for biosynthesis of aromatic compounds and is 
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essential for all aromatic amino acids, as well as other metabolites such as folic acid and 
ubiquinone.298 Shikimate kinase (SK) is responsible for the phosphate transfer from ATP onto the 
3-hydroxy group of shikimic acid.299 SK has been found in bacteria, fungi, algae, and higher 
plants, but not in mammals,300 so it has the potential to be a valuable target for antibacterial drugs. 
The structures of shikimate kinases are similar to those of NMP kinases. The crystal structure of 
MtSK has been elucidated as an unliganded form;301,302 a binary complex with MgADP,303 
MgATP,301 shikimic acid;302 a ternary complex of SK with shikimic acid as one substrate and 
ADP,304 MgADP,305 or ATP analogue302 as another substrate; or a ternary complex with 
shikimate-3-phosphate and ADP.301 Based on most of these crystal structures of MtSK, many 
efforts have been made to explain the mechanisms of protein binding and design the MtSK 
inhibitors. The Bartunik group set up a model for the transition state and provided a putative 
mechanism of phosphoryl transfer by MtSK (Figure 127).301 The conformational changes caused 
by binding shikimate, magnesium and chloride ions to MtSK are also helpful to understand the 
catalytic mechanism.306 Another kinetics and structural dynamic study of MtSK was performed. 
The measurement of hydrogen/deuterium (H/D) exchange on the amide bonds of protein using 
MS/MS is able to track energy transfer, thus facilitating the studies of protein dynamics and 
protein-ligand interaction.307   
Pyrazolone derivatives (Figure 128A), which are patented by AstraZeneca, have been 
reported as potential inhibitors of MtSK, and most of these analogues have IC50 < 20 μM.308  
More recently, in silico high-throughput screenings on MtSK inhibitors have been 
completed.309,310 Drug-like compounds from the online service Free ADME/Tox Filtering (FAF)-
drugs exhibited better docking scores were screened based on Lipinski’s Rule of Five or other 
rules. The key interactions between  top-scoring compounds and MtSK suggested that a five-
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membered heteroaromatic system (triazole or tetrazole) is crucial in drug development, in which 
the inhibitor asxe1 showed the best binding affinity (Figure 128B).309 Since small peptide 
inhibitors show several advantages compared to these small molecules in treating diseases, such 
as high specificity and affinity to target proteins, greater potency, and lower toxicity, they are 
appealing to scientists and to the pharmaceutical industry, though they are likely to be 
metabolically unstable. Kaur’s group developed dipeptides using a structure-based in silico 
approach. A dipeptide Arg-Asp displayed the best binding affinity by far with Kd of 5.49 nM, 
which is 10 times lower than that of asxe1.311 
 
Figure 127 Structure model of the transition state for in-line associative phosphoryl transfer 
Reprinted from reference 301 with the permission of Elsevier B.V. 
 
Figure 128 (A) Pyrazolone derivatives; (B) Inhibitors with heteroaromatic system 
5.7 NAD Kinase 
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Mtb NAD kinase carries out the phosphorylation of NAD to form NADP and hence is 
important for the control of essential cellular processes. The Mtb NAD kinase was identified 
being able to utilize either inorganic polyphosphate [poly(P)] or ATP as a phosphate donor.312 
The kinetic analysis showed that it has a higher affinity for poly(P) than ATP,313 whereas human 
NAD kinase only utilizes ATP.314 Additionally, the full length of MtNAD kinase has an allosteric 
aspect which was not observed in the human NAD kinase.313 In a synthetic study completed by 
Bonnac et al., the NAD+ analogue benzamide adenine dinucleotide (BAD) displayed a weak 
inhibition on human NAD kinase but not on Mtb enzyme,315 which also provided the evidence to 
support the difference between Mtb and the human NAD kinases. The crystal structure of 
MtNAD kinase has been solved as apo or using NAD as a substrate.316,317 Modeling studies 
confirmed that the GGDG motif and residues 189-210 are crucial in catalysis, which was 
identified by comparing activity with mutants.313  In addition, the importance of an NE/D short 
motif in NAD-binding was observed.317 Although MtNAD has the potential to be a good target, 
the development of inhibitor for it seems difficult. When screening was completed using PknB, 
PknG, NAD kinase, and NAD synthetase as multiple targets, as discussed previously, only one 
compound, VI-13632, exhibited inhibition at IC50 of 53 μM.207 Some other reported analogues 
showing inhibition of MtNAD are not selective. They are able to inhibit human NAD kinase as 
well.318  
5.8 Pantothenate Kinase 
Pantothenate kinase (PanK, CoaA) is a key regulatory enzyme for coenzyme-A (CoA) 
biosynthesis.319 It phosphorylates pantothenate at its 4'-position forming 4'-phosphopantothenate, 
which is involved in the CoA biosynthetic pathway. The prokaryotic PanKs are classified in the 
P-loop kinase family, whereas the eukaryotic PanKs are identified as a member of the 
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ribonuclease H-like family.320 This classification indicates their sequence and structural disparity. 
There are three isoforms of PanK found: most bacteria have type I PanK, a few bacteria and 
eukaryotes possess type II Pank, and type III enzyme was identified in several bacteria recently. 
Mtb has both type I and type III enzymes; however, only type I was found to be crucial for the 
function of Mtb in a gene inactivation study.321 The crystal structure of type I MtPanK was 
solved by using CoA,322,323 citrate, nonhydrolysable ATP analogue AMPPCP, ADP and 
pantothenate,323 GMPPCP, GDP, GDP or GMPPCP with pantothenate, GDP with 
phosphopantothenate324 as substrates. MtPanK presents a dual substrate specificity for both ATP 
and GTP.324,325 When compared with the crystal structure of E. coli PanK and analyzing other 
known sequences of bacterial PanKs, there are some small differences in the N-terminal stretch, 
C-terminal region of H4, the subsequent loop, and another region involving the loop between S6 
and H10, which are related to the intersubunit interface in the dimeric molecule (Figure 129).322 
All the differences can be considered in inhibitor design to improve the selectivity. It is reported 
that the activity of murine pantothenate kinase isoform PanK3 is feedback-regulated by acetyl-
CoA (IC50=1 µM) and palmitoyl-CoA (IC50=2 µM)  through competitively binding to the ATP.326 
However, their inhibitory activities on Mtb are not known. Pantothenol was reported to exert 
inhibition on bacterial PanK as well.327,328 The inhibition could be attributed to the formation of 
4'-phosphopatothenol when pantothenol serving as a substrate of PanK, thus competitively 
inhibiting 4'-phosphopantothenoylcysteine decarboxylase (CoaBC) to utilize 4'-
phosphopatothenate.329 A high-throughput screening of MtPanK inhibitors was performed by 
measuring the protein thermal stability. This assay reveals the mode of the inhibition such as 
competitive or noncompetitive. Among all the compounds screened, a triazole compound 
displayed an ATP-competitive inhibition with IC50 at 0.07 μM; a thiazole compound showed an 
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uncompetitive inhibition with IC50 at 2.57 μM; and a biaryl acetic acid compound exerted mixed 
inhibitions with the best IC50 at 0.12 μM (Figure 130).330 
 
Figure 129 The PanK subunit 
N-terminus and C-terminus are marked as N and C.  
Reprinted from reference 322 with the permission of The International Union of Crystallography 
 
 
Figure 130 Structures of MtPanK inhibitors 
5.9 Dephosphocoenzyme A Kinase  
Dephosphocoenzyme A kinase (CoaE), participating in the last step of the mycobacterial 
CoA biosynthesis pathway, is crucial to the Mtb’s survival as well. Its sequence similarity to that 
of human is as low as 15%.331 Therefore, it could be another potential target for Mtb inhibitors. 
The dephosphocoenzyme A (DCoA) and CTP are substrates of CoaE.331 MtCoaE belongs to P-
loop containing NMPK family, which has mobile LID and CoA domains. The enzyme presents 
as a mixture of the monomer and trimer. The trimer form restricts the mobility of LID and CoA 
domains due to its spatial constraints, thus keeping the enzyme inactive. When binding to its 
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specific substrate DCoA, the conformation of CoaE changed, and the spatial constraints are 
released, thus leading its active monomer become predominant.332 The activation, however, 
could be prevented in the presence of CTP. The oligomeric equilibrium suggests that CTP 
analogues could be potent MtCoaE inhibitors.332    
6. Conclusion and Perspectives  
Protein kinases are one of the largest protein families, and are essential in regulating cell 
activities. Kinase inhibitors have been attracting attention because of their potential therapeutic 
utility. However, no inhibitor of Mtb histidine kinases targeting two-component system has been 
generated to date. As we discussed above, some HKs such as MtrB, PhoR are not essential for 
the growth of Mtb. In some two-component systems such as SenX3-RegX3, a phosphoryl group 
can also be transferred from other small phosphodonor compounds to RR.163 Hence, more 
studies focused on structural analysis of RRs instead of HKs.146,333,334,335,336 However, 
considering the characteristics of two-component systems, histidine kinases in Mtb still can be 
good targets. Firstly, two-component systems regulate antimicrobial resistance. The resistances 
of some drugs such as vancomycin, β-lactams, polymixin, and tetracycline are all related to two-
component systems.337 Secondly, pairs including DosS/DosT/DosR, MprB/MprA, SenX3/RegX3, 
are absolutely required for mycobacterium growth and persistence, while eukaryotes do not use a 
two-component system for signal transduction. Inhibitors targeting these HK/RR pairs therefore 
should possess good selectivity. Moreover, the autophosphorylation of HKs always occurs in the 
catalytic domain with the conserved histidine residue, indicating that an inhibitor might be able 
to target multiple two-component systems. A recent study on a noncognate HK/RR interaction 
between DosS/NarL provided a clue of cross interaction between HK/RR,338 which also suggest 
the possibility of multiple targets on the two-component system. In previous reviews, many HKs 
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including AlgR2, CheA, NRII, KinA, HpkA, YycG have been studied as targets for antimicrobial 
agents.337,339 However, the functions of some two-component systems in Mtb, such as 
SenX3/RegX3, NarS/NarL and TcrY/TcrX are not well characterized. To develop HK inhibitors, 
more studies need to be conducted. 
Unlike other prokaryotes, many serine/threonine protein kinases take the place of two-
component systems in signal transduction in Mtb. Table 19 shows the sequence 
identity/similarity for the kinase domains for pairs of the STPKs, with the lowest identity ~19% 
and the highest ~70%. It has been shown that M. tuberculosis STPKs form a distinct cluster close 
to human CK1.169 The sequence identity with human CK1a of the Mtb Pkns varies from 9.9-
16.5%, which is significantly lower than the identity within Pkns. These STPKs can be good 
targets because of the good selectivity. As we discussed above, some inhibitors of PknB and 
PknG have already shown potential in treating TB. Except for STPKs, PTKs could be interesting, 
even if there is only one tyrosine kinase found in Mtb until now. With the studies and knowledge 
on this family increasing, PTKs might be becoming more attractive targets. 
Table 19 Sequence identity in the kinase domain of STPKs and human CK1a computed from 
multiple sequence alignment# 
 PknA  PknB PknD PknE PknF PknG PknH PknI PknJ PknK 
PknB       41.5          
PknD       36.1 37.3         
PknE       37.4 35.9 65.1        
PknF       32.7 38.6 39 36.9       
PknG       23.5 21.1 22 20.2 19.3      
PknH       36.9 35.4 69.3 69.6 39 20.2     
PknI       26.2 27.2 32.9 30.4 49.2 19.7 32.9    
PknJ       33 41.5 40.9 38.3 48.3 19.1 38.7 39.1   
PknK       32.5 34.9 35.2 31.4 31.6 20.2 32.1 27.6 34.2  
PknL       40.2 44.7 34.2 34.7 32.2 22 32.3 23.6 32.2 34.7 
# Multiple sequence alignment was carried using ClustalW 340 and sequence identity matrix was calculated using 
BioEdit 341 
The mechanism of action employed by nucleoside analogues differs from existing 
antitubercular drugs, which might help to avoid cross-resistance. To use the best studied ADK 
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and TMPK as examples, both of them have low sequence and structural homology to eukaryotes 
which suggests they are potential antibacterial targets. Other kinases in Mtb display different 
characteristics from those in humans as well, such as AspK and SK are observed in bacteria, 
fungi, algae, or higher plants, but not in mammals; MtNAD is [poly(P)]/ATP dependent of which 
poly(P) has higher affinity, while that of human is only ATP-dependent; MtPanK shows sequence 
and structural disparity from both human and other bacteria, all these aspects can be used to 
develop highly selective and less toxic antibacterial agents. 
Natural products, especially marine organisms which are widely distributed over 70% of 
the earth’s surface, provide a major source of new drug candidates. All the species are able to 
produce secondary metabolites with different activities due to defense, competition, or a number 
of other environmental reasons.72 Many potent kinase inhibitors (Table 20) have been isolated to 
date. One of the major tools used in new drug development is the screening of drug leads from 
natural products. With the development of bioassays, many techniques are utilized for the 
screening of Mtb kinase inhibitors: The measurement of protein thermal stability was applied 
into screening of MtPanK;330 A high-throughput screening using the measurement of 
phosphorylation status via detecting the remaining ATP was utilized to explore PknB 
inhibitors;208 To improve the accuracy of the assay, a method using western blot coupling to 
mass spectrometry was designed to identify the substrates of PknB;342 Additionally, with the well 
characterized protein structures, as well as computational prediction of drug targets using a 
complete proteome level comparisons between Mtb and other species,343 the development of Mtb 
kinase inhibitors could benefit from combinatorial and rational drug designs. Natural and 
synthetic products screening can provide antitubercular leads, and with the use of computer aided 
drug design (CADD), we are confident that Mtb kinase inhibitors with high selectivity will 
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indeed be developed.  
 
 
Table 20 Typical kinase inhibitors from marine natural products 
Compound Structure Origin Activity Reference 
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Brown alga  
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Marine bacterium 
SANK 71896 
Sphingosine kinase 
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Halenaquinone 
 
Sponge 
X. exigua 
Phosphatidylinositol 3-
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Brown alga 
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350 
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